Common Mental Disorders — MCQs

Q: A 43-year-old woman presents with episodes of severe anxiety, palpitations, and sweating. These occur unpredictably and last 10-15 minutes. Between episodes she feels well. What is the most likely diagnosis?

Panic disorder. ***Panic disorder***- The patient is presenting with classic symptoms of a **panic attack**: discrete, unexpected episodes of intense fear accompanied by physical symptoms (palpitations, sweating) that peak rapidly (usually within 10 minutes) and then resolve.- A **Panic disorder** diagnosis requires recurrent unexpected panic attacks, followed by worry about future attacks or significant behavioral changes related to the attacks.*Generalized anxiety disorder*- GAD involves **chronic, pervasive, excessive worry** about numerous events or activities, often lasting for at least six months.- The symptoms are persistent instability rather than the acute, time-limited, discrete episodes described in this clinical vignette.*Social anxiety disorder*- This disorder involves intense fear or anxiety specifically related to **social or performance situations** where the individual may be exposed to scrutiny by others.- The patient's episodes are described as **unpredictable** and not tied to specific social contexts, making this diagnosis unlikely.*Hyperthyroidism*- While **hyperthyroidism** can cause anxiety-like symptoms (nervousness, palpitations, sweating) due to elevated metabolism, these symptoms are typically **persistent** rather than occurring as short, discrete attacks.- Diagnosis is confirmed by laboratory evidence (e.g., low **TSH**).*Pheochromocytoma*- This neuroendocrine tumor causes episodes of anxiety, palpitations, and sweating due to **catecholamine surges**.- Paroxysms are often associated with life-threatening **hypertensive crises** and severe headaches, which are not mentioned, and panic disorder is statistically much more common for this presentation.

Q: A 28-year-old woman presents with episodes of palpitations, sweating, and tremor lasting 15 minutes. These occur 2-3 times weekly. Physical examination is normal between episodes. What is the most likely diagnosis?

Panic disorder. ***Panic disorder*** - The clinical picture describes classic **panic attacks**, which are abrupt, time-limited episodes of intense fear or discomfort peaking within minutes and involving symptoms like **palpitations**, sweating, and tremor.- Panic disorder is the most likely diagnosis when such recurrent, unexpected attacks occur and the physical examination is **unremarkable** between episodes.*Hyperthyroidism* - Symptoms of hyperthyroidism, such as palpitations and tremor, are typically **persistent** and chronic, not brief, self-limiting episodes lasting only 15 minutes.- A physical examination would likely reveal persistent findings like **tachycardia** or *goiter*, which are noted to be normal in this patient between episodes.*Pheochromocytoma* - Although this condition causes episodic symptoms (paroxysms) mimicking anxiety, they are often associated with severe, paroxysmal **hypertension** and are usually less frequent than 2-3 times per week.- Given the high prevalence of anxiety disorders, **panic disorder** is epidemiologically the most likely diagnosis compared to this rare tumor, before requiring biochemical confirmation.*Cardiac arrhythmia* - While some arrhythmias cause palpitations, episodes that spontaneously resolve in precisely 15 minutes and recur frequently without evidence of **structural heart disease** are less typical of primary arrhythmia.- Significant recurrent arrhythmias often present with more alarming red-flag symptoms such as **syncope** or chest pain, which are not mentioned here.*Hypoglycemia* - Symptoms typically occur in association with **fasting** or excessive insulin/medication and are usually characterized by both adrenergic symptoms (sweating) and neuroglycopenic symptoms (e.g., confusion).- The episodic nature, unrelated to food intake or diabetic status (implied), and consistency of the 15-minute duration favor an **autonomic surge** related to anxiety over a metabolic cause.

Q: A 30-year-old woman presents with episodes of feeling detached from herself and her surroundings, as if watching herself from outside her body. These episodes last 10-15 minutes and cause significant distress. What is the most likely diagnosis?

Dissociative disorder. ***Dissociative disorder***- The presenting symptoms of feeling detached from oneself (**depersonalization**) and surroundings (**derealization**) are pathognomonic features of **Depersonalization/Derealization Disorder**, a type of dissociative disorder.- These episodic experiences, lasting 10-15 minutes and causing distress, clearly align with the diagnostic criteria for this condition.*Panic disorder*- Characterized by recurrent, unexpected **panic attacks** that include severe physical symptoms like **palpitations**, shortness of breath, and chest pain, peaking within minutes.- Although depersonalization/derealization can occur during a panic attack, the core complaint here is pure detachment, not an overwhelming surge of **physical anxiety** or intense fear.*Schizophrenia*- Schizophrenia is primarily characterized by **psychotic symptoms** such as **hallucinations** (e.g., auditory) and **delusions**, which are absent in this presentation.- The disorder requires a minimum duration of symptoms and active phase criteria (e.g., disorganized speech or behavior) distinct from isolated episodic detachment.*Depression*- Core features of depression involve persistent **depressed mood** and **anhedonia** (loss of pleasure or interest), along with changes in sleep, appetite, and energy.- While sometimes associated with severe mental illness, episodic dissociation is not the defining criterion for Major Depressive Disorder.*Anxiety disorder*- This term is broad, but common diagnoses like Generalized Anxiety Disorder (GAD) involve persistent, excessive, and uncontrollable **worry** about various life events.- The clinical picture involves profound subjective detachment rather than chronic high levels of pervasive **anxiety** or restlessness.

Q: A 34-year-old woman presents with recurrent episodes of palpitations, anxiety, and tremor lasting 10-15 minutes. These occur 2-3 times per week with no obvious trigger. Physical examination and ECG during an episode are normal. What is the most likely diagnosis?

Panic disorder. ***Panic disorder***- This is supported by the recurrent, unprovoked episodes of intense **anxiety**, **palpitations**, and **tremor**, consistent with **panic attacks**.- Panic attacks are typically brief, peaking within 10 minutes and resolving within 30 minutes, and are associated with a **normal physical examination** and **ECG** during the episode.*Hyperthyroidism*- Symptoms like palpitations and tremor in **hyperthyroidism** are usually constant and persistent, not brief and episodic (10-15 minutes).- Hyperthyroidism is associated with other signs like **weight loss**, heat intolerance, and requires abnormal **thyroid function tests (TFTs)** for diagnosis.*Cardiac arrhythmia*- Although the patient reports palpitations, a true **cardiac arrhythmia** would typically manifest with identifiable changes on the **ECG performed during the episode**.- The **normal ECG** during the episode makes a significant arrhythmia less likely, and sustained arrhythmias suggest an underlying electrical instability or **structural heart disease**.*Pheochromocytoma*- This condition causes episodic symptoms (paroxysms) but classically includes severe, pounding **headache**, diaphoresis, and marked, though transient, **hypertension**, which are critical differentiating factors not noted here.- Diagnosis relies on demonstrating elevated plasma or urinary **metanephrines**, which would be pursued if more typical features were present.*Caffeine excess*- Symptoms due to **caffeine excess** would have a clear, identifiable trigger (recent high caffeine consumption), which contradicts the finding of "no obvious trigger" in this patient history.- Caffeine-induced anxiety and palpitations would typically resolve reliably upon reducing or eliminating **caffeine** from the diet.

Q: A 27-year-old woman presents with amenorrhea, weight loss, and excessive exercise. She has fine lanugo hair and her BMI is 16 kg/m². She denies having an eating disorder. What is the most likely diagnosis?

Anorexia nervosa. ***Anorexia nervosa***- The combination of **severe underweight** (BMI 16 kg/m²), **amenorrhea**, deliberate **excessive exercise**, and the presence of **lanugo hair** (a sign of severe caloric deficit/starvation) is classic for Anorexia Nervosa.- Denial of an eating disorder, despite clear clinical indications, is a common psychological feature of this psychiatric condition.*Hyperthyroidism*- While hyperthyroidism causes weight loss and sometimes amenorrhea, it is characterized by symptoms of **hypermetabolism** like **tachycardia**, tremor, anxiety, and intolerance to heat.- It would not typically involve the specific psychological drive for **excessive exercise** seen in this presentation, nor is **lanugo hair** a typical finding.*Depression*- Depression can cause significant weight loss, but this is usually due to **anorexia** (loss of appetite), not the intense **deliberate restriction** and **driven excessive exercise** seen in this patient.- The presence of severe physical signs of starvation, such as **lanugo hair** at this BMI, points toward a primary eating disorder rather than depression alone.*Celiac disease*- Celiac disease causes weight loss due to malabsorption, typically accompanied by **gastrointestinal symptoms** such as chronic diarrhea, abdominal pain, or **steatorrhea**.- This diagnosis lacks the specific behavioral components of **body image distortion** and pathological restriction/excessive exercise central to Anorexia Nervosa.*Addison's disease*- Addison's disease (primary adrenal insufficiency) can cause unexplained weight loss and amenorrhea, but the hallmark is **hyperpigmentation** (especially in skin folds and mucous membranes) and specific electrolyte abnormalities (**hyponatremia** and **hyperkalemia**).- This patient lacks these adrenal features, and the clinical picture is dominated by the behavioral components of starvation.

A 60-year-old woman with treatment-resistant depression has been referred for electroconvulsive therapy (ECT) after failing adequate trials of four different antidepressants including augmentation strategies. She has severe depression with psychomotor retardation, significant weight loss, and pervasive guilt. Her family is concerned about potential cognitive side effects of ECT. They ask about factors that might be modified to minimise cognitive adverse effects while maintaining treatment efficacy. Which modification would most effectively reduce cognitive side effects while preserving antidepressant efficacy?

A 38-year-old solicitor presents with a 10-week history of low mood, anhedonia, fatigue, and reduced concentration. She describes feeling guilty about her work performance despite no objective evidence of problems. She has prominent anxiety symptoms including worry, restlessness, and muscle tension present most days. Her PHQ-9 is 17 and GAD-7 is 14. She has no past psychiatric history. What is the most appropriate initial pharmacological treatment choice?

A 35-year-old woman with panic disorder has been stable on escitalopram 20mg daily for 18 months, remaining panic-free for 12 months. She wishes to discontinue medication as she is planning pregnancy. She previously had severe panic disorder with 8-10 attacks weekly and significant agoraphobic avoidance requiring 6 months off work. She received CBT alongside medication. Which approach to discontinuation carries the optimal balance of minimising withdrawal symptoms while reducing recurrence risk?

Q10

A 52-year-old businessman presents with symptoms of both panic disorder and alcohol dependence. He reports drinking 60-80 units per week for the past 3 years. He experiences 3-4 panic attacks weekly, mostly in the morning, with palpitations, sweating, and tremor. He recognises he uses alcohol to manage his anxiety symptoms. He has no history of seizures or delirium tremens. He is motivated to address both problems. What is the most appropriate initial management strategy?

Common Mental Disorders UK Medical PG Practice Questions and MCQs

Question 1: A 43-year-old woman presents with episodes of severe anxiety, palpitations, and sweating. These occur unpredictably and last 10-15 minutes. Between episodes she feels well. What is the most likely diagnosis?

A. Generalized anxiety disorder
B. Panic disorder (Correct Answer)
C. Social anxiety disorder
D. Hyperthyroidism
E. Pheochromocytoma

Explanation: ***Panic disorder***- The patient is presenting with classic symptoms of a **panic attack**: discrete, unexpected episodes of intense fear accompanied by physical symptoms (palpitations, sweating) that peak rapidly (usually within 10 minutes) and then resolve.- A **Panic disorder** diagnosis requires recurrent unexpected panic attacks, followed by worry about future attacks or significant behavioral changes related to the attacks.*Generalized anxiety disorder*- GAD involves **chronic, pervasive, excessive worry** about numerous events or activities, often lasting for at least six months.- The symptoms are persistent instability rather than the acute, time-limited, discrete episodes described in this clinical vignette.*Social anxiety disorder*- This disorder involves intense fear or anxiety specifically related to **social or performance situations** where the individual may be exposed to scrutiny by others.- The patient's episodes are described as **unpredictable** and not tied to specific social contexts, making this diagnosis unlikely.*Hyperthyroidism*- While **hyperthyroidism** can cause anxiety-like symptoms (nervousness, palpitations, sweating) due to elevated metabolism, these symptoms are typically **persistent** rather than occurring as short, discrete attacks.- Diagnosis is confirmed by laboratory evidence (e.g., low **TSH**).*Pheochromocytoma*- This neuroendocrine tumor causes episodes of anxiety, palpitations, and sweating due to **catecholamine surges**.- Paroxysms are often associated with life-threatening **hypertensive crises** and severe headaches, which are not mentioned, and panic disorder is statistically much more common for this presentation.

Question 2: A 28-year-old woman presents with episodes of palpitations, sweating, and tremor lasting 15 minutes. These occur 2-3 times weekly. Physical examination is normal between episodes. What is the most likely diagnosis?

A. Hyperthyroidism
B. Panic disorder (Correct Answer)
C. Pheochromocytoma
D. Cardiac arrhythmia
E. Hypoglycemia

Explanation: ***Panic disorder*** - The clinical picture describes classic **panic attacks**, which are abrupt, time-limited episodes of intense fear or discomfort peaking within minutes and involving symptoms like **palpitations**, sweating, and tremor.- Panic disorder is the most likely diagnosis when such recurrent, unexpected attacks occur and the physical examination is **unremarkable** between episodes.*Hyperthyroidism* - Symptoms of hyperthyroidism, such as palpitations and tremor, are typically **persistent** and chronic, not brief, self-limiting episodes lasting only 15 minutes.- A physical examination would likely reveal persistent findings like **tachycardia** or *goiter*, which are noted to be normal in this patient between episodes.*Pheochromocytoma* - Although this condition causes episodic symptoms (paroxysms) mimicking anxiety, they are often associated with severe, paroxysmal **hypertension** and are usually less frequent than 2-3 times per week.- Given the high prevalence of anxiety disorders, **panic disorder** is epidemiologically the most likely diagnosis compared to this rare tumor, before requiring biochemical confirmation.*Cardiac arrhythmia* - While some arrhythmias cause palpitations, episodes that spontaneously resolve in precisely 15 minutes and recur frequently without evidence of **structural heart disease** are less typical of primary arrhythmia.- Significant recurrent arrhythmias often present with more alarming red-flag symptoms such as **syncope** or chest pain, which are not mentioned here.*Hypoglycemia* - Symptoms typically occur in association with **fasting** or excessive insulin/medication and are usually characterized by both adrenergic symptoms (sweating) and neuroglycopenic symptoms (e.g., confusion).- The episodic nature, unrelated to food intake or diabetic status (implied), and consistency of the 15-minute duration favor an **autonomic surge** related to anxiety over a metabolic cause.

Question 3: A 30-year-old woman presents with episodes of feeling detached from herself and her surroundings, as if watching herself from outside her body. These episodes last 10-15 minutes and cause significant distress. What is the most likely diagnosis?

A. Panic disorder
B. Dissociative disorder (Correct Answer)
C. Schizophrenia
D. Depression
E. Anxiety disorder

Explanation: ***Dissociative disorder***- The presenting symptoms of feeling detached from oneself (**depersonalization**) and surroundings (**derealization**) are pathognomonic features of **Depersonalization/Derealization Disorder**, a type of dissociative disorder.- These episodic experiences, lasting 10-15 minutes and causing distress, clearly align with the diagnostic criteria for this condition.*Panic disorder*- Characterized by recurrent, unexpected **panic attacks** that include severe physical symptoms like **palpitations**, shortness of breath, and chest pain, peaking within minutes.- Although depersonalization/derealization can occur during a panic attack, the core complaint here is pure detachment, not an overwhelming surge of **physical anxiety** or intense fear.*Schizophrenia*- Schizophrenia is primarily characterized by **psychotic symptoms** such as **hallucinations** (e.g., auditory) and **delusions**, which are absent in this presentation.- The disorder requires a minimum duration of symptoms and active phase criteria (e.g., disorganized speech or behavior) distinct from isolated episodic detachment.*Depression*- Core features of depression involve persistent **depressed mood** and **anhedonia** (loss of pleasure or interest), along with changes in sleep, appetite, and energy.- While sometimes associated with severe mental illness, episodic dissociation is not the defining criterion for Major Depressive Disorder.*Anxiety disorder*- This term is broad, but common diagnoses like Generalized Anxiety Disorder (GAD) involve persistent, excessive, and uncontrollable **worry** about various life events.- The clinical picture involves profound subjective detachment rather than chronic high levels of pervasive **anxiety** or restlessness.

Question 4: A 40-year-old woman presents with recurrent episodes of palpitations, sweating, and tremor lasting 10-15 minutes. These occur 2-3 times per week with no obvious trigger. Physical examination and ECG during an episode are normal. What is the most likely diagnosis?

A. Hyperthyroidism
B. Panic disorder (Correct Answer)
C. Cardiac arrhythmia
D. Pheochromocytoma
E. Caffeine excess

Explanation: ***Panic disorder***- The sudden, recurrent, brief attacks (10–15 minutes) of intense fear with physical symptoms like **palpitations**, **sweating**, and **tremor**, in the absence of an underlying medical condition (normal ECG), are characteristic of a **panic attack**.- The unpredictable nature ("no obvious trigger") and recurrence (2–3 times per week) fulfill the diagnostic criteria for **Panic Disorder**.*Hyperthyroidism*- While hyperthyroidism causes symptoms like **palpitations**, **sweating**, and **tremor**, these are typically persistent and chronic, not episodic and brief (10-15 minutes) as described.- A physical examination would likely reveal additional signs such as **goiter**, **exophthalmos**, or sustained **tachycardia**, which are absent here.*Cardiac arrhythmia*- Arrhythmias, even paroxysmal ones (e.g., PSVT), almost always cause demonstrable **ECG changes** (e.g., tachycardia, rhythm irregularity) during an episode, which are explicitly stated as normal in this patient.- The prominence of diffuse **sweating** and **tremor** alongside palpitations, in the context of a normal ECG, points away from a primary cardiac etiology.*Pheochromocytoma*- Paroxysms due to pheochromocytoma (episodic catecholamine release) typically involve severe, episodic **hypertension** and intense **headaches** along with palpitations, findings not mentioned in this clinically normal presentation.- While attacks can mimic panic, the underlying pathology often results in profound physiological changes (e.g., significant BP surge) that would likely be detected or at least suspected during physical examination.*Caffeine excess*- Symptoms from caffeine excess are often continuous or predictable based on **recent high consumption**, rather than occurring spontaneously 2–3 times per week with "no obvious trigger."- Significant caffeine intoxication would usually present with more sustained **tremor**, **restlessness**, or high resting heart rate, symptoms inconsistent with a completely normal physical exam.

Question 5: A 34-year-old woman presents with recurrent episodes of palpitations, anxiety, and tremor lasting 10-15 minutes. These occur 2-3 times per week with no obvious trigger. Physical examination and ECG during an episode are normal. What is the most likely diagnosis?

A. Hyperthyroidism
B. Panic disorder (Correct Answer)
C. Cardiac arrhythmia
D. Pheochromocytoma
E. Caffeine excess

Explanation: ***Panic disorder***- This is supported by the recurrent, unprovoked episodes of intense **anxiety**, **palpitations**, and **tremor**, consistent with **panic attacks**.- Panic attacks are typically brief, peaking within 10 minutes and resolving within 30 minutes, and are associated with a **normal physical examination** and **ECG** during the episode.*Hyperthyroidism*- Symptoms like palpitations and tremor in **hyperthyroidism** are usually constant and persistent, not brief and episodic (10-15 minutes).- Hyperthyroidism is associated with other signs like **weight loss**, heat intolerance, and requires abnormal **thyroid function tests (TFTs)** for diagnosis.*Cardiac arrhythmia*- Although the patient reports palpitations, a true **cardiac arrhythmia** would typically manifest with identifiable changes on the **ECG performed during the episode**.- The **normal ECG** during the episode makes a significant arrhythmia less likely, and sustained arrhythmias suggest an underlying electrical instability or **structural heart disease**.*Pheochromocytoma*- This condition causes episodic symptoms (paroxysms) but classically includes severe, pounding **headache**, diaphoresis, and marked, though transient, **hypertension**, which are critical differentiating factors not noted here.- Diagnosis relies on demonstrating elevated plasma or urinary **metanephrines**, which would be pursued if more typical features were present.*Caffeine excess*- Symptoms due to **caffeine excess** would have a clear, identifiable trigger (recent high caffeine consumption), which contradicts the finding of "no obvious trigger" in this patient history.- Caffeine-induced anxiety and palpitations would typically resolve reliably upon reducing or eliminating **caffeine** from the diet.

Question 6: A 27-year-old woman presents with amenorrhea, weight loss, and excessive exercise. She has fine lanugo hair and her BMI is 16 kg/m². She denies having an eating disorder. What is the most likely diagnosis?

A. Hyperthyroidism
B. Anorexia nervosa (Correct Answer)
C. Depression
D. Celiac disease
E. Addison's disease

Explanation: ***Anorexia nervosa***- The combination of **severe underweight** (BMI 16 kg/m²), **amenorrhea**, deliberate **excessive exercise**, and the presence of **lanugo hair** (a sign of severe caloric deficit/starvation) is classic for Anorexia Nervosa.- Denial of an eating disorder, despite clear clinical indications, is a common psychological feature of this psychiatric condition.*Hyperthyroidism*- While hyperthyroidism causes weight loss and sometimes amenorrhea, it is characterized by symptoms of **hypermetabolism** like **tachycardia**, tremor, anxiety, and intolerance to heat.- It would not typically involve the specific psychological drive for **excessive exercise** seen in this presentation, nor is **lanugo hair** a typical finding.*Depression*- Depression can cause significant weight loss, but this is usually due to **anorexia** (loss of appetite), not the intense **deliberate restriction** and **driven excessive exercise** seen in this patient.- The presence of severe physical signs of starvation, such as **lanugo hair** at this BMI, points toward a primary eating disorder rather than depression alone.*Celiac disease*- Celiac disease causes weight loss due to malabsorption, typically accompanied by **gastrointestinal symptoms** such as chronic diarrhea, abdominal pain, or **steatorrhea**.- This diagnosis lacks the specific behavioral components of **body image distortion** and pathological restriction/excessive exercise central to Anorexia Nervosa.*Addison's disease*- Addison's disease (primary adrenal insufficiency) can cause unexplained weight loss and amenorrhea, but the hallmark is **hyperpigmentation** (especially in skin folds and mucous membranes) and specific electrolyte abnormalities (**hyponatremia** and **hyperkalemia**).- This patient lacks these adrenal features, and the clinical picture is dominated by the behavioral components of starvation.

Question 7: A 60-year-old woman with treatment-resistant depression has been referred for electroconvulsive therapy (ECT) after failing adequate trials of four different antidepressants including augmentation strategies. She has severe depression with psychomotor retardation, significant weight loss, and pervasive guilt. Her family is concerned about potential cognitive side effects of ECT. They ask about factors that might be modified to minimise cognitive adverse effects while maintaining treatment efficacy. Which modification would most effectively reduce cognitive side effects while preserving antidepressant efficacy?

A. Using unilateral electrode placement on the non-dominant hemisphere rather than bilateral placement (Correct Answer)
B. Reducing the electrical dose to just above seizure threshold regardless of electrode placement
C. Extending the interval between treatments from twice weekly to once weekly throughout the course
D. Using ultra-brief pulse width stimulation with bilateral electrode placement
E. Limiting the total number of ECT sessions to a maximum of 6 treatments

Explanation: ***Using unilateral electrode placement on the non-dominant hemisphere rather than bilateral placement*** - **Right-unilateral (RUL) ECT** is consistently associated with significantly fewer **cognitive adverse effects**, particularly regarding verbal memory and orientation, compared to **bilateral ECT**. - While bilateral placement is generally faster-acting, RUL ECT maintains comparable **antidepressant efficacy** provided the electrical dose is sufficiently higher (typically 6 times) than the **seizure threshold**. *Reducing the electrical dose to just above seizure threshold regardless of electrode placement* - While lower doses minimize cognitive side effects, using a dose just above the **seizure threshold** in unilateral ECT is often **ineffective** for treating depression. - To ensure efficacy in RUL placement, the dose must be significantly above threshold; therefore, reducing it too low risks a non-therapeutic response. *Extending the interval between treatments from twice weekly to once weekly throughout the course* - Reducing treatment frequency to **once weekly** may slow the rate of cognitive decline but significantly delays the **speed of remission** and clinical improvement. - **Twice-weekly sessions** are the standard of care to balance clinical response time with the risk of cumulative cognitive impairment. *Using ultra-brief pulse width stimulation with bilateral electrode placement* - **Ultra-brief pulse (0.3ms)** stimulation reduces cognitive side effects compared to standard brief pulse, but the benefits are most established when combined with **unilateral placement**. - Combining ultra-brief pulses with **bilateral placement** still poses a higher risk of cognitive deficits compared to the unilateral alternative. *Limiting the total number of ECT sessions to a maximum of 6 treatments* - Arbitrarily limiting sessions may result in **incomplete remission** or early relapse, as many patients require 8 to 12 sessions for a full therapeutic response. - Treatment course length should be determined by **clinical response** and recovery from symptoms like psychomotor retardation, rather than a fixed number of treatments.

Question 8: A 38-year-old solicitor presents with a 10-week history of low mood, anhedonia, fatigue, and reduced concentration. She describes feeling guilty about her work performance despite no objective evidence of problems. She has prominent anxiety symptoms including worry, restlessness, and muscle tension present most days. Her PHQ-9 is 17 and GAD-7 is 14. She has no past psychiatric history. What is the most appropriate initial pharmacological treatment choice?

A. Commence sertraline as it effectively treats both depressive and anxiety symptoms (Correct Answer)
B. Commence mirtazapine for its combined antidepressant and anxiolytic effects with rapid onset
C. Commence pregabalin for the generalised anxiety disorder with review to add an antidepressant if depression persists
D. Commence a low-dose benzodiazepine for anxiety symptoms with an SSRI added after anxiety is controlled
E. Commence venlafaxine as an SNRI is more effective than SSRIs for mixed anxiety-depression

Explanation: ***Commence sertraline as it effectively treats both depressive and anxiety symptoms***- In a mixed presentation, **NICE guidelines** recommend treating the **depression** first, and **SSRIs** like sertraline are the first-line choice for both **Moderately Severe Depression** (PHQ-9: 17) and **GAD**.- Sertraline is preferred due to its **extensive evidence base**, cost-effectiveness, and better **safety profile** compared to secondary options.*Commence mirtazapine for its combined antidepressant and anxiolytic effects with rapid onset*- While effective for sleep and anxiety, **mirtazapine** is generally considered a second-line option due to side effects like **sedation** and **weight gain**.- It is often reserved for patients who cannot tolerate SSRIs or have specific needs for **appetite stimulation**.*Commence pregabalin for the generalised anxiety disorder with review to add an antidepressant if depression persists*- **Pregabalin** is licensed for Generalised Anxiety Disorder but is not an effective treatment for **depressive symptoms** or clinical depression.- It is classified as second or third-line for anxiety and carries a risk of **dependence and misuse**.*Commence a low-dose benzodiazepine for anxiety symptoms with an SSRI added after anxiety is controlled*- **Benzodiazepines** should be avoided as initial treatment due to the high risk of **dependence**, tolerance, and lack of efficacy for **depressive symptoms**.- Managing anxiety first with these agents can mask symptoms and delay the effective treatment of the **underlying clinical depression**.*Commence venlafaxine as an SNRI is more effective than SSRIs for mixed anxiety-depression*- Evidence does not support **SNRIs** being more effective than **SSRIs** for the initial treatment of mixed anxiety and depression.- **Venlafaxine** is usually a second-line choice because of a more difficult **side effect profile** and significant **withdrawal/discontinuation syndrome**.

Question 9: A 35-year-old woman with panic disorder has been stable on escitalopram 20mg daily for 18 months, remaining panic-free for 12 months. She wishes to discontinue medication as she is planning pregnancy. She previously had severe panic disorder with 8-10 attacks weekly and significant agoraphobic avoidance requiring 6 months off work. She received CBT alongside medication. Which approach to discontinuation carries the optimal balance of minimising withdrawal symptoms while reducing recurrence risk?

A. Discontinue escitalopram abruptly as SSRIs can be safely stopped without tapering due to long half-lives
B. Reduce by 50% every week for 2 weeks then stop, as escitalopram has relatively low discontinuation syndrome risk
C. Gradually taper over at least 4 weeks while reinstating CBT techniques and monitoring for early signs of recurrence (Correct Answer)
D. Switch to fluoxetine for 2 weeks before discontinuation due to its longer half-life reducing withdrawal symptoms
E. Reduce dose by 25% every 2 weeks while commencing a tricyclic antidepressant which is safer in pregnancy

Explanation: ***Gradually taper over at least 4 weeks while reinstating CBT techniques and monitoring for early signs of recurrence*** - A **gradual taper** over at least 4 weeks is recommended by **NICE guidelines** to minimize the risk of **discontinuation syndrome** and allow monitoring of symptom recurrence. - Incorporating **CBT techniques** provides the patient with non-pharmacological coping specialized for panic disorder, which is crucial given her history of severe **agoraphobic avoidance**. *Discontinue escitalopram abruptly as SSRIs can be safely stopped without tapering due to long half-lives* - **Abrupt discontinuation** of SSRIs is not recommended as it significantly increases the risk of **withdrawal symptoms** such as dizziness, electric shock sensations, and rebound anxiety. - While **fluoxetine** has a long half-life, **escitalopram** has a moderate half-life and requires a tapered approach to ensure safety and stability. *Reduce by 50% every week for 2 weeks then stop, as escitalopram has relatively low discontinuation syndrome risk* - A 50% reduction per week is considered a **rapid taper** and may still trigger significant **discontinuation symptoms** in a patient who has been on treatment for 18 months. - Stability for 12 months is positive, but her history of **8-10 attacks weekly** suggests a high underlying vulnerability that warrants a more cautious, slower reduction. *Switch to fluoxetine for 2 weeks before discontinuation due to its longer half-life reducing withdrawal symptoms* - While switching to **fluoxetine** is a recognized strategy for drugs with very short half-lives (like paroxetine), it is generally an **unnecessary extra step** for escitalopram. - This approach adds the complexity of transitioning between medications and does not inherently address the need for **psychological support** during the final cessation phase. *Reduce dose by 25% every 2 weeks while commencing a tricyclic antidepressant which is safer in pregnancy* - Introduction of a **tricyclic antidepressant (TCA)** is inappropriate when the patient's explicit goal is to be **medication-free** for pregnancy planning. - TCAs are not necessarily "safer" than SSRIs in pregnancy and carry their own risks, including higher **toxicity in overdose** and significant side-effect profiles.

Question 10: A 52-year-old businessman presents with symptoms of both panic disorder and alcohol dependence. He reports drinking 60-80 units per week for the past 3 years. He experiences 3-4 panic attacks weekly, mostly in the morning, with palpitations, sweating, and tremor. He recognises he uses alcohol to manage his anxiety symptoms. He has no history of seizures or delirium tremens. He is motivated to address both problems. What is the most appropriate initial management strategy?

A. Commence an SSRI immediately for panic disorder while simultaneously initiating alcohol reduction strategies
B. Manage alcohol withdrawal first using a benzodiazepine-assisted reduction regimen before addressing panic disorder (Correct Answer)
C. Start propranolol for panic symptoms and naltrexone for alcohol dependence simultaneously
D. Refer to specialist dual diagnosis services before initiating any specific treatment
E. Commence CBT for panic disorder while the patient continues to drink at current levels to establish therapeutic alliance

Explanation: ***Manage alcohol withdrawal first using a benzodiazepine-assisted reduction regimen before addressing panic disorder*** - The patient's heavy alcohol consumption (60-80 units/week for 3 years) and morning symptoms like **palpitations, sweating, and tremor** strongly indicate **alcohol withdrawal**, which requires immediate and safe management, typically with **benzodiazepines**, to prevent serious complications. - Many anxiety and panic symptoms are often **exacerbated by or secondary to alcohol use and withdrawal**; therefore, stabilizing the patient through detoxification allows for a more accurate assessment and effective treatment of the underlying panic disorder. *Commence an SSRI immediately for panic disorder while simultaneously initiating alcohol reduction strategies* - Starting an **SSRI** while the patient is actively drinking heavily is not advisable as alcohol can significantly **interfere with the medication's efficacy** and increase the risk of side effects. - This approach makes it challenging to differentiate between **medication-induced side effects**, ongoing **alcohol withdrawal symptoms**, and the primary **panic disorder**. *Start propranolol for panic symptoms and naltrexone for alcohol dependence simultaneously* - **Propranolol** is a beta-blocker that primarily addresses the **physical symptoms of anxiety** (e.g., palpitations, tremor) but does not treat the core panic disorder or manage the underlying risks of **alcohol withdrawal**. - **Naltrexone** is effective for **reducing cravings and preventing relapse** in alcohol dependence but is not indicated for the acute management of **alcohol withdrawal** itself. *Refer to specialist dual diagnosis services before initiating any specific treatment* - While a **dual diagnosis service** is crucial for integrated care, delaying all treatment for a referral can put the patient at risk of **severe alcohol withdrawal complications** that require prompt intervention. - Initial **detoxification and stabilization** are often initiated in acute care settings or by the primary team before a comprehensive dual diagnosis assessment can be completed. *Commence CBT for panic disorder while the patient continues to drink at current levels to establish therapeutic alliance* - **Cognitive Behavioral Therapy (CBT)** for panic disorder is significantly less effective during active heavy alcohol use because alcohol impairs **cognitive function, memory, and insight**, hindering the patient's ability to engage with and benefit from therapy. - Continuing to drink at high levels undermines the therapeutic goals of CBT, which aim to help patients develop **healthy coping mechanisms** for anxiety without relying on substances.

Question 11: A 40-year-old man with generalised anxiety disorder has been receiving high-intensity CBT for 14 weeks. Initially his GAD-7 score was 18, and after 8 sessions it has reduced to 15. He reports using thought challenging techniques and has reduced some avoidance behaviours, but continues to experience significant worry about health and work, with persistent muscle tension and poor sleep. What is the most appropriate next step in management?

A. Continue CBT for a further 6-8 weeks as response is evident and further improvement is likely
B. Discontinue CBT and commence an SSRI as first-line pharmacological treatment
C. Add an SSRI while continuing with psychological therapy to optimise treatment response (Correct Answer)
D. Switch to a different psychological intervention such as mindfulness-based cognitive therapy
E. Refer to specialist mental health services for consideration of pregabalin or duloxetine

Explanation: ***Add an SSRI while continuing with psychological therapy to optimise treatment response*** - For patients with **Generalised Anxiety Disorder (GAD)** who show a partial but inadequate response to high-intensity **CBT**, NICE guidelines suggest offering the pharmacological option not already tried (Step 4 care). - A **GAD-7 score** of 15 remains in the severe category, indicating that combining **pharmacotherapy** and psychological therapy is necessary to achieve better symptom control. *Continue CBT for a further 6-8 weeks as response is evident and further improvement is likely* - While the patient shows some engagement, a reduction of only 3 points on the **GAD-7** after 14 weeks suggests that monotherapy is insufficient for this patient's severity. - Relying solely on a slow-responding intervention delays **remission** and functional recovery in a patient suffering from persistent physical symptoms like **muscle tension**. *Discontinue CBT and commence an SSRI as first-line pharmacological treatment* - Discontinuing a therapy that the patient has begun to master (e.g., **thought challenging**) is counter-productive to long-term **relapse prevention**. - The goal in partial responders is to build upon the gains of **CBT** by adding **pharmacological support**, not replacing it entirely. *Switch to a different psychological intervention such as mindfulness-based cognitive therapy* - **Mindfulness-based interventions** are typically adjuncts and there is no clinical evidence that switching would be superior to enhancing the current **evidence-based CBT**. - The primary barrier here is the intensity of **residual symptoms** which is better addressed by adding an **SSRI** rather than changing psychological modalities. *Refer to specialist mental health services for consideration of pregabalin or duloxetine* - **Pregabalin** and **Duloxetine** are typically considered second-line pharmacological treatments after an **SSRI** or **SNRI** trial has failed. - Referral to **specialist services** is reserved for complex, treatment-resistant cases where primary care combinations of therapy and **first-line medication** have been exhausted.

Question 12: A 45-year-old teacher presents with a 9-week history of low mood, anhedonia, reduced energy, and poor concentration affecting her work. She has early morning wakening and has lost 4kg in weight. Her past psychiatric history includes two previous depressive episodes, the first 8 years ago requiring 6 months of citalopram, and the second 3 years ago requiring 18 months of sertraline. She achieved full remission after both episodes. What is the most appropriate duration of antidepressant treatment once remission is achieved in this current episode?

A. 6 months following remission, as she previously responded well to this duration
B. 12 months following remission, as recommended for a second depressive episode
C. At least 2 years following remission due to the recurrent nature of her depression (Correct Answer)
D. Treatment should be continued indefinitely given three episodes of depression
E. 9 months following remission to match the duration of the current episode

Explanation: ***At least 2 years following remission due to the recurrent nature of her depression*** - This patient has a history of **three depressive episodes**, classifying her depression as recurrent. - **NICE guidelines** recommend that individuals with a history of two or more previous depressive episodes should continue antidepressant treatment for at least **2 years** after achieving remission to significantly reduce the risk of relapse. *6 months following remission, as she previously responded well to this duration* - A **6-month continuation phase** is typically recommended after a **first episode of depression** once remission is achieved. - This duration is insufficient for a patient with recurrent depression as the risk of relapse is significantly higher, requiring a longer prophylactic period. *12 months following remission, as recommended for a second depressive episode* - While longer than 6 months, **12 months** is still considered insufficient for someone with a history of **three depressive episodes**. - Guidelines suggest longer durations for recurrent depression, especially after multiple episodes, to ensure adequate prophylaxis against relapse. *Treatment should be continued indefinitely given three episodes of depression* - Indefinite antidepressant treatment is typically reserved for individuals with **highly recurrent**, severe, or treatment-resistant depression, or those with a very high risk of suicide upon discontinuation. - Although this patient has had three episodes, the initial recommendation is usually **2 years** post-remission, with indefinite treatment being considered if relapses occur despite this extended duration or if other risk factors are present. *9 months following remission to match the duration of the current episode* - The duration of antidepressant maintenance treatment is determined by the **number of previous depressive episodes** and the risk of recurrence, not by the length of the current acute episode. - There is no evidence-based guideline supporting a **9-month** maintenance period specifically tied to the acute episode length, and it would be inadequate for recurrent depression.

Question 13: A 28-year-old woman presents with recurrent panic attacks over 4 months. She describes attacks occurring both in crowded places and at home alone, sometimes waking her from sleep. During attacks she experiences palpitations, breathlessness, chest tightness, dizziness, and fear of dying. She has developed extensive avoidance of public transport and shopping centres. Cardiac investigations including ECG and echocardiogram are normal. What is the most appropriate initial psychological intervention?

A. Psychodynamic psychotherapy focusing on unconscious conflicts underlying the anxiety
B. Applied relaxation training to reduce physiological arousal during panic attacks
C. Cognitive behavioural therapy including exposure to feared situations and cognitive restructuring of catastrophic misinterpretations (Correct Answer)
D. Mindfulness-based stress reduction to increase acceptance of panic sensations
E. Eye movement desensitisation and reprocessing (EMDR) to process traumatic memories

Explanation: ***Cognitive behavioural therapy including exposure to feared situations and cognitive restructuring of catastrophic misinterpretations***- **Cognitive Behavioural Therapy (CBT)** is the **first-line evidence-based psychological intervention** for **Panic Disorder** with **agoraphobia**, effectively breaking the cycle of **catastrophic misinterpretations** of bodily sensations. - Its key components, such as **interoceptive exposure** (to physiological symptoms) and **in vivo exposure** (to feared situations), directly target the **panic attacks** and the **agoraphobic avoidance** presented by the patient.*Psychodynamic psychotherapy focusing on unconscious conflicts underlying the anxiety*- This approach has **less direct evidence** for the initial, acute management of **panic disorder** compared to CBT.- It primarily explores **unconscious conflicts** and **early life experiences**, which are not the immediate targets for effective symptom reduction in panic disorder.*Applied relaxation training to reduce physiological arousal during panic attacks*- While beneficial for **reducing physiological arousal**, it is **less comprehensive** than CBT for panic disorder.- It does not directly address the **cognitive misinterpretations** of bodily sensations or the specific **agoraphobic avoidance behaviors** that are central to this patient's presentation.*Mindfulness-based stress reduction to increase acceptance of panic sensations*- **Mindfulness-based stress reduction** can be a useful **adjunct** for managing general anxiety and increasing distress tolerance but is **not the primary initial intervention** for panic disorder with significant agoraphobia.- It focuses more on **acceptance** rather than the active **exposure** and **cognitive restructuring** necessary to overcome panic attacks and avoidance.*Eye movement desensitisation and reprocessing (EMDR) to process traumatic memories*- **EMDR** is an evidence-based treatment specifically for **Post-Traumatic Stress Disorder (PTSD)**.- There is **no indication of a traumatic memory** as the underlying cause of the panic attacks in the patient's history, making it an inappropriate initial intervention.

Question 14: A 57-year-old woman with a 10-week history of severe depression has been taking venlafaxine 225mg daily for 8 weeks with minimal improvement. She has previously failed adequate trials of sertraline and mirtazapine. She has no psychotic symptoms but has persistent suicidal ideation without specific plans. Her medical history includes well-controlled hypertension. What is the most appropriate next step in her management?

A. Augment venlafaxine with lithium and continue for a further 4-6 weeks (Correct Answer)
B. Switch to a monoamine oxidase inhibitor after appropriate washout period
C. Refer for urgent psychiatric assessment for consideration of electroconvulsive therapy
D. Add an atypical antipsychotic such as quetiapine for augmentation
E. Switch to duloxetine as an alternative SNRI with a different side effect profile

Explanation: ***Augment venlafaxine with lithium and continue for a further 4-6 weeks*** - This patient has **treatment-resistant depression (TRD)**, defined as failure to respond to two or more antidepressants of different classes at adequate doses. - **Lithium augmentation** has the strongest evidence base for efficacy in TRD, significantly increasing response rates when added to an existing antidepressant like **venlafaxine**. *Switch to a monoamine oxidase inhibitor after appropriate washout period* - **MAOIs** are generally reserved as a later-line treatment due to their complex **dietary restrictions** and risk of hypertensive crisis. - Switching would require a lengthy **washout period** (2 weeks or more), during which the patient's depressive symptoms and suicidal ideation could worsen without treatment. *Refer for urgent psychiatric assessment for consideration of electroconvulsive therapy* - **Electroconvulsive therapy (ECT)** is highly effective but usually indicated for **life-threatening** depression, such as severe catatonia or immediate high risk of suicide. - While the patient has suicidal ideation, she lacks **psychotic symptoms** or a specific plan, making a trial of pharmacological augmentation appropriate first. *Add an atypical antipsychotic such as quetiapine for augmentation* - While **atypical antipsychotics** are used for augmentation, lithium currently holds a superior evidence profile for non-psychotic **treatment-resistant depression**. - Antipsychotics carry a significant metabolic side effect burden, including **weight gain** and potential **glucose intolerance**, which may be less desirable than lithium in this clinical context. *Switch to duloxetine as an alternative SNRI with a different side effect profile* - **Duloxetine** belongs to the same class (**SNRI**) as venlafaxine; switching within the same class after a failure is generally less effective than augmentation. - Effective management of TRD prioritizes switching to a **different drug class** or adding an augmenting agent rather than a lateral switch.

Question 15: A 33-year-old woman with panic disorder presents to her GP 5 days after starting escitalopram 10mg daily. She reports feeling significantly more anxious, experiencing increased tremor, and having two additional panic attacks since starting the medication. She is concerned the medication is making her worse and wants to stop it immediately. What is the most appropriate management approach?

A. Stop escitalopram immediately and switch to a different class of antidepressant such as mirtazapine
B. Reassure her this is an expected initial effect, consider adding a short course of benzodiazepine, and continue escitalopram with close monitoring (Correct Answer)
C. Increase the escitalopram dose to 20mg daily to achieve therapeutic effect more rapidly
D. Stop escitalopram and commence CBT as first-line treatment instead
E. Continue escitalopram at the same dose but add propranolol for symptomatic control

Explanation: ***Reassure her this is an expected initial effect, consider adding a short course of benzodiazepine, and continue escitalopram with close monitoring*** - Patients with **panic disorder** are particularly sensitive to the initial stimulatory effects of **SSRIs**, often experiencing a transient increase in anxiety, known as **activation syndrome** or **jitteriness syndrome**. - Management involves **reassurance** and **psychoeducation** to prevent premature discontinuation, along with the temporary use of a **short-acting benzodiazepine** to alleviate acute symptoms until the SSRI's therapeutic effects manifest (typically 2-4 weeks). *Stop escitalopram immediately and switch to a different class of antidepressant such as mirtazapine* - Stopping the medication after only 5 days is premature, as the **therapeutic efficacy** of an SSRI cannot be assessed until after several weeks of consistent treatment. - **Mirtazapine** is generally not considered a first-line treatment for panic disorder, and switching classes immediately would prevent the patient from potentially benefiting from escitalopram after the initial side effects subside. *Increase the escitalopram dose to 20mg daily to achieve therapeutic effect more rapidly* - Increasing the dose so early would likely **exacerbate** the reported symptoms of increased anxiety, tremor, and panic attacks, worsening the initial **activation syndrome**. - For panic disorder, the recommended approach is to **start with a low dose** (often 5mg for escitalopram) and **titrate slowly** to minimize adverse effects. *Stop escitalopram and commence CBT as first-line treatment instead* - While **Cognitive Behavioral Therapy (CBT)** is an effective first-line treatment for panic disorder, it is often used **in conjunction with** or as an alternative to medication, not as a reason to abruptly discontinue medication during its initial titration phase. - Abruptly stopping medication at this stage may reinforce the patient's fear of symptoms and medications, hindering overall treatment adherence and success. *Continue escitalopram at the same dose but add propranolol for symptomatic control* - **Propranolol**, a beta-blocker, can help with peripheral symptoms like **tremor** and **palpitations** but is less effective in addressing the core cognitive and acute anxiety symptoms of panic attacks or the central activating effects of SSRIs. - **Benzodiazepines** are generally more appropriate for the acute management of increased anxiety and panic attacks during the initial phase of SSRI treatment due to their anxiolytic properties.

Question 16: A 49-year-old man presents with an 8-week history of low mood, fatigue, poor appetite, and disturbed sleep. He describes waking at 4am unable to return to sleep, feeling worst in the early morning with slight improvement as the day progresses. He has lost interest in his hobbies and feels slowed down. There is no diurnal variation in his physical symptoms. His PHQ-9 score is 19. Which feature of his presentation most specifically indicates melancholic features according to diagnostic classifications?

A. The 8-week duration of symptoms meeting criteria for a depressive episode
B. The combination of early morning wakening with diurnal mood variation showing worst symptoms in the morning (Correct Answer)
C. The presence of psychomotor retardation with subjective feeling of being slowed down
D. Loss of interest in previously enjoyed activities indicating anhedonia
E. The PHQ-9 score of 19 indicating moderately severe depression

Explanation: ***The combination of early morning wakening with diurnal mood variation showing worst symptoms in the morning*** - **Early morning awakening** (terminal insomnia, usually at least 2 hours before habitual time) and **diurnal variation** of mood (mood worst in the morning) are classic vegetative symptoms specific to **melancholic depression** (DSM-5 specifier "with melancholic features"). - These features reflect a distinct neurobiological pattern, often associated with a better response to biological treatments like **antidepressants** or **ECT**, differentiating it from atypical depression. *The 8-week duration of symptoms meeting criteria for a depressive episode* - The **duration** of symptoms (minimum 2 weeks) is a general criterion for **Major Depressive Disorder**, not specific to melancholic features. - It indicates the presence of a depressive episode but does not differentiate between subtypes like melancholic, atypical, or anxious depression. *The presence of psychomotor retardation with subjective feeling of being slowed down* - While **psychomotor retardation** (observable slowing of thought and movement) is a common feature of severe depression, it can also be present in other severe depressive episodes without specific melancholic features. - It is less specific than the **diurnal variation** and **early morning awakening** for defining melancholic specifiers according to diagnostic criteria. *Loss of interest in previously enjoyed activities indicating anhedonia* - **Anhedonia** (loss of interest or pleasure) is a **core diagnostic criterion** for *any* major depressive episode, not just melancholic. At least one of depressed mood or anhedonia is required for diagnosis. - While often severe in melancholic depression, its presence alone does not specifically indicate melancholic features according to diagnostic classifications. *The PHQ-9 score of 19 indicating moderately severe depression* - A **PHQ-9 score** of 19 indicates **moderately severe depression**, reflecting the overall symptom burden. - However, the PHQ-9 is a **severity scale** and a **screening tool**, not a diagnostic instrument for differentiating specific depressive subtypes like **melancholic features**.

Question 17: A 36-year-old woman with panic disorder has been taking sertraline 50mg daily for 3 weeks. She reports some reduction in anticipatory anxiety but continues to experience 3-4 panic attacks weekly. She is tolerating the medication well with only mild nausea initially. She asks how long it typically takes for panic attacks to improve with SSRI treatment. What is the most appropriate response regarding the expected timeline for therapeutic response in panic disorder?

A. Maximum benefit is usually achieved within 2-4 weeks of starting treatment
B. Panic attacks should resolve within 1 week if the medication is going to be effective
C. Full therapeutic effect on panic attacks typically takes 8-12 weeks, with gradual improvement from 4-6 weeks (Correct Answer)
D. Response should be evident within 6 weeks; if not, the medication is unlikely to be effective
E. Improvement in panic attacks parallels improvement in general anxiety, typically within 2-3 weeks

Explanation: ***Full therapeutic effect on panic attacks typically takes 8-12 weeks, with gradual improvement from 4-6 weeks*** - In **panic disorder**, the full therapeutic response to **SSRIs** is often slower than for other anxiety symptoms, typically requiring **8-12 weeks** for substantial reduction or cessation of panic attacks. - The patient has only been on **sertraline** for 3 weeks, which is an insufficient duration to assess the medication's full impact on **panic attack frequency**. *Maximum benefit is usually achieved within 2-4 weeks of starting treatment* - While side effects often subside by this time, and some initial relief from **generalized anxiety** may occur, maximal **antipanic effects** are rarely observed within the first month. - This timeframe is typically too short for the significant **neuroadaptive changes** required to fully mitigate panic attacks. *Panic attacks should resolve within 1 week if the medication is going to be effective* - **SSRIs** have a **delayed onset of action**, requiring several weeks for **neuroreceptor downregulation** and downstream signaling changes to achieve therapeutic effects. - Expecting resolution of **panic attacks** within 1 week is clinically unrealistic and may lead to premature conclusions about **treatment ineffectiveness**. *Response should be evident within 6 weeks; if not, the medication is unlikely to be effective* - While some improvement in **panic symptoms** may be observed by 6 weeks, this is not the definitive timeframe for determining **treatment failure** in panic disorder. - Many patients require **dose optimization** and a full course of at least 8-12 weeks before evaluating the efficacy of the **pharmacotherapy**. *Improvement in panic attacks parallels improvement in general anxiety, typically within 2-3 weeks* - **Anticipatory anxiety** (the patient's 'anticipatory anxiety reduction') often improves earlier than the actual **paroxysmal panic attacks**. - The **neurobiological pathways** involved in acute panic are distinct and generally take longer to stabilize under **serotonergic modulation** compared to generalized anxiety.

Question 18: A 41-year-old accountant presents with a 6-month history of excessive worry about work performance, family health, and finances. She reports constant muscle tension, difficulty concentrating, irritability, and poor sleep. She avoids social situations due to worry about being judged. Her GAD-7 score is 16. Which feature most clearly distinguishes generalised anxiety disorder from social anxiety disorder in this presentation?

A. The presence of muscle tension and difficulty concentrating
B. The 6-month duration of symptoms
C. The excessive worry extending across multiple domains rather than being limited to social evaluation (Correct Answer)
D. The GAD-7 score of 16 indicating moderate to severe anxiety
E. The presence of sleep disturbance and irritability

Explanation: ***The excessive worry extending across multiple domains rather than being limited to social evaluation***- The hallmark of **Generalized Anxiety Disorder (GAD)** is pervasive, "free-floating" anxiety regarding various aspects of life, such as **work, health, and finances**, rather than a single specific trigger.- In contrast, **Social Anxiety Disorder** is strictly characterized by a fear of **scrutiny** or **negative evaluation** by others in social or performance-based situations.*The presence of muscle tension and difficulty concentrating*- These are **somatic and cognitive symptoms** commonly found in GAD but are not unique enough to rule out other anxiety disorders.- While they support a diagnosis of GAD, they do not help distinguish it from the specific focus on social evaluation seen in Social Anxiety Disorder.*The 6-month duration of symptoms*- A **6-month duration** is a core diagnostic criterion for GAD according to the **DSM-5**, but it is also common for Social Anxiety Disorder to be chronic.- Mentioning the timeline confirms the chronicity required for diagnosis but does not differentiate between the **themes of the worries**.*The GAD-7 score of 16 indicating moderate to severe anxiety*- The **GAD-7** is a screening tool used to measure the **severity** of anxiety symptoms rather than to provide a definitive differential diagnosis.- A high score indicates significant clinical impairment but does not specify whether the etiology is generalized or social in nature.*The presence of sleep disturbance and irritability*- These symptoms are part of the **diagnostic criteria** for GAD but are frequently associated with various other stress and mood disorders.- They represent the **physiological arousal** of anxiety but do not clarify the primary focus of the patient's apprehension or fear.

Question 19: A 54-year-old woman presents with a 7-week history of low mood, anhedonia, poor concentration, and insomnia. She has lost 5kg in weight and feels she is a burden to her family. She has no past psychiatric history. Her PHQ-9 score is 22. Physical examination and routine blood tests are normal. According to ICD-10 criteria, what is the minimum number of total symptoms (core and additional) required to diagnose a severe depressive episode?

A. At least 6 symptoms including all 3 core symptoms
B. At least 7 symptoms including all 3 core symptoms
C. At least 8 symptoms including all 3 core symptoms (Correct Answer)
D. At least 5 symptoms including at least 2 core symptoms
E. At least 9 symptoms including all 3 core symptoms

Explanation: ***At least 8 symptoms including all 3 core symptoms*** - Under **ICD-10 criteria**, a **severe depressive episode** mandates the presence of all three **core symptoms**: depressed mood, anhedonia (loss of interest or pleasure), and decreased energy or increased fatigability. - In addition to these three core symptoms, a minimum of **five additional symptoms** from the standard list of depressive features must be present, totaling at least **eight symptoms** for diagnosis. *At least 6 symptoms including all 3 core symptoms* - This criterion typically describes a **moderate depressive episode** under **ICD-10**, which requires at least two core symptoms and a total of six or more symptoms, or all three core symptoms and three or more additional symptoms. - It does not meet the specified minimum symptom count for a **severe depressive episode**. *At least 7 symptoms including all 3 core symptoms* - While seven symptoms indicate significant distress and likely a **moderate to severe** presentation, **ICD-10** specifically requires a minimum of **eight symptoms** including all three core symptoms for a diagnosis of severe depression. - This threshold is often considered the higher end of a **moderate depressive episode** or just below the minimum for severe. *At least 5 symptoms including at least 2 core symptoms* - This symptom count aligns with the **ICD-10 criteria** for a **mild depressive episode**, which requires at least two core symptoms and a total of four to five symptoms. - It is insufficient for diagnosing a **severe depressive episode**, which demands a higher number and intensity of symptoms. *At least 9 symptoms including all 3 core symptoms* - Although a patient presenting with nine symptoms would unequivocally meet the criteria for a **severe depressive episode**, this option does not represent the **minimum number** required by **ICD-10**. - The established minimum for severe depression is **eight symptoms**, including all three core symptoms.

Question 20: A 44-year-old solicitor presents with a 9-week history of low mood, anhedonia, fatigue, and reduced concentration affecting his work performance. He has no previous psychiatric history. On systematic enquiry, he reports drinking 6-8 units of alcohol daily for the past 3 months to help him sleep. Liver function tests show GGT 185 U/L (normal <50), with other results normal. What is the most appropriate initial approach to management?

A. Start sertraline 50mg daily immediately as he has moderate depression
B. Advise alcohol reduction and reassess mood after 4 weeks of abstinence (Correct Answer)
C. Refer to community alcohol services before addressing mood symptoms
D. Start mirtazapine 30mg at night to address both depression and sleep
E. Admit for inpatient alcohol detoxification before treating depression

Explanation: ***Advise alcohol reduction and reassess mood after 4 weeks of abstinence*** - Alcohol is a **central nervous system depressant** that can cause or exacerbate depressive symptoms; therefore, clarifying the primary diagnosis requires a period of **abstinence** (typically 3-4 weeks). - Clinical guidelines suggest that treating underlying **harmful alcohol use** (evidenced by the elevated **GGT**) often leads to spontaneous improvement in mood symptoms, avoiding unnecessary medication. *Start sertraline 50mg daily immediately as he has moderate depression* - Antidepressants are less effective when used concurrently with active **alcohol misuse**, as ethanol interferes with neurotransmitter regulation and recovery. - It is premature to diagnose a **primary depressive disorder** until the effects of a known depressant (alcohol) have been removed. *Refer to community alcohol services before addressing mood symptoms* - While referral may eventually be needed, the patient is currently engaging with **primary care**, and his intake (42-56 units/week) can often be initially managed with **brief interventions**. - This approach is too narrow, as it ignores the need to monitor and plan for the clinical reassessment of his **mental health** status. *Start mirtazapine 30mg at night to address both depression and sleep* - Using **mirtazapine** for its sedative properties may mask the sleep disturbance without addressing the **alcohol-induced** disruption of sleep architecture. - **Polypharmacy** involving sedating medications and daily alcohol significantly increases the risk of excessive **CNS depression** and respiratory suppression. *Admit for inpatient alcohol detoxification before treating depression* - Inpatient detoxification is generally reserved for patients with high levels of **physical dependence**, severe withdrawal risks, or failed community attempts, which are not indicated here. - The patient's consumption of 6-8 units daily is better managed through **gradual reduction** and community-based support rather than **acute hospitalization**.

Question 21: A 52-year-old man with panic disorder presents to his GP reporting that for the past 3 months, he has been having panic attacks exclusively upon waking from sleep, typically 2-3 hours after falling asleep. He has no daytime attacks. He is otherwise healthy with no sleep apnea or other medical conditions. His nocturnal panic attacks have identical symptoms to his previous daytime attacks. What aspect of nocturnal panic attacks is most important for the GP to understand when counseling this patient?

A. Nocturnal panic attacks suggest an underlying cardiac arrhythmia and require cardiology referral
B. Nocturnal panic attacks are a distinct condition requiring different treatment than daytime panic disorder
C. Nocturnal panic attacks occur during non-REM sleep and are part of panic disorder requiring standard treatment (Correct Answer)
D. Nocturnal panic attacks indicate comorbid sleep disorder and require sleep study
E. Nocturnal panic attacks are always secondary to nightmares and require trauma-focused therapy

Explanation: ***Nocturnal panic attacks occur during non-REM sleep and are part of panic disorder requiring standard treatment***- **Nocturnal panic attacks** are a recognized part of the **Panic Disorder** spectrum, occurring in up to 45% of affected patients, and typically occur during the transition from **Stage 2 to Stage 3 (non-REM) sleep**.- Because they are physiologically consistent with daytime attacks, they respond to identical standard treatments, including **SSRIs** and **Cognitive Behavioral Therapy (CBT)**.*Nocturnal panic attacks suggest an underlying cardiac arrhythmia and require cardiology referral*- While symptoms like palpitations occur, these attacks are identical to the patient's previous **psychological panic attacks**, making a primary **cardiac arrhythmia** unlikely in an otherwise healthy patient.- A referral is not routinely indicated unless there are specific clinical red flags for **structural heart disease** or specific EKG abnormalities.*Nocturnal panic attacks are a distinct condition requiring different treatment than daytime panic disorder*- Clinical evidence suggests that individuals with nocturnal attacks have similar **comorbidity profiles** and treatment responses as those with only daytime symptoms.- They are categorized under the same **DSM-5 criteria** for Panic Disorder and do not necessitate a specialized pharmacological protocol.*Nocturnal panic attacks indicate comorbid sleep disorder and require sleep study*- **Polysomnography** is generally reserved for patients showing signs of **Obstructive Sleep Apnea (OSA)** or specific movement disorders, which this patient does not have.- The absence of snoring, apneas, or daytime sleepiness helps differentiate simple nocturnal panic from **primary sleep disorders**.*Nocturnal panic attacks are always secondary to nightmares and require trauma-focused therapy*- Unlike **nightmares** or **night terrors**, which occur during REM sleep or Stage 4 sleep respectively, nocturnal panic attacks occur without a dream trigger.- **Trauma-focused therapy** is indicated for PTSD-related nightmares, but the spontaneous nature of panic attacks requires standard **CBT for Panic Disorder**.

Question 22: A 36-year-old woman with moderate depression has been taking citalopram 20mg daily for 5 weeks. She reports some improvement in energy levels and sleep, but low mood and anhedonia persist. She asks whether she should increase the dose or try a different medication. What is the most appropriate response based on evidence-based guidelines?

A. Switch to venlafaxine as she has had inadequate response to an SSRI
B. Increase citalopram to 40mg daily as the current dose may be subtherapeutic
C. Continue citalopram 20mg for at least another 2 weeks before making changes (Correct Answer)
D. Add mirtazapine 15mg to augment the citalopram
E. Switch to sertraline as it may be more effective for her symptoms

Explanation: ***Continue citalopram 20mg for at least another 2 weeks before making changes*** - Evidence-based guidelines (e.g., **NICE**) recommend an adequate trial of **6–8 weeks** at a therapeutic dose before determining a treatment is ineffective. - Since the patient is showing **partial improvement** (energy and sleep) at 5 weeks, maintaining the current dose is appropriate to allow the full therapeutic effect to manifest. *Switch to venlafaxine as she has had inadequate response to an SSRI* - Switching to an **SNRI** like venlafaxine is generally reserved for patients who have failed at least one full **6–8 week trial** of an SSRI. - It is premature to switch classes when the patient is currently experiencing a **positive trajectory** and has not reached the minimum trial duration. *Increase citalopram to 40mg daily as the current dose may be subtherapeutic* - **Citalopram 20mg** is a standard therapeutic dose; increasing it before the 8-week mark may unnecessarily increase the risk of **dose-dependent side effects** such as **QT prolongation**. - Dose escalation is typically considered only after an adequate time trial shows a **stall in progress** or insufficient response. *Add mirtazapine 15mg to augment the citalopram* - **Augmentation strategies** are secondary steps in treatment-resistant depression protocols, usually occurring after several failed monotherapy trials. - Introducing a second agent at this stage significantly increases the **pill burden** and risk of adverse effects without a proven need. *Switch to sertraline as it may be more effective for her symptoms* - Switching from one **SSRI** to another is a valid strategy for non-responders, but this patient is already demonstrating a **partial response**. - Changing medications now resets the **latency period** for clinical effect, potentially delaying the patient's recovery process.

Question 23: A 48-year-old woman with severe depression and prominent psychomotor retardation has been on optimal doses of fluoxetine for 8 weeks and subsequently venlafaxine for 10 weeks, with no significant improvement. Augmentation with lithium and then quetiapine has been tried without success. She has lost 8kg in weight and is drinking minimal fluids. Her psychiatrist recommends electroconvulsive therapy (ECT). What is the most likely clinical reason ECT is being considered at this stage?

A. ECT is always indicated after two failed antidepressant trials
B. The severe depression with life-threatening physical decline requires rapid intervention (Correct Answer)
C. ECT is first-line treatment for depression with psychomotor retardation
D. The patient has not responded to augmentation strategies so ECT is the only remaining option
E. Psychomotor symptoms respond better to ECT than to pharmacotherapy

Explanation: ***The severe depression with life-threatening physical decline requires rapid intervention*** - **Electroconvulsive therapy (ECT)** is indicated as a first-line or urgent intervention when depression results in **life-threatening physical decline**, such as severe **dehydration** and significant **weight loss**. - ECT provides the **fastest onset of action** and highest response rates (70-90%) for patients residing in a critical state where pharmacotherapy would take too long to work. *ECT is always indicated after two failed antidepressant trials* - While treatment-resistant depression (TRD) is an indication, there is no rule that ECT is **"always"** indicated; it depends on the **severity**, clinical context, and patient preference. - Guidelines suggest considering it after multiple failures, but the immediate priority here is the **medical urgency**, not just the number of failed trials. *ECT is first-line treatment for depression with psychomotor retardation* - Pharmacotherapy remains the standard **first-line treatment** for most depressive presentations regardless of the presence of psychomotor retardation. - ECT is typically reserved for cases where there is **treatment resistance**, **psychotic features**, **catatonia**, or an immediate **risk to life**. *The patient has not responded to augmentation strategies so ECT is the only remaining option* - Other pharmacological options like **MAOIs**, alternative augmentation, or switching to different classes (e.g., tricyclics) remain, so ECT is not the **exclusive** remaining choice. - The decision for ECT is driven by the **clinical urgency** of her physical state rather than the exhaustion of every possible drug combination. *Psychomotor symptoms respond better to ECT than to pharmacotherapy* - While it is true that **psychomotor retardation** and **catatonic features** show high sensitivity to ECT, this pharmacological comparison is not the primary reason for its use here. - The recommendation is based on the need for a **rapid response** to prevent further physical deterioration from her **minimal fluid intake**.

Question 24: A 29-year-old man presents with panic disorder and reports that his panic attacks are always triggered by being in crowded places like supermarkets or public transport. Between attacks, he experiences persistent anticipatory anxiety about these situations. He has started avoiding shopping and using buses. What is the most accurate description of his clinical presentation?

A. Panic disorder with agoraphobia (Correct Answer)
B. Agoraphobia without panic disorder
C. Social anxiety disorder with panic attacks
D. Situationally-bound panic attacks indicating specific phobia
E. Panic disorder with situational triggers only

Explanation: ***Panic disorder with agoraphobia*** - The patient experiences recurrent **panic attacks** and persistent **anticipatory anxiety**, indicative of panic disorder. - The **avoidance of crowded places** like supermarkets and public transport, fearing panic symptoms where escape is difficult, is a hallmark of **agoraphobia**. *Agoraphobia without panic disorder* - This diagnosis is used when agoraphobia occurs in the absence of a history of **panic attacks**, which is not the case for this patient. - The patient clearly reports experiencing **panic attacks**, making this option inaccurate. *Social anxiety disorder with panic attacks* - **Social anxiety disorder** is characterized by a fear of **negative evaluation** in social situations, whereas this patient's primary fear is of having a **panic attack** itself. - His avoidance is driven by the potential for panic symptoms, not by fear of judgment from others. *Situationally-bound panic attacks indicating specific phobia* - While the attacks are situationally bound, **specific phobias** involve a much more circumscribed fear of a particular object or situation, not the broad pattern of **agoraphobic avoidance**. - The pervasive avoidance across multiple distinct public environments and the presence of **panic disorder** rule out a simple specific phobia. *Panic disorder with situational triggers only* - This option does not fully capture the clinical picture, as the patient also exhibits significant **agoraphobic avoidance** and **anticipatory anxiety** related to these situations. - The development of **agoraphobia** is a distinct and crucial component of his presentation, extending beyond mere situational triggers.

Question 25: According to the ICD-10 diagnostic criteria, what is the minimum number of symptoms required from the list of cognitive and somatic symptoms to diagnose a depressive episode, assuming both core symptoms are present?

A. At least 2 additional symptoms for mild, 3 for moderate, and 4 for severe (Correct Answer)
B. At least 2 additional symptoms regardless of severity
C. At least 3 additional symptoms for mild, 4 for moderate, and 5 for severe
D. At least 4 additional symptoms regardless of severity
E. At least 1 additional symptom for mild, 2 for moderate, and 3 for severe

Explanation: ***At least 2 additional symptoms for mild, 3 for moderate, and 4 for severe*** - In **ICD-10**, the diagnosis of a depressive episode requires a combination of **core symptoms** (mood, anhedonia, energy) and **additional symptoms** (e.g., sleep, guilt, concentration). - To reach the diagnostic threshold, a **mild episode** requires 2 core + 2 additional (total 4), a **moderate episode** requires 2 core + 3-4 additional (total 6), and a **severe episode** requires 3 core + 4 or more additional (total 7+). *At least 2 additional symptoms regardless of severity* - This violates the tiered **severity classification** used in the ICD-10, which scales symptoms based on the intensity of the clinical presentation. - While 2 additional symptoms satisfy the criteria for a **mild episode**, they are insufficient for categorizing **moderate or severe** depression. *At least 3 additional symptoms for mild, 4 for moderate, and 5 for severe* - This overestimates the requirements for a **mild depressive episode**, which only requires a minimum of **two additional symptoms** alongside two core symptoms. - This scale shifts the threshold higher than what is clinically defined in the **ICD-10 Blue Book** criteria. *At least 4 additional symptoms regardless of severity* - Using a fixed number of additional symptoms ignores the **diagnostic hierarchy** and fails to differentiate between levels of **functional impairment**. - A requirement of 4 additional symptoms would exclude patients who clinically present with **mild depression**, leading to under-diagnosis. *At least 1 additional symptom for mild, 2 for moderate, and 3 for severe* - These thresholds are too low; a **mild depressive episode** must have a total of at least **four symptoms** in total to meet diagnostic standards. - Using these criteria would lead to the **over-diagnosis** of depression by including patients with transient or normal sadness that does not meet the clinical duration or symptom count.

Question 26: A 33-year-old woman with panic disorder has been taking paroxetine 40mg daily for 9 months with excellent response. She has had no panic attacks for 6 months and has successfully overcome her agoraphobic avoidance. She now wishes to conceive and is concerned about medication risks in pregnancy. What is the most appropriate management regarding her paroxetine?

A. Continue paroxetine as the risk of relapse outweighs teratogenic risk
B. Switch to sertraline as it has a better safety profile in pregnancy (Correct Answer)
C. Gradually discontinue paroxetine and remain off medication during pregnancy
D. Continue paroxetine in first trimester then switch to sertraline in second trimester
E. Stop paroxetine immediately and commence propranolol

Explanation: ***Switch to sertraline as it has a better safety profile in pregnancy*** - **Paroxetine** is specifically avoided in women planning pregnancy due to an increased risk of **congenital heart defects** (such as ventricular septal defects) during the first trimester. - **Sertraline** is often the preferred SSRI during pregnancy and breastfeeding because it has a **well-established safety profile** and lower rates of placental transfer. *Continue paroxetine as the risk of relapse outweighs teratogenic risk* - While preventing relapse is critical, paroxetine's specific association with **fetal malformations** makes it less desirable than other SSRIs with better safety data. - Since the patient is in the **pre-conception planning** phase, there is an ideal window to switch to a safer alternative like **sertraline** or fluoxetine. *Gradually discontinue paroxetine and remain off medication during pregnancy* - This patient has a history of **panic disorder with agoraphobia**, which carries a high risk of **relapse** during the physiological and psychological stress of pregnancy. - Untreated maternal mental illness is associated with poor neonatal outcomes, making **maintenance therapy** with a safer medication preferable to total discontinuation. *Continue paroxetine in first trimester then switch to sertraline in second trimester* - This approach is incorrect because the **first trimester** is the period of organogenesis when the teratogenic risk of paroxetine is most significant. - Switching mid-pregnancy unnecessarily exposes the fetus to **multiple different medications**, which is generally avoided in perinatal pharmacology. *Stop paroxetine immediately and commence propranolol* - **Propranolol** is used to manage physical symptoms of anxiety but is not an effective primary treatment for maintaining remission in **panic disorder**. - Stopping paroxetine abruptly can cause **discontinuation syndrome** (especially likely with paroxetine due to its short half-life) and rapid symptom recurrence.

Question 27: A 41-year-old teacher with a 9-month history of generalised anxiety disorder has completed 16 weeks of high-intensity CBT with good engagement but minimal symptom improvement. She has tried sertraline 200mg daily for 12 weeks (maximum tolerated dose due to gastrointestinal side effects) with no response. She continues to experience severe anxiety affecting her work performance. What is the most appropriate next pharmacological step?

A. Switch to venlafaxine 75mg daily and titrate
B. Add pregabalin 150mg twice daily to sertraline
C. Switch to mirtazapine 30mg at night
D. Add quetiapine 50mg at night to sertraline
E. Switch to duloxetine 60mg daily (Correct Answer)

Explanation: ***Switch to duloxetine 60mg daily*** - Per **NICE guidelines**, if a patient with **Generalized Anxiety Disorder (GAD)** fails to respond to an SSRI (like sertraline), the next recommended step is switching to an **SNRI** such as duloxetine. - **Duloxetine 60mg** is an effective starting dose and offers a straightforward trial since the patient has already completed adequate **high-intensity CBT** and maximum-dose SSRI therapy. *Switch to venlafaxine 75mg daily and titrate* - While **venlafaxine** is also an SNRI recommended for GAD, the starting dose of 75mg often requires **careful titration** to reach an effective therapeutic range compared to duloxetine. - It is a valid alternative, but typically considered alongside or after other SNRI options depending on the clinical profile. *Add pregabalin 150mg twice daily to sertraline* - **Pregabalin** is used if SSRIs and SNRIs are not tolerated or are contraindicated, rather than as a primary augmentation for a partial SSRI failure. - Switching to a different class of mainline antidepressants (SNRI) is prioritized over **augmentation** after only one failed medication trial. *Switch to mirtazapine 30mg at night* - **Mirtazapine** is not considered a first-line pharmacological treatment for GAD according to evidence-based guidelines. - It is more commonly utilized for **Major Depressive Disorder**, particularly when insomnia or weight loss are concurrent symptoms. *Add quetiapine 50mg at night to sertraline* - **Atypical antipsychotics** like quetiapine are generally reserved for highly treatment-resistant cases under **specialist supervision**. - NICE guidelines do not support routine augmentation with quetiapine for GAD until multiple standard monotherapies have been exhausted.

Question 28: A 57-year-old woman presents with an 8-week history of low mood, anhedonia, fatigue, and weight loss. She also reports subjective memory problems and difficulty making simple decisions. Her daughter mentions she has become increasingly withdrawn. The patient expresses concern that she has early-onset dementia. Cognitive screening with MMSE scores 28/30. What feature of her presentation most strongly suggests a depressive disorder rather than a neurodegenerative condition?

A. The relatively short duration of symptoms (8 weeks)
B. The presence of anhedonia and low mood
C. The pattern of cognitive complaints being subjective with preserved objective testing (Correct Answer)
D. The presence of weight loss
E. The social withdrawal reported by family

Explanation: ***The pattern of cognitive complaints being subjective with preserved objective testing*** - In **pseudodementia** (depression-related cognitive impairment), patients are often **highly distressed** and vocal about their memory loss, while **objective testing** (like the MMSE score of 28/30) remains largely normal. - Conversely, patients with **neurodegenerative dementia** typically lack insight into their deficits (**anosognosia**) and attempt to minimize or hide cognitive failures that are evident on objective screening. *The relatively short duration of symptoms (8 weeks)* - While an **acute/subacute onset** favors depression, some neurodegenerative conditions like **Creutzfeldt-Jakob disease** or rapidly progressive dementias can present within short timeframes. - Duration alone is less specific than the discrepancy between **subjective distress** and **objective performance** in distinguishing the two. *The presence of anhedonia and low mood* - Although these are core symptoms of **Major Depressive Disorder**, they frequently occur as **comorbidities** or prodromal symptoms in the early stages of dementia. - The presence of mood symptoms does not rule out a neurodegenerative process, making it a weaker discriminator than the **cognitive testing pattern**. *The presence of weight loss* - **Weight loss** is a non-specific biological symptom that occurs in severe depression but is also common in various dementias due to **forgetting to eat** or metabolic changes. - Because it is a feature of both systemic illness and psychiatric disorders, it cannot reliably differentiate between **pseudodementia** and true dementia. *The social withdrawal reported by family* - **Social withdrawal** is common in depression due to **anergy** and lack of interest, but it is also a hallmark of **frontotemporal dementia** or early Alzheimer's as patients struggle with social cues. - Since both conditions result in the patient becoming increasingly withdrawn, this feature lacks the **diagnostic specificity** provided by formal cognitive screening.

Question 29: A 39-year-old man with panic disorder has been taking escitalopram 10mg daily for 6 weeks. He reports a 40% reduction in panic attack frequency but still experiences 3-4 attacks per week. He tolerates the medication well with no significant side effects. His cognitions remain dominated by catastrophic interpretations of bodily sensations. What is the most appropriate next step in management?

A. Increase escitalopram to 20mg daily (Correct Answer)
B. Add propranolol 40mg three times daily
C. Switch to venlafaxine 75mg daily
D. Add low-dose quetiapine 25mg at night
E. Continue current dose and add diazepam 2mg as required

Explanation: ***Increase escitalopram to 20mg daily***- The patient has shown a **partial response** (40% reduction) after an adequate trial of 6 weeks, and since he **tolerates the medication well**, dose escalation to the maximum licensed dose is the priority.- **Panic disorder** often requires higher SSRI doses for full remission; optimizing the current first-line agent is the most appropriate next step before switching or augmenting.*Add propranolol 40mg three times daily*- This primarily targets **autonomic physical symptoms** (like palpitations) but does not treat the underlying **panic disorder** core pathology or catastrophic cognitions.- It is not considered a first-line treatment or a standard augmentation strategy for achieving **remission** in panic disorder.*Switch to venlafaxine 75mg daily*- Switching to an **SNRI** like venlafaxine is only indicated after a patient has failed to respond to a **full therapeutic dose** of an SSRI.- Moving to a different class prematurely is discouraged when the patient is currently tolerating the SSRI and showing some clinical benefit.*Add low-dose quetiapine 25mg at night*- **Atypical antipsychotics** are not first-line or second-line treatments for panic disorder and should be reserved for **treatment-resistant** cases.- Quetiapine carries a risk of metabolic side effects and is not warranted given that the primary SSRI has not yet been **dose-optimized**.*Continue current dose and add diazepam 2mg as required*- **Benzodiazepines** are generally avoided for long-term management due to the risk of **dependence** and withdrawal complications.- Use of "as-required" diazepam can act as a **safety behavior**, which may reinforce the patient's catastrophic interpretations and hinder the effectiveness of cognitive interventions.

Question 30: A 43-year-old woman with recurrent depressive disorder has been taking citalopram 40mg daily for 14 months following her third depressive episode. She has been in full remission for 10 months with no residual symptoms. She asks about stopping her antidepressant. According to evidence-based guidelines, what is the most appropriate recommendation regarding continuation of treatment?

A. Continue citalopram for at least another 10 months as she has had multiple episodes (Correct Answer)
B. Gradually reduce and stop citalopram over 4 weeks as she has been well for 10 months
C. Switch to a lower dose of 20mg and continue indefinitely
D. Continue citalopram indefinitely as she has had three episodes
E. Stop citalopram immediately as the risk of relapse is now minimal

Explanation: ***Continue citalopram for at least another 10 months as she has had multiple episodes*** - For patients with **Recurrent Depressive Disorder** (three or more episodes), clinical guidelines like **NICE** recommend continuing antidepressant therapy for at least **2 years**. - Since she has completed 14 months of treatment, she requires at least another 10 months to fulfill the recommended duration for **relapse prevention**. *Gradually reduce and stop citalopram over 4 weeks as she has been well for 10 months* - While a 6-9 month continuation is standard for a single episode, **recurrent episodes** carry a much higher risk of relapse, necessitating longer-term therapy. - Stopping after only 10 months of remission in a patient with three episodes significantly increases the risk of a **depressive relapse**. *Switch to a lower dose of 20mg and continue indefinitely* - Maintenance therapy should generally be conducted at the **full therapeutic dose** that achieved remission, rather than a sub-therapeutic "maintenance" dose. - Lowering the dose prematurely (before the 2-year mark) does not provide the evidence-based **prophylactic effect** needed for recurrent depression. *Continue citalopram indefinitely as she has had three episodes* - While indefinite treatment is an option for some high-risk patients, guidelines prioritize a **review after 2 years** rather than an automatic lifetime prescription. - The immediate recommendation is to complete the 2-year course before reassessing the need for **lifelong maintenance** based on patient preference and risk factors. *Stop citalopram immediately as the risk of relapse is now minimal* - Abrupt cessation is contraindicated as it can cause **antidepressant discontinuation syndrome**, characterized by flu-like symptoms and irritability. - The risk of relapse remains high in the **first year** of remission for patients with a history of multiple depressive episodes.

Question 31: A 26-year-old woman presents to the emergency department with her second panic attack in 3 weeks. During the attack, she experienced sudden onset palpitations, sweating, trembling, shortness of breath, and intense fear of dying. The episode lasted approximately 15 minutes. ECG, troponin, and chest X-ray are normal. She is extremely worried about having further attacks. What is the most appropriate advice regarding immediate management?

A. Reassure that panic attacks are self-limiting and arrange GP follow-up within 1 week (Correct Answer)
B. Admit for 24-hour cardiac monitoring
C. Prescribe alprazolam 0.5mg to take during panic attacks
D. Commence propranolol 40mg three times daily
E. Refer urgently to cardiology for exercise stress testing

Explanation: ***Reassure that panic attacks are self-limiting and arrange GP follow-up within 1 week***- After excluding organic causes with normal **ECG, troponin**, and **chest X-ray**, immediate management focuses on **reassurance** that the symptoms are non-life-threatening and self-limiting.- **Timely GP follow-up** is essential to establish a long-term management plan, which typically includes **Cognitive Behavioral Therapy (CBT)** or **SSRIs** for panic disorder.*Admit for 24-hour cardiac monitoring*- The patient's acute cardiac workup was normal, making **24-hour cardiac monitoring** unnecessary and potentially counterproductive by fueling **health anxiety**.- This intervention is reserved for suspected cardiac arrhythmias or conditions not ruled out by initial tests, which is not the case here.*Prescribe alprazolam 0.5mg to take during panic attacks*- **Benzodiazepines** like alprazolam are generally discouraged for routine management due to the risk of **dependence** and the potential to interfere with effective psychological therapies.- Relying on medication can prevent the patient from developing **coping strategies** and may reinforce the idea that panic attacks are dangerous and require immediate pharmacological intervention.*Commence propranolol 40mg three times daily*- **Beta-blockers** such as propranolol can alleviate some physical symptoms of anxiety like **palpitations** and **tremors**, but they do not treat the core psychological aspects of panic disorder.- They are not considered first-line agents for panic disorder; **SSRIs** and **CBT** are the primary recommended treatments.*Refer urgently to cardiology for exercise stress testing*- Given the normal initial cardiac evaluations and a clear presentation of panic attacks, an **urgent cardiology referral** for exercise stress testing is unwarranted.- This could unnecessarily increase the patient's **anxiety about their heart** and delay the initiation of appropriate mental health treatment.

Question 32: A 34-year-old man with generalised anxiety disorder presents with a 6-month history of excessive worry about work performance, finances, and family health. He reports constant muscle tension, difficulty concentrating, and irritability. He has tried cognitive behavioural therapy for 10 weeks with minimal improvement. He has no significant past medical history and takes no regular medications. What is the most appropriate pharmacological intervention?

A. Propranolol 40mg three times daily
B. Diazepam 5mg twice daily for 2 weeks
C. Sertraline 50mg once daily (Correct Answer)
D. Buspirone 10mg three times daily
E. Pregabalin 150mg twice daily

Explanation: ***Sertraline 50mg once daily*** - **Selective Serotonin Reuptake Inhibitors (SSRIs)** like sertraline are the **first-line pharmacological treatment** for Generalized Anxiety Disorder (GAD), especially when cognitive behavioral therapy (CBT) has shown minimal improvement. - Sertraline effectively addresses the **chronic excessive worry**, muscle tension, and difficulty concentrating, which are core symptoms of GAD, making it the most appropriate long-term intervention. *Propranolol 40mg three times daily* - **Propranolol**, a beta-blocker, is effective for managing **autonomic symptoms of anxiety** such as palpitations, tremor, and sweating, but it does not treat the cognitive aspects of worry and tension in GAD. - It is typically used for **situational anxiety** or as an adjunct for specific somatic symptoms, not as a primary monotherapy for the overall disorder. *Diazepam 5mg twice daily for 2 weeks* - **Benzodiazepines** like diazepam are useful for **short-term, acute anxiety relief** due to their rapid onset of action, but they carry a high risk of **dependence, tolerance, and withdrawal symptoms** with prolonged use. - They are not recommended for long-term management of chronic GAD, especially for a 6-month history, and should be limited to very brief durations (2-4 weeks) if used at all. *Buspirone 10mg three times daily* - **Buspirone** is a non-benzodiazepine anxiolytic that can be used for GAD, but its **onset of action is delayed** (often 2-4 weeks) and its efficacy is generally considered less robust than SSRIs. - It is often reserved as a **second-line agent** for GAD, particularly in patients who cannot tolerate or do not respond to SSRIs/SNRIs. *Pregabalin 150mg twice daily* - **Pregabalin** is an effective treatment for GAD but is typically considered a **second-line or alternative treatment** for patients who have not responded to or tolerated SSRIs or SNRIs. - It is also associated with potential side effects such as **sedation and dizziness**, and has a risk of **misuse and dependence**, making it less ideal as a first-line choice.

Question 33: A 51-year-old woman presents to her GP with a 7-week history of low mood, reduced concentration, and disturbed sleep. She reports loss of appetite with 4kg weight loss. She describes feeling guilty about minor past events and has thoughts that life is not worth living, though no active suicidal plans. Her PHQ-9 score is 18. Physical examination and blood tests including thyroid function are normal. What is the most appropriate initial management?

A. Start fluoxetine 20mg daily and arrange review in 2 weeks (Correct Answer)
B. Refer urgently to the community mental health team
C. Prescribe a 2-week course of zopiclone for sleep disturbance
D. Recommend self-help materials and review in 4 weeks
E. Start mirtazapine 15mg at night and arrange review in 1 week

Explanation: ***Start fluoxetine 20mg daily and arrange review in 2 weeks*** - A **PHQ-9 score of 18** indicates **moderate to severe depression**, for which NICE guidelines recommend starting a first-line antidepressant like a **Selective Serotonin Reuptake Inhibitor (SSRI)** such as fluoxetine. - Reviewing the patient in **2 weeks** is the standard safety protocol to monitor for early side effects and assess for any increases in **suicidal ideation** following the initiation of treatment. *Refer urgently to the community mental health team* - Urgent referral is reserved for patients at **immediate risk** of self-harm, active suicidal plans, or those demonstrating **psychotic symptoms**. - This patient reports only **passive suicidal ideation** without active plans, making initial primary care management with close monitoring appropriate. *Prescribe a 2-week course of zopiclone for sleep disturbance* - **Zopiclone** is a hypnotic agent that treats a symptom (insomnia) but does not address the **underlying depressive episode**, which is the primary cause of the sleep disturbance. - Use of **Z-drugs** should be restricted due to the high risk of **dependency** and tolerance, especially when the core mood disorder remains untreated. *Recommend self-help materials and review in 4 weeks* - Guided **self-help** or watchful waiting is typically reserved for **subthreshold or mild depression** (PHQ-9 scores below 10-15). - Given the **biological symptoms** (weight loss, sleep disturbance) and severity (PHQ-9 18), relying solely on self-help would be inadequate management. *Start mirtazapine 15mg at night and arrange review in 1 week* - While **mirtazapine** is an effective antidepressant and can assist with sleep and appetite, **SSRIs** are generally preferred as first-line therapy due to their superior safety profile and tolerability for initial treatment. - A **one-week review** is usually reserved for patients under 25 or those identified as high-risk for specific reasons, whereas two weeks is a standard initial review for this demographic.

Question 34: A 47-year-old man presents with a 12-week history of low mood, anhedonia, fatigue, poor concentration, and insomnia with early morning wakening. He has lost interest in previously enjoyed activities and describes feeling hopeless about the future. His PHQ-9 score is 22. He works as a bus driver and mentions he has been having occasional thoughts that life is not worth living, but denies any suicidal plans or intent. He has no past psychiatric history. What is the most important initial assessment that must be completed before considering treatment options?

A. Full cardiovascular assessment including exercise ECG due to his occupation
B. Thyroid function tests to exclude organic causes
C. Cognitive assessment to exclude early dementia
D. Comprehensive suicide risk assessment (Correct Answer)
E. Assessment for bipolar disorder through detailed mood history

Explanation: ***Comprehensive suicide risk assessment*** - The patient's **low mood**, **anhedonia**, **hopelessness**, and reported **thoughts that life is not worth living** (passive suicidal ideation) necessitate an immediate and thorough assessment of **suicide risk**. - A PHQ-9 score of 22 indicates **severe depression**, which is a significant risk factor, making patient safety the **highest priority** before any other diagnostic or treatment steps. *Full cardiovascular assessment including exercise ECG due to his occupation* - While his occupation as a **bus driver** implies a responsibility for public safety, a cardiovascular assessment is **not the most urgent initial step** compared to addressing immediate mental health risks. - This assessment would be more relevant later, especially if considering certain **antidepressants** that can affect cardiac function, but not as the first step for suicidal ideation. *Thyroid function tests to exclude organic causes* - **Thyroid dysfunction** can mimic depressive symptoms and is part of a routine workup for depression to rule out organic causes. - However, excluding a physical cause is secondary to ensuring the patient's **immediate safety** when **suicidal thoughts** are present. *Cognitive assessment to exclude early dementia* - **Poor concentration** and other cognitive complaints are common symptoms of severe depression, sometimes referred to as **pseudodementia**, and are expected given his presentation. - A cognitive assessment is generally considered after addressing acute mood symptoms or in cases with more prominent or persistent **memory deficits** not explained by mood. *Assessment for bipolar disorder through detailed mood history* - It is crucial to screen for **bipolar disorder** before initiating antidepressant monotherapy to prevent **manic or hypomanic switches**, especially as this patient has no past psychiatric history. - Nevertheless, the presence of **suicidal ideation** makes a comprehensive **suicide risk assessment** the absolute first priority to ensure the patient's safety.

Question 35: A 31-year-old woman with a new diagnosis of panic disorder is commenced on escitalopram 5mg daily. On day 4 of treatment, she contacts the surgery reporting that her anxiety has worsened, with increased restlessness and one additional panic attack. She is concerned the medication is making her worse and wants to stop it. What is the most appropriate management advice?

A. Stop escitalopram and switch immediately to propranolol
B. Stop escitalopram and arrange urgent psychiatric assessment
C. Continue escitalopram, provide reassurance about transient initial anxiety increase, and review in one week (Correct Answer)
D. Increase escitalopram dose to 10mg immediately to achieve faster therapeutic effect
E. Stop escitalopram and trial a different SSRI such as sertraline

Explanation: ***Continue escitalopram, provide reassurance about transient initial anxiety increase, and review in one week*** - Initial worsening of anxiety, known as **'jitteriness syndrome'** or **SSRI activation syndrome**, is a common and **transient** side effect occurring within the first **1-2 weeks** of starting SSRIs, especially for anxiety disorders like panic disorder. - Patients need **reassurance** that this effect is temporary and that continued treatment is essential for achieving the full **therapeutic benefits** and long-term symptom control. A **review in one week** is appropriate to monitor progress and reinforce adherence. *Stop escitalopram and switch immediately to propranolol* - **Propranolol** is a beta-blocker primarily used to manage **somatic symptoms** of anxiety (e.g., palpitations, tremor) but is not an effective **first-line monotherapy** for the core symptoms of panic disorder. - Abruptly stopping an SSRI during the initial phase prevents the patient from reaching the **therapeutic window** and misses the opportunity for the medication to become effective. *Stop escitalopram and arrange urgent psychiatric assessment* - The described symptoms (worsened anxiety, restlessness, one additional panic attack) are expected **initial side effects** of SSRIs and do not typically indicate a **psychiatric emergency** or severe deterioration warranting urgent assessment. - Such a response is a predictable pharmacological effect, not necessarily a sign of **suicidal ideation** or severe functional impairment requiring immediate specialist intervention. *Increase escitalopram dose to 10mg immediately to achieve faster therapeutic effect* - Increasing the dose of escitalopram would likely **exacerbate** the initial anxiety, restlessness, and risk of panic attacks, making the side effects even more pronounced and potentially leading to **treatment non-adherence**. - SSRIs for panic disorder are usually started at **very low doses** (e.g., 5mg for escitalopram) precisely to mitigate the **initial activation syndrome** and improve tolerability. *Stop escitalopram and trial a different SSRI such as sertraline* - The **initial activation syndrome** (worsened anxiety, restlessness) is a **class effect** of SSRIs; switching to another SSRI like sertraline would likely induce similar initial side effects. - The issue is not the specific SSRI but the **physiological adjustment** period, which requires patient education and reassurance, not a change in medication at this early stage.

Question 36: A 42-year-old woman with moderate depression has been taking citalopram 40mg daily for 3 months with good response. She has a history of recurrent depression with two previous episodes in the past 5 years. She is now in remission and asks about stopping her medication as she feels well. According to NICE guidelines, what is the recommended minimum duration of continued antidepressant treatment after remission for someone with recurrent depression?

A. 6 months after remission
B. 12 months after remission
C. 24 months after remission (Correct Answer)
D. Continue indefinitely given recurrent episodes
E. Can stop now as she is in remission

Explanation: ***24 months after remission***- For patients with **recurrent depression** (defined as two or more previous episodes plus the current one), **NICE guidelines** recommend continuing antidepressant treatment for at least **2 years** after remission to significantly reduce the risk of relapse.- This patient has a history of two previous episodes, making the current episode her third, thus placing her in the high-risk category for recurrence where extended maintenance is crucial.*6 months after remission*- This duration is typically recommended for individuals experiencing their **first episode of depression** to consolidate recovery and prevent early relapse.- It is considered **insufficient** for patients with a history of recurrent depression due to their significantly higher risk of relapse.*12 months after remission*- While longer than the standard 6 months, this duration is not specifically mandated by **NICE guidelines** for the management of recurrent depressive disorder.- Evidence suggests that a **24-month maintenance period** offers superior protection against relapse in individuals with a history of recurrent episodes compared to 12 months.*Continue indefinitely given recurrent episodes*- **Indefinite continuation** of antidepressants is usually reserved for individuals with a very high frequency of severe relapses, a history of poor response to previous cessation attempts, or when relapse carries significant clinical risk.- While this patient has recurrent depression, indefinite treatment is typically considered after **multiple failed attempts** at discontinuation or for exceptionally severe cases, rather than an initial recommendation for a third episode.*Can stop now as she is in remission*- Stopping antidepressants immediately upon achieving **remission** carries a very high risk of **relapse** due to the underlying neurobiological vulnerabilities in recurrent depression.- Furthermore, abrupt discontinuation can lead to unpleasant **antidepressant discontinuation syndrome**, which can be distressing and mistaken for a relapse.

Question 37: A 39-year-old man with panic disorder presents to the emergency department during an acute panic attack. He describes severe chest tightness, difficulty breathing, tingling in his fingers, and feelings of unreality. His respiratory rate is 28 breaths per minute. He appears distressed and anxious. Observations show: heart rate 110 bpm, blood pressure 145/88 mmHg, oxygen saturations 99% on air. ECG shows sinus tachycardia. Arterial blood gas shows pH 7.48, PaCO2 3.8 kPa, PaO2 13.2 kPa, HCO3 24 mmol/L. What physiological process best explains his paraesthesia and feelings of unreality?

A. Hypoxia due to inadequate ventilation
B. Metabolic alkalosis from excessive CO2 production
C. Respiratory alkalosis from hyperventilation causing decreased cerebral blood flow (Correct Answer)
D. Hypercapnia from respiratory fatigue
E. Lactic acidosis from increased muscle tension

Explanation: ***Respiratory alkalosis from hyperventilation causing decreased cerebral blood flow*** - **Hyperventilation** during a panic attack leads to excessive **CO2 washout**, resulting in **hypocapnia** (PaCO2 3.8 kPa) and **respiratory alkalosis** (pH 7.48). - **Hypocapnia** causes **cerebral vasoconstriction**, reducing blood flow to the brain, which leads to **feelings of unreality**. The alkalosis also decreases **ionized calcium**, causing **paraesthesia**. *Hypoxia due to inadequate ventilation* - The patient is not hypoxic; his **O2 saturations are 99%** and his PaO2 is within the normal range at 13.2 kPa. - Excessive ventilation (RR 28 bpm), rather than inadequate ventilation, is the primary drive during a typical **panic attack**. *Metabolic alkalosis from excessive CO2 production* - **Metabolic alkalosis** is characterized by a high **HCO3** level, whereas this patient has a normal bicarbonate of 24 mmol/L. - Excessive CO2 production would lead to **respiratory acidosis**, not alkalosis, and is not a feature of hyperventilation. *Hypercapnia from respiratory fatigue* - **Hypercapnia** refers to elevated PaCO2 levels, but this patient's PaCO2 is low (3.8 kPa) due to rapid breathing. - Respiratory fatigue usually occurs in chronic or severe end-stage lung disease, which is not consistent with an **acute panic attack** in a young patient. *Lactic acidosis from increased muscle tension* - **Lactic acidosis** would result in a **low pH** (acidosis) and a metabolic gap, which contradicts the alkaline pH of 7.48 found here. - While muscle tension occurs in anxiety, it does not typically generate enough lactic acid to cause systematic **metabolic acidosis** or explain the specific neurological symptoms in this clinical context.

Question 38: A 53-year-old woman with treatment-resistant depression has failed adequate trials of sertraline, venlafaxine, and mirtazapine. She has also completed a course of CBT without benefit. Her psychiatrist plans to start augmentation therapy with lithium added to her current antidepressant. What is the target therapeutic plasma lithium level range for augmentation in depression?

A. 0.2-0.4 mmol/L
B. 0.4-0.6 mmol/L
C. 0.6-1.0 mmol/L (Correct Answer)
D. 1.0-1.2 mmol/L
E. 1.2-1.5 mmol/L

Explanation: ***0.6-1.0 mmol/L*** - This range is the recommended therapeutic target for **lithium augmentation** in **treatment-resistant depression**, aiming to enhance antidepressant effects. - Achieving levels within this window balances efficacy with a reduced risk of **adverse effects**, making it suitable for long-term use in augmentation. *0.2-0.4 mmol/L* - This range is typically considered **sub-therapeutic** for both acute treatment and augmentation, and it is unlikely to provide a significant antidepressant effect. - Such low levels may not adequately modulate the neurotransmitter systems involved in depression, thus failing to improve symptoms. *0.4-0.6 mmol/L* - While sometimes tolerated better by **elderly patients** or those sensitive to side effects, this range is generally below the optimal level for robust augmentation in treatment-resistant depression. - Most clinical guidelines suggest a slightly higher target to achieve a more definitive **therapeutic response** in augmentation strategies. *1.0-1.2 mmol/L* - Levels in this range are typically sought for the **acute treatment of bipolar mania**, not for augmentation in depression, where lower doses are often sufficient. - Using such high levels for augmentation significantly increases the risk of **lithium toxicity** symptoms, such as tremor, nausea, and cognitive impairment, without additional benefit for depression. *1.2-1.5 mmol/L* - These levels are definitively in the **toxic range** for lithium, risking severe adverse effects like ataxia, dysarthria, severe GI upset, and even seizures or cardiac arrhythmias. - Such concentrations are not indicated for depression augmentation and require immediate medical intervention to prevent serious **lithium poisoning**.

Question 39: A 35-year-old woman presents with panic disorder and has been experiencing 4-5 panic attacks per week for the past 3 months. She describes intense fear during attacks with palpitations, trembling, and fear of losing control. She has developed avoidance of crowded places. She has never taken psychotropic medication and is anxious about side effects. After discussion, she agrees to try pharmacological treatment. Which SSRI has the most evidence and is specifically licensed for panic disorder in the UK?

A. Fluoxetine
B. Citalopram
C. Paroxetine (Correct Answer)
D. Sertraline
E. Escitalopram

Explanation: ***Paroxetine*** - **Paroxetine** was one of the first **SSRIs** to receive specific licensing for **panic disorder** in the UK and is supported by a robust evidence base for this indication. - It is known for its high efficacy in reducing the frequency of **panic attacks**, though it is associated with a higher risk of **discontinuation syndrome** due to its short half-life. *Fluoxetine* - While effective for **depression** and **OCD**, **Fluoxetine** is not specifically licensed for the treatment of **panic disorder** in the UK. - Its long half-life may be beneficial for some, but it can initially be more **activating**, potentially worsening acute anxiety symptoms. *Citalopram* - **Citalopram** is widely used for **depression**, but it lacks a specific license for **panic disorder** in the UK. - Caution is required with higher doses due to the risk of **QT interval prolongation**, which necessitates monitoring in certain populations. *Sertraline* - **Sertraline** is licensed for panic disorder and often used as first-line due to its **tolerability**, but the question highlights paroxetine's historical precedence in licensing and evidence. - It is generally preferred in patients with **cardiac comorbidities** but was not the primary focus of early specific licensing for this condition. *Escitalopram* - **Escitalopram** is a licensed and effective treatment for **panic disorder** with a favorable side effect profile. - Although highly effective, it typically carries higher costs and was licensed later than **Paroxetine** for this specific indication.

Question 40: A 49-year-old woman with severe depression and significant suicidal ideation has been started on venlafaxine 75mg daily. She has hypertension, currently well-controlled on ramipril 5mg daily. Before increasing the venlafaxine dose, you review her blood pressure which is 148/94 mmHg on two separate readings. This is elevated compared to her baseline of 125/78 mmHg. What is the most appropriate management of her blood pressure in this context?

A. Stop venlafaxine immediately and switch to mirtazapine
B. Continue venlafaxine at current dose, optimize antihypertensive therapy, and monitor blood pressure closely (Correct Answer)
C. Reduce venlafaxine dose to 37.5mg daily
D. Continue current management as this blood pressure elevation is not clinically significant
E. Switch to fluoxetine which has no effect on blood pressure

Explanation: ***Continue venlafaxine at current dose, optimize antihypertensive therapy, and monitor blood pressure closely***- **Venlafaxine** is an **SNRI** that can cause dose-dependent **hypertension** due to its noradrenergic effects, but given the patient's **severe depression** and **suicidal ideation**, maintaining psychiatric stability is a priority.- Since her blood pressure (148/94 mmHg) is elevated but not in a hypertensive crisis, the safest approach is to **optimize her antihypertensive medication** (e.g., increasing ramipril) to allow for continued antidepressant therapy.*Stop venlafaxine immediately and switch to mirtazapine*- Immediate cessation of an antidepressant in a patient with **suicidal ideation** poses a high risk of acute clinical deterioration and potential **withdrawal symptoms**.- Medication changes should be managed cautiously and are generally reserved for when blood pressure remains **uncontrolled** despite optimization of antihypertensives.*Reduce venlafaxine dose to 37.5mg daily*- A dose reduction would likely lead to **subtherapeutic** levels, which is inappropriate for a patient experiencing **severe depression**.- Reducing the dose does not address the underlying need for blood pressure management if the patient eventually requires dose escalation for **symptom control**.*Continue current management as this blood pressure elevation is not clinically significant*- An increase from 125/78 to 148/94 mmHg is a **clinically significant** rise that increases cardiovascular risk if left unaddressed.- Guidelines mandate **monitoring blood pressure** both before and during venlafaxine treatment, especially before any planned **dose increases**.*Switch to fluoxetine which has no effect on blood pressure*- While **SSRIs** like fluoxetine generally do not affect blood pressure, switching treatments unnecessarily disrupts the therapeutic timeline for a high-risk patient.- There is no guarantee of immediate efficacy with a new agent, making **optimization of current therapy** a more stable clinical choice in the acute phase.

Question 41: A 56-year-old man presents with a 7-month history of excessive, uncontrollable worry about minor matters including finances, his children's wellbeing, and his health, despite having no objective problems in these areas. He reports restlessness, muscle tension, poor concentration, and sleep disturbance. His symptoms occur most days. He has no history of depression or substance misuse. Physical examination is unremarkable. What is the minimum symptom duration required to meet diagnostic criteria for generalised anxiety disorder?

A. 2 weeks
B. 1 month
C. 3 months
D. 6 months (Correct Answer)
E. 12 months

Explanation: ***6 months*** - According to both **ICD-10 and DSM-5** diagnostic criteria, **Generalised Anxiety Disorder (GAD)** requires excessive anxiety and worry to be present for at least **6 months**. - This criteria helps differentiate GAD from **short-term stress reactions** or **adjustment disorders**, ensuring the condition is chronic and persistent. *2 weeks* - A **2-week duration** is the minimum requirement for diagnosing a **Major Depressive Episode**, but it is insufficient for a GAD diagnosis. - Symptoms lasting only two weeks may represent an **acute stress reaction** rather than a long-standing anxiety disorder. *1 month* - **1 month** is the required duration for diagnosing **Panic Disorder** (following an attack) or **Post-Traumatic Stress Disorder (PTSD)**. - For GAD, a one-month history is too brief to meet the clinical threshold for a generalized, pervasive worry pattern. *3 months* - **3 months** is often the timeframe used for **Adjustment Disorder**, where symptoms develop in response to a specific stressor. - While technically a chronic state if it persists, it does not meet the standardized **6-month threshold** required for a definitive GAD diagnosis. *12 months* - A **12-month duration** is not required for GAD; waiting this long would delay diagnosis and necessary clinical intervention. - This period is more commonly associated with certain pediatric diagnoses like **Conduct Disorder** or to define **remission** periods.

Question 42: A 28-year-old woman with moderate depression has been taking fluoxetine 40mg daily for 5 weeks. She reports some improvement in sleep and appetite but continues to have low mood and anhedonia. She asks when she should expect to feel better. What is the most appropriate advice regarding the expected timeframe for full therapeutic response?

A. Maximum benefit typically occurs at 2-4 weeks and she should be at full response now
B. Continue current treatment as full response may take up to 12 weeks (Correct Answer)
C. The lack of significant mood improvement at 5 weeks indicates treatment failure
D. Partial response at 5 weeks is unusual and suggests fluoxetine is not effective
E. Improvement in neurovegetative symptoms like sleep suggests full response is imminent within days

Explanation: ***Continue current treatment as full response may take up to 12 weeks***- While initial signs of efficacy can appear within 2-4 weeks, the **full therapeutic response** for an SSRI like fluoxetine often requires **6-12 weeks** of consistent use.- This patient shows a **partial response** with improved neurovegetative symptoms (sleep/appetite), which is a positive prognostic indicator for eventual **remission of mood** symptoms.*Maximum benefit typically occurs at 2-4 weeks and she should be at full response now*- The **2-4 week window** is usually the time to observe the **onset of action**, not the peak or maximum clinical benefit.- **Neurovegetative symptoms** often improve early, but core emotional symptoms like **anhedonia** take significantly longer to resolve.*The lack of significant mood improvement at 5 weeks indicates treatment failure*- **Treatment failure** is typically defined after a trial of at least **6-8 weeks** at a therapeutic dose; 5 weeks is insufficient time for a definitive assessment.- Fluoxetine has a very **long half-life**, which can sometimes lead to a slightly slower steady-state achievement and clinical response compared to other SSRIs.*Partial response at 5 weeks is unusual and suggests fluoxetine is not effective*- A **partial response** at 5 weeks is actually a common and expected clinical trajectory, suggesting the medication is biologically active.- It provides a basis to **maintain the current dose** rather than declaring it ineffective or switching medications prematurely.*Improvement in neurovegetative symptoms like sleep suggests full response is imminent within days*- Improvement in sleep and appetite indicates the medication is working, but **mood and anhedonia** do not typically follow within a matter of days.- It is essential to manage **patient expectations** to ensure they do not discontinue treatment when mood symptoms do not shift immediately after physical ones.

Question 43: A 32-year-old man with panic disorder has been taking sertraline 100mg daily for 6 weeks. His panic attacks have reduced from daily to twice weekly, but he reports troublesome side effects including delayed ejaculation and reduced libido, which are affecting his relationship. He is keen to continue treatment but wants to address the sexual dysfunction. What is the most appropriate management of his sexual side effects?

A. Add sildenafil to be taken before sexual activity
B. Reduce sertraline dose to 50mg daily
C. Switch to mirtazapine (Correct Answer)
D. Add bupropion to augment current therapy
E. Continue current dose and reassure that side effects will resolve within 2-3 weeks

Explanation: ***Switch to mirtazapine*** - **Mirtazapine** is an effective antidepressant and anxiolytic with a significantly lower propensity for **sexual side effects** compared to SSRIs like sertraline. - Its mechanism involves **alpha-2 adrenergic antagonism** and potent **5-HT2 and 5-HT3 receptor blockade**, which avoids the common serotonergic pathways responsible for sexual dysfunction. *Add sildenafil to be taken before sexual activity* - **Sildenafil** primarily treats **erectile dysfunction (ED)** by improving blood flow, but it does not address **delayed ejaculation** or **reduced libido**, which are the patient's main complaints. - This approach is incomplete and may lead to increased **pill burden** without resolving the core issues of sexual dysfunction in this context. *Reduce sertraline dose to 50mg daily* - While reducing the dose might lessen sexual side effects, the patient is not in full remission from **panic attacks** (still experiencing them twice weekly), so a dose reduction risks a relapse or worsening of his primary disorder. - Maintaining an **effective therapeutic dose** for the panic disorder should take precedence unless other options are exhausted. *Add bupropion to augment current therapy* - **Bupropion** is an antidepressant that can sometimes alleviate SSRI-induced sexual dysfunction, particularly **reduced libido**, but it is generally **contraindicated** in patients with **panic disorder** due to its activating and **pro-adrenergic** effects, which can worsen anxiety or precipitate panic attacks. - It is not routinely recommended for augmentation in **panic disorder** due to this risk and may not be licensed for this indication in all regions. *Continue current dose and reassure that side effects will resolve within 2-3 weeks* - **SSRI-induced sexual dysfunction** is often persistent and **dose-dependent**, typically not resolving spontaneously with continued treatment or over a short period like 2-3 weeks. - Ignoring these significant and distressing side effects can lead to poor **patient adherence** and discontinuation of effective treatment for panic disorder.

Question 44: A 44-year-old woman presents with an 8-week history of low mood, anhedonia, reduced concentration, and feelings of worthlessness. Her PHQ-9 score is 16. She reports passive suicidal ideation but no plans or intent. She has tried self-help strategies without benefit. She mentions that 4 years ago she had a similar episode treated successfully with citalopram 20mg daily, which she took for 8 months before stopping. What is the most appropriate initial management?

A. Refer for computerised CBT and review in 6 weeks
B. Start citalopram 20mg daily with follow-up in 2 weeks (Correct Answer)
C. Start citalopram 10mg daily with follow-up in 2 weeks
D. Arrange urgent psychiatric assessment due to suicidal ideation
E. Offer group CBT and reassess pharmacological options if no improvement

Explanation: ***Start citalopram 20mg daily with follow-up in 2 weeks***- For a patient with **moderate depression** (PHQ-9 score 16) and a history of successful treatment, **antidepressants** are indicated, especially when self-help has failed.- Restarting the **previously effective dose** of citalopram (20mg) is appropriate, and a **two-week follow-up** is mandatory to monitor side effects and **suicidal ideation** in patients under 30 or those with risk factors.*Refer for computerised CBT and review in 6 weeks*- While **computerised CBT** is a low-intensity intervention, it is typically insufficient as a standalone treatment for **moderate depression** when the patient has already failed self-help.- A **six-week review** is too late for a patient starting a new treatment phase or presenting with **passive suicidal ideation**.*Start citalopram 10mg daily with follow-up in 2 weeks*- Although a lower dose might reduce initial side effects, there is no history of **intolerance**, and 20mg was the **proven therapeutic dose** for this specific patient.- Starting at sub-therapeutic levels may **delay clinical improvement** in a patient experiencing significant distress and functional impairment.*Arrange urgent psychiatric assessment due to suicidal ideation*- **Passive suicidal ideation** without specific plans, intent, or access to means does not meet the criteria for **urgent secondary care referral**.- Management can safely occur in **primary care** unless risk escalates or the patient becomes unresponsive to standard treatments.*Offer group CBT and reassess pharmacological options if no improvement*- NICE guidelines suggest that for **moderate depression**, medication should be offered either alone or in combination with high-intensity psychological interventions, rather than delaying it.- Given her **past positive response** to medication, delaying pharmacological treatment would likely prolong her current **depressive episode** unnecessarily.

Question 45: A 37-year-old woman presents with a 4-month history of recurrent panic attacks. She describes sudden episodes of breathlessness, palpitations, and fear of dying that peak within minutes and last approximately 20 minutes. Between attacks, she worries constantly about having another attack while driving, and has stopped using motorways. She has no past psychiatric history. Physical examination and ECG are normal. What is the most appropriate initial management approach?

A. Prescribe propranolol 40mg to be taken as required before potentially triggering situations
B. Initiate escitalopram 10mg daily and provide psychoeducation about panic disorder (Correct Answer)
C. Refer for formal psychodynamic psychotherapy
D. Prescribe alprazolam 0.5mg to be taken during panic attacks
E. Arrange 24-hour Holter monitoring before considering psychiatric treatment

Explanation: ***Initiate escitalopram 10mg daily and provide psychoeducation about panic disorder*** - First-line treatment for **panic disorder** includes either **Cognitive Behavioral Therapy (CBT)** or an **SSRI** like escitalopram, which manages both the attacks and the **anticipatory anxiety**. - Psychoeducation is vital to help the patient understand that the physical symptoms of panic are not life-threatening, reducing the **catastrophic misinterpretation** of sensations. *Prescribe propranolol 40mg to be taken as required before potentially triggering situations* - While **beta-blockers** can mask peripheral autonomic symptoms like palpitations, they do not treat the underlying **anxiety or psychological components** of panic disorder. - Propranolol is more commonly used for **performance-based social anxiety** rather than preventing spontaneous panic attacks. *Refer for formal psychodynamic psychotherapy* - **Psychodynamic psychotherapy** is not considered a first-line psychological intervention for panic disorder; **CBT** is the evidence-based gold standard. - Treatment should focus on addressing the current **avoidance behaviors** (agoraphobia) and panic cycles rather than long-term personality or past-relationship exploration. *Prescribe alprazolam 0.5mg to be taken during panic attacks* - **Benzodiazepines** like alprazolam are not recommended first-line due to the high risk of **dependence**, tolerance, and potential for causing **rebound anxiety**. - Using medication "as needed" during an attack can lead to **safety behaviors** that prevent the patient from learning that the panic attack will naturally subside. *Arrange 24-hour Holter monitoring before considering psychiatric treatment* - Further cardiac testing is unnecessary as the patient has a **normal ECG** and physical examination, and the symptoms are classic for panic attacks. - Excessive medical investigations can be counterproductive by reinforcing the patient's **illness anxiety** and delaying necessary psychiatric treatment.

Question 46: A 41-year-old man with generalised anxiety disorder has been taking sertraline 200mg daily for 12 weeks with minimal improvement. He has completed a full course of high-intensity CBT without significant benefit. His anxiety significantly impairs his ability to work and maintain relationships. On assessment, his GAD-7 score is 18. He has no history of substance misuse or bipolar disorder. What is the most appropriate next pharmacological management?

A. Switch to pregabalin
B. Add buspirone to current sertraline
C. Switch to duloxetine (Correct Answer)
D. Add diazepam 5mg three times daily for ongoing use
E. Augment with quetiapine

Explanation: ***Switch to duloxetine*** - According to **NICE guidelines**, if a first-line **SSRI** like sertraline is ineffective after an adequate trial, the next step is to offer an **alternative SSRI** or an **SNRI** such as **duloxetine** or venlafaxine. - This patient has failed the maximum dose of sertraline and **high-intensity CBT**, making an **SNRI** the most logical and evidence-based pharmacological progression. *Switch to pregabalin* - While **pregabalin** is effective for GAD, it is generally considered a subsequent step after trials of an **alternative SSRI or SNRI** have failed. - Clinical caution is required due to its status as a **controlled substance** and the potential for **dependence** and misuse. *Add buspirone to current sertraline* - **Buspirone** has limited evidence of efficacy in GAD compared to SNRIs and is not typically used for **augmentation** in UK clinical practice. - The guidelines prioritize switching to a different class of primary antidepressant rather than adding low-efficacy adjuncts at this stage. *Add diazepam 5mg three times daily for ongoing use* - **Benzodiazepines** such as diazepam should not be used for long-term management of GAD due to high risks of **tolerance** and **physical dependence**. - They are only indicated for **short-term** (2–4 weeks) crisis management or to cover the initial side effects of starting an antidepressant. *Augment with quetiapine* - **Quetiapine** augmentation is considered an advanced strategy for **treatment-resistant GAD**, typically initiated by specialists after multiple first-line agents have failed. - Due to its **metabolic side effects** and sedative properties, it is not the appropriate next step before trying a licensed **SNRI**.

Question 47: A 63-year-old woman with a 10-week history of severe depression presents with profound psychomotor retardation, complete loss of appetite with 8kg weight loss, and delusional beliefs that her internal organs are rotting. She refuses to eat or drink. Physical examination reveals marked dehydration. Blood tests show acute kidney injury. She has previously failed trials of sertraline and mirtazapine. What is the most appropriate next management step?

A. Commence venlafaxine and arrange urgent psychiatric outpatient review
B. Admit for urgent electroconvulsive therapy (Correct Answer)
C. Start combination therapy with fluoxetine and olanzapine
D. Arrange for augmentation with lithium and continue current antidepressant
E. Initiate high-dose mirtazapine 45mg and monitor as outpatient

Explanation: ***Admit for urgent electroconvulsive therapy***- **Electroconvulsive therapy (ECT)** is the treatment of choice in life-threatening psychiatric emergencies where rapid response is required, such as **refusal of food/fluids** and **acute kidney injury**.- This patient exhibits **Cotard’s syndrome** (delusions of rotting organs) and severe psychomotor retardation, both of which are highly responsive to ECT as a first-line intervention.*Commence venlafaxine and arrange urgent psychiatric outpatient review*- **Venlafaxine** (an SNRI) is insufficient in this scenario as oral medications take weeks to reach therapeutic effect, which the patient cannot afford given her medical stability.- Outpatient review is inappropriate because the patient has developed **acute renal failure** and requires inpatient medical and psychiatric monitoring.*Start combination therapy with fluoxetine and olanzapine*- While combining an **antidepressant and antipsychotic** is a standard treatment for psychotic depression, it is not rapid enough to address the immediate risk of **dehydration and starvation**.- The severity of the clinical presentation (physical deterioration) prioritizes ECT, which has a faster **onset of action** than pharmacological combinations.*Arrange for augmentation with lithium and continue current antidepressant*- **Lithium augmentation** is a strategy for treatment-resistant depression but is contraindicated here due to the presence of **acute kidney injury** (AKI).- Lithium is primarily **renally excreted**, and its use in a dehydrated patient with AKI would lead to a high risk of **lithium toxicity**.*Initiate high-dose mirtazapine 45mg and monitor as outpatient*- Increasing the dose of **mirtazapine** would not provide the urgent intervention needed for a patient who has already failed two antidepressant trials and is physically unstable.- **Outpatient monitoring** is unsafe for a patient with delusional psychosis and severe physical complications requiring **intravenous rehydration**.

Question 48: A 56-year-old woman with recurrent depressive disorder has been stable on fluoxetine 40mg daily for 18 months following her third depressive episode. She wishes to discontinue her antidepressant as she feels fully recovered and dislikes taking medication. Her previous episodes occurred 7 years ago and 4 years ago, both requiring 6-8 months of treatment. She has no current depressive symptoms and good social support. According to current NICE guidance, what is the most appropriate advice regarding discontinuation?

A. Advise continuing fluoxetine for at least another 6 months before considering discontinuation
B. Support discontinuation but recommend rapid taper over 1-2 weeks given her stable condition
C. Advise continuing treatment indefinitely given her three episodes of depression
D. Support gradual discontinuation but advise this should be done over at least 4 weeks (Correct Answer)
E. Advise switching to a lower dose of fluoxetine 20mg for 6 months before stopping completely

Explanation: ***Support gradual discontinuation but advise this should be done over at least 4 weeks*** - NICE guidelines state that antidepressants should be withdrawn gradually over a period of at least **4 weeks** to minimize the risk of **discontinuation syndrome**.- Although this patient has had three episodes, she has completed **18 months** of maintenance therapy, making it reasonable to support her choice to stop, provided it is done safely.*Advise continuing fluoxetine for at least another 6 months before considering discontinuation* - Guidelines suggest considering maintenance for **2 years** after a third episode, but this is a **shared decision** and the patient has a strong preference to stop now after 18 months of stability.- There is no clinical mandate to wait specifically 6 more months if the patient is fully recovered and is currently **euthymic**.*Support discontinuation but recommend rapid taper over 1-2 weeks given her stable condition* - A **rapid taper** (1-2 weeks) increases the risk of **relapse** and physical withdrawal symptoms, regardless of clinical stability.- **Gradual reduction** is essential for all antidepressants, even for those with long half-lives like **fluoxetine**.*Advise continuing treatment indefinitely given her three episodes of depression* - While some guidelines mention maintenance for **at least 2 years** for recurrent depression, "indefinite" treatment is not a mandatory rule and must respect **patient autonomy**.- Given the long intervals (approx. 3 years) between her previous episodes, an attempt at supervised **discontinuation** is clinically acceptable.*Advise switching to a lower dose of fluoxetine 20mg for 6 months before stopping completely* - Simply switching to a lower dose for 6 months does not directly address the patient's immediate desire to **discontinue** the medication.- The recommended protocol is a **progressive reduction** in dose rather than a single step-down for a prolonged fixed duration.

Question 49: A 27-year-old man presents with panic disorder. He experiences unexpected panic attacks 4-5 times per week, characterized by palpitations, sweating, trembling, shortness of breath, and fear of dying. He has developed significant avoidance of situations where escape might be difficult. His GP has explained the diagnosis and offered treatment options. The patient is willing to try either medication or psychological therapy but wants to know which has the best evidence for long-term outcome. What does the evidence suggest about the comparative long-term effectiveness of CBT versus SSRIs for panic disorder?

A. SSRIs have superior long-term outcomes because CBT effects decline rapidly after treatment ends
B. CBT and SSRIs have equivalent long-term outcomes when treatment is maintained
C. CBT has superior long-term outcomes with better maintenance of gains after treatment discontinuation (Correct Answer)
D. SSRIs are superior in the acute phase but CBT becomes more effective after 12 months
E. Combined CBT and SSRI treatment is necessary for sustained long-term benefit

Explanation: ***CBT has superior long-term outcomes with better maintenance of gains after treatment discontinuation*** - Evidence suggests that **Cognitive Behavioural Therapy (CBT)** provides patients with durable skills, such as **exposure techniques** and **cognitive restructuring**, which continue to prevent relapse after the therapist is no longer present. - While medications are effective, **CBT** demonstrates more robust **maintenance of gains** at 6 to 24-month follow-up assessments compared to pharmacological interventions alone. *SSRIs have superior long-term outcomes because CBT effects decline rapidly after treatment ends* - This statement is incorrect as **CBT** is specifically noted for its **enduring effects** and low relapse rates long after the active treatment phase concludes. - **SSRIs** generally carry a higher risk of **relapse** once the medication is tapered or discontinued compared to psychological therapy. *CBT and SSRIs have equivalent long-term outcomes when treatment is maintained* - While outcomes may appear similar during active treatment, **CBT** is generally considered more **cost-effective** and durable in the long term because it does not require indefinite use to maintain benefits. - Clinical evidence indicates that **treatment gains** from CBT are more likely to persist even after the intervention has technically finished. *SSRIs are superior in the acute phase but CBT becomes more effective after 12 months* - Both treatments show similar **efficacy rates** in the acute phase, although **SSRIs** may have a slightly faster **onset of action** for symptom relief. - It is not that SSRIs are "superior" initially; rather, both are first-line, but the **sustainability** of CBT is what distinguishes it over a 12-month period. *Combined CBT and SSRI treatment is necessary for sustained long-term benefit* - Although **combination therapy** can be highly effective in the acute phase, it is not **necessary** for long-term recovery; many patients achieve sustained remission with **monotherapy** (specifically CBT). - Some evidence even suggests that certain medications (like benzodiazepines) might interfere with the **habituation process** required for CBT to be fully effective.

Question 50: A 48-year-old woman with treatment-resistant depression has failed adequate trials of sertraline, mirtazapine, and venlafaxine. She is currently taking venlafaxine 225mg daily. Her psychiatrist considers augmentation with lithium carbonate. Before initiating lithium, which combination of investigations must be performed as a baseline assessment?

A. Thyroid function tests, renal function, ECG, full blood count
B. Thyroid function tests, renal function, calcium levels, ECG (Correct Answer)
C. Renal function, liver function tests, thyroid function tests, ECG
D. Thyroid function tests, renal function, ECG, bone profile
E. Thyroid function tests, renal function, calcium levels, prolactin level

Explanation: ***Thyroid function tests, renal function, calcium levels, ECG*** - **Lithium** is primarily excreted by the kidneys and can cause **hypothyroidism** and **hyperparathyroidism**, necessitating baseline **renal function (eGFR)**, **TSH**, and **calcium levels**. - An **ECG** is required per guidelines (NICE/Maudsley) to rule out pre-existing conduction abnormalities, especially in patients with cardiac risk factors or those over 40-50 years old. *Thyroid function tests, renal function, ECG, full blood count* - While **thyroid** and **renal** tests are essential, a **Full Blood Count (FBC)** is not a standard requirement for monitoring lithium therapy. - This option omit **calcium levels**, which are critical due to the risk of lithium-induced **hypercalcaemia**. *Renal function, liver function tests, thyroid function tests, ECG* - **Lithium** is not metabolized by the liver, making **Liver Function Tests (LFTs)** unnecessary for its baseline assessment. - This selection fails to include **calcium level** monitoring, a key safety requirement due to potential **parathyroid** disturbance. *Thyroid function tests, renal function, ECG, bone profile* - Although a **bone profile** includes calcium, clinical guidelines specifically emphasize **serum calcium** as the primary electrolyte of concern beyond renal markers. - The correct option focusing on **calcium levels** is generally preferred over the broader bone profile in professional examinations based on specific adverse effect monitoring (hyperparathyroidism). *Thyroid function tests, renal function, calcium levels, prolactin level* - **Prolactin levels** are monitored for antipsychotic medications that block **dopamine** (D2 receptors), not for **lithium**. - This option also misses the mandatory **ECG** assessment required for patients initiating lithium to ensure baseline cardiac safety.

Question 51: A 33-year-old woman presents with recurrent panic attacks over the past 5 months. She describes sudden episodes of palpitations, sweating, trembling, and feeling like she cannot breathe, accompanied by intense fear of dying. Between attacks, she worries constantly about having another attack and has started avoiding shopping centres and public transport. She has no other psychiatric history. Cardiovascular examination and ECG are normal. She wishes to understand the psychological mechanisms underlying her condition. Which cognitive model best explains the maintenance of her panic disorder?

A. Classical conditioning where panic attacks become associated with specific triggers through repeated pairing
B. Catastrophic misinterpretation of normal bodily sensations leading to a self-perpetuating cycle of anxiety (Correct Answer)
C. Learned helplessness resulting from inability to control or predict panic attacks
D. Operant conditioning where avoidance behaviours are negatively reinforced by anxiety reduction
E. Dysfunctional schemas from early childhood experiences of abandonment or unpredictability

Explanation: ***Catastrophic misinterpretation of normal bodily sensations leading to a self-perpetuating cycle of anxiety*** - This model, developed by **David Clark**, explains that panic attacks arise when physiological signals (e.g., palpitations) are incorrectly perceived as evidence of a disaster like a **heart attack** or **imminent death**. - This creates a **positive feedback loop** where the resulting anxiety produces more physical symptoms, which further confirms the patient's fears, maintaining the **panic cycle**. *Classical conditioning where panic attacks become associated with specific triggers through repeated pairing* - This describes how **neutral stimuli** (like a shopping center) become **conditioned triggers** for anxiety after being paired with a panic event. - While it explains why specific environments trigger fear, it does not explain the **cognitive appraisal** of internal sensations that drives the attack itself. *Learned helplessness resulting from inability to control or predict panic attacks* - This theory suggests that repeated exposure to **uncontrollable stressors** leads to a state of passivity and and is primarily a model for **depression**. - While patients with panic disorder may feel helpless, this model does not account for the **autonomic arousal** and cognitive distortions seen in panic attacks. *Operant conditioning where avoidance behaviours are negatively reinforced by anxiety reduction* - This explains the maintenance of **agoraphobia** and avoidance, where escaping a situation leads to a **reduction in distress**, reinforcing the habit of avoiding. - While important for understanding **safety behaviors**, it is a behavioral explanation rather than the primary **cognitive model** for the panic mechanism. *Dysfunctional schemas from early childhood experiences of abandonment or unpredictability* - These are **long-standing cognitive frameworks** often associated with **personality disorders** or chronic depression rather than acute panic events. - Panic disorder is better explained by **state-specific misinterpretations** of physical sensations rather than these deep-seated, early developmental schemas.

Question 52: A 61-year-old woman with moderate depression has been taking citalopram 40mg daily for 4 weeks with good tolerability but minimal symptom improvement. Blood tests reveal a sodium level of 128 mmol/L (normal range 135-145 mmol/L). She is clinically euvolaemic with no signs of fluid overload or dehydration. Her thyroid function, glucose, and lipid profiles are normal. She takes no other regular medications. What is the most likely diagnosis?

A. SSRI-induced syndrome of inappropriate antidiuretic hormone secretion (Correct Answer)
B. Adrenal insufficiency
C. Renal salt-wasting syndrome
D. Primary hypothyroidism causing hyponatraemia
E. Psychogenic polydipsia related to depression

Explanation: ***SSRI-induced syndrome of inappropriate antidiuretic hormone secretion***- SSRIs like **citalopram** are a common cause of **SIADH**, particularly in **elderly patients** and often within the first few weeks of treatment.- The patient's **hyponatraemia** (128 mmol/L) with **euvolaemic** status, along with normal thyroid and adrenal function (implied by normal labs and no symptoms), strongly points to SIADH.*Adrenal insufficiency*- **Adrenal insufficiency** usually causes **hypovolaemic hyponatraemia** due to mineralocorticoid deficiency, often accompanied by **hyperkalaemia** and **hypotension**.- The patient is **euvolaemic** and has no other clinical signs like hyperpigmentation or postural hypotension, making this diagnosis less likely.*Renal salt-wasting syndrome*- **Renal salt-wasting syndrome** is characterized by **hypovolaemia** and significant sodium loss in the urine, often associated with intracranial disease.- The patient is described as **euvolaemic** and without signs of dehydration or fluid overload, which rules out this condition.*Primary hypothyroidism causing hyponatraemia*- The patient's **thyroid function tests** are explicitly stated as **normal**, directly contradicting primary hypothyroidism as the cause.- Hyponatraemia due to **hypothyroidism** is typically seen in severe, prolonged cases and is generally accompanied by other clear symptoms of thyroid dysfunction.*Psychogenic polydipsia related to depression*- **Psychogenic polydipsia** involves excessive water intake, leading to **dilutional hyponatraemia** with **low urine osmolality** and typically **polyuria**.- While the patient has depression, the clear association with recent **SSRI initiation** and euvolaemia makes **drug-induced SIADH** a more direct and probable cause.

Question 53: A 44-year-old man with a 4-month history of panic disorder has been taking escitalopram 10mg daily for 6 weeks. He reports that the frequency of his panic attacks has reduced from daily to 2-3 times per week, but he still experiences significant anticipatory anxiety about having attacks. His GP considers increasing the dose. What is the maximum licensed daily dose of escitalopram for panic disorder?

A. 10mg daily
B. 15mg daily
C. 20mg daily (Correct Answer)
D. 30mg daily
E. 40mg daily

Explanation: ***20mg daily***- The maximum licensed daily dose of **escitalopram** for **panic disorder**, as well as for **major depressive disorder** and **social anxiety disorder**, is 20mg daily.- Given the patient's partial response and ongoing anticipatory anxiety after 6 weeks on 10mg, a dose increase up to this maximum is clinically appropriate to achieve full therapeutic effect.*10mg daily*- While 10mg daily is a common starting or maintenance dose for many patients, it is not the **maximum licensed dose** for escitalopram in panic disorder.- The patient's persistent symptoms indicate that 10mg is insufficient to achieve full symptom control, thus warranting a dose escalation.*15mg daily*- Although a 15mg dose might be used during titration for some individuals, it is not recognized as the **maximum licensed daily dose** for escitalopram.- The official prescribing information and clinical guidelines define the upper limit for safety and efficacy at 20mg daily.*30mg daily*- This dose exceeds the **maximum licensed daily dose** of 20mg for escitalopram in panic disorder and other indications.- Doses above 20mg are considered **off-label** and are associated with a higher risk of adverse effects, including **QTc prolongation**, without proven additional clinical benefit.*40mg daily*- This dose is significantly above the **maximum licensed daily dose** for escitalopram.- While 40mg is the traditional maximum for **citalopram** (the racemic mixture from which escitalopram is derived), escitalopram at this dose would carry a substantially elevated risk of **cardiac toxicity** and other severe adverse drug reactions.

Question 54: A 38-year-old woman presents with a 6-month history of persistent, excessive worry about multiple everyday concerns including her children's safety, household finances, and her job performance. She finds the worry difficult to control and it occurs most days. She also reports feeling restless, experiencing muscle tension, having poor concentration, and feeling easily fatigued. She has no significant physical health problems. Her GAD-7 score is 16. She declined psychological therapy. What is the most appropriate first-line pharmacological treatment?

A. Pregabalin 150mg twice daily
B. Diazepam 5mg three times daily for 2 weeks then review
C. Sertraline starting at 50mg daily (Correct Answer)
D. Mirtazapine 15mg at night
E. Propranolol 40mg three times daily

Explanation: ***Sertraline starting at 50mg daily*** - According to **NICE guidelines**, a selective serotonin reuptake inhibitor (**SSRI**) like **Sertraline** is the first-line pharmacological treatment for **Generalized Anxiety Disorder (GAD)**, especially when psychological therapy is declined. - It is preferred due to its favorable **safety profile** and effectiveness in addressing the psychological symptoms of chronic worry and tension. *Pregabalin 150mg twice daily* - **Pregabalin** is considered a **second-line** option for GAD if the patient cannot tolerate or does not respond to SSRIs or SNRIs. - There are also increasing concerns regarding its potential for **dependence and misuse**, making it less suitable as an initial choice. *Diazepam 5mg three times daily for 2 weeks then review* - **Benzodiazepines** are not recommended for long-term management of GAD due to the significant risk of **tolerance and dependence**. - They may be used briefly for **acute crisis management**, but they do not treat the underlying pathology of a 6-month history of anxiety. *Mirtazapine 15mg at night* - While **Mirtazapine** has sedative and anxiolytic properties, it is not recommended as a **first-line** treatment for GAD. - It is usually reserved for cases where patients have **treatment-resistant** depression/anxiety or significant insomnia as a primary symptom. *Propranolol 40mg three times daily* - **Beta-blockers** like Propranolol only manage the **peripheral autonomic symptoms** of anxiety, such as palpitations and tremors. - They are ineffective against the core **psychological symptoms** of GAD, such as persistent worry and rumination.

Question 55: According to the ICD-10 diagnostic criteria for a depressive episode, what is the minimum duration of symptoms required to make this diagnosis?

A. 1 week
B. 2 weeks (Correct Answer)
C. 4 weeks
D. 6 weeks
E. 8 weeks

Explanation: ***2 weeks*** - According to **ICD-10** criteria, the minimum duration for a **depressive episode** is **two weeks**, ensuring the symptoms represent a persistent change from previous functioning. - This timeframe is consistent with **DSM-5** and is used to distinguish clinically significant depression from transient shifts in mood or **normal grief**. *1 week* - This duration is insufficient for a diagnosis of a **depressive episode** under standard classification systems, which require longer persistence of symptoms. - A **one-week** duration is, however, the minimum required for the diagnosis of a **manic episode** in the DSM-5. *4 weeks* - While symptoms may certainly last this long, **four weeks** is double the minimum requirement set by the **ICD-10** for a depressive episode. - This timeframe does not align with the standard diagnostic threshold for **acute mood disorders**, though it may be relevant for evaluating treatment response. *6 weeks* - This period is much longer than the required diagnostic window and is generally associated with the timing of a **clinical trial** review or the **peak effect** of antidepressants. - Relying on a **six-week** threshold would delay diagnosis and treatment for patients suffering from severe depressive symptoms. *8 weeks* - An **eight-week** requirement is not a standard for a depressive episode; symptoms that persist for **two years** or more would instead point toward **dysthymia** (persistent depressive disorder). - Using an eight-week minimum would lead to significant **under-diagnosis** and failure to provide timely intervention for those in acute distress.

Question 56: A 52-year-old man presents with an 8-week history of low mood, anhedonia, reduced energy, poor concentration, and feelings of worthlessness. He has lost 6kg in weight and wakes at 4am most mornings unable to return to sleep. His symptoms are worse in the morning. He describes his mood as qualitatively different from normal sadness. He has no past psychiatric history. His PHQ-9 score is 21. Physical examination and blood tests including thyroid function are normal. What feature of his presentation most strongly suggests melancholic depression?

A. Significant weight loss of 6kg
B. Early morning wakening at 4am
C. PHQ-9 score of 21 indicating severe depression
D. Mood described as qualitatively different from normal sadness
E. Symptoms being worse in the morning (diurnal mood variation) (Correct Answer)

Explanation: ***Symptoms being worse in the morning (diurnal mood variation)*** - **Diurnal variation** where mood is consistently worse in the morning is a highly characteristic and the most specific feature of **melancholic depression**. - This circadian pattern reflects the profound biological disturbances in this subtype, distinguishing it from other forms of **major depressive disorder**. *Significant weight loss of 6kg* - While **anorexia** and significant weight loss are common vegetative symptoms in depression, they are not exclusive to the **melancholic specifier**. - Weight changes can also occur in other depressive subtypes, for example, weight gain is characteristic of **atypical depression**. *Early morning wakening at 4am* - **Terminal insomnia** (early morning wakening, often at least two hours before usual time) is a classic somatic symptom associated with **melancholic depression**. - Although indicative, it is considered less specific for the melancholic subtype than the pronounced **diurnal mood variation**. *PHQ-9 score of 21 indicating severe depression* - A PHQ-9 score of 21 signifies **severe depression**, reflecting the overall severity of the depressive episode. - However, this score does not differentiate between specific **phenotypic subtypes** such as melancholic, atypical, or psychotic features. *Mood described as qualitatively different from normal sadness* - Describing the mood as **qualitatively distinct** (e.g., a profound sense of emptiness or despair) is indeed a feature of **melancholic depression**. - While suggestive, this subjective experience is less specific and objective than the observed **diurnal mood variation**.

Question 57: A 29-year-old woman with panic disorder has been experiencing panic attacks exclusively when travelling on underground trains. She has started avoiding the underground entirely and takes buses instead, which adds 90 minutes to her daily commute. She is taking sertraline 100mg daily and has been compliant for 8 weeks with moderate improvement in panic frequency. What is the most appropriate additional intervention?

A. Increase sertraline to 150mg daily
B. Add propranolol to be taken before underground travel
C. Refer for cognitive behavioural therapy with graded exposure (Correct Answer)
D. Add short-term diazepam to be taken before underground travel
E. Switch from sertraline to venlafaxine

Explanation: ***Refer for cognitive behavioural therapy with graded exposure***- The patient has developed **agoraphobic avoidance** secondary to panic disorder; **CBT with graded exposure** is the gold-standard treatment for addressing such avoidance behaviors.- This intervention helps patients systematically confront feared situations to break the cycle of **conditioned fear**, which medication alone does not effectively target.*Increase sertraline to 150mg daily*- While the patient has had a moderate response, increasing the dose focuses on **panic frequency** rather than the specific **maladaptive avoidance** of underground trains.- According to **NICE guidelines**, if a patient is responding at a standard therapeutic dose, adding psychological therapy is more effective for functional impairment than dose escalation alone.*Add propranolol to be taken before underground travel*- **Propranolol** only manages the **peripheral autonomic symptoms** (like palpitations) and does not treat the underlying psychological triggers of panic disorder.- It does not address the **cognitive distortions** or behavioral avoidance that are significantly impacting the patient's daily commute.*Add short-term diazepam to be taken before underground travel*- **Benzodiazepines** are generally discouraged because they can lead to **dependence** and often act as "safety behaviors" that prevent long-term recovery.- Using diazepam during travel prevents the **habituation process** required in therapy, effectively maintaining the phobia by reinforcing that the situation is only "safe" when medicated.*Switch from sertraline to venlafaxine*- Switching medications is premature as the patient is showing a **moderate clinical response** and has only been on sertraline for 8 weeks.- **Venlafaxine** is usually reserved for cases where first-line **SSRIs** have failed, and it would still not directly treat the specific **avoidance behavior** as effectively as CBT.

Question 58: A 46-year-old woman with recurrent depressive disorder has been taking sertraline 200mg daily for 10 weeks with minimal improvement. Her PHQ-9 score remains at 19 (previously 22). She has previously failed to respond to adequate trials of citalopram and mirtazapine. She has no psychotic symptoms and no significant suicidal ideation. Her past psychiatric history includes good response to venlafaxine during a previous episode 5 years ago. What is the most appropriate next step in management?

A. Switch to venlafaxine (Correct Answer)
B. Add lithium augmentation to sertraline
C. Refer for electroconvulsive therapy
D. Add aripiprazole augmentation to sertraline
E. Switch to a monoamine oxidase inhibitor

Explanation: ***Switch to venlafaxine*** - A **previous good response** to venlafaxine during an earlier depressive episode is a strong indicator of its potential efficacy again, making it the most appropriate next step. - The patient has failed multiple adequate trials of other antidepressants (sertraline, citalopram, mirtazapine), suggesting a need to switch to a **different class or previously effective agent**. *Add lithium augmentation to sertraline* - While **lithium** is an effective augmentation strategy for treatment-resistant depression, it is typically considered after trying switches to other classes or if no previously effective monotherapy is known. - Switching to a known effective monotherapy like **venlafaxine** is generally preferred due to a potentially simpler regimen and fewer side effects compared to combination therapy with lithium. *Refer for electroconvulsive therapy* - **ECT** is typically reserved for severe, life-threatening depression, often with psychotic features, severe suicidal ideation, or catatonia, none of which are present here. - The patient has not yet exhausted all appropriate pharmacological strategies, particularly a known previously effective antidepressant, making **ECT premature**. *Add aripiprazole augmentation to sertraline* - **Aripiprazole augmentation** is an option for treatment-resistant depression, but it is often considered when the primary antidepressant has shown some partial response or after switching strategies have been exhausted. - Given the minimal improvement on sertraline (PHQ-9 19 from 22), a **switch to a previously effective agent** is more likely to yield a full response than augmenting a largely ineffective current medication. *Switch to a monoamine oxidase inhibitor* - **MAOIs** are generally considered third- or fourth-line treatments for depression due to their significant **dietary restrictions** and potential for severe **drug-drug interactions**. - There are still less restrictive and potentially effective options, such as switching to venlafaxine, that should be pursued before resorting to an **MAOI**.

Question 59: A 35-year-old man presents to the emergency department with sudden onset chest pain, breathlessness, dizziness, and a feeling of impending doom that started 20 minutes ago. He appears distressed and is hyperventilating. His observations show: heart rate 118 bpm, blood pressure 155/92 mmHg, respiratory rate 28/min, oxygen saturation 99% on air, temperature 36.8°C. ECG shows sinus tachycardia. Troponin is normal. He has experienced three similar episodes in the past 2 months. What is the most appropriate immediate management?

A. Administer intravenous lorazepam 1mg
B. Provide reassurance and teach controlled breathing techniques (Correct Answer)
C. Prescribe propranolol 40mg orally
D. Refer urgently for cardiology assessment
E. Administer oxygen via face mask

Explanation: ***Provide reassurance and teach controlled breathing techniques*** - The patient's presentation with sudden onset chest pain, breathlessness, dizziness, a **feeling of impending doom**, and **hyperventilation**, coupled with normal ECG and **Troponin**, and recurrent episodes, is highly suggestive of a **panic attack**. - Immediate management involves **reassurance** and teaching **controlled breathing techniques** to reverse hyperventilation-induced respiratory alkalosis and reduce anxiety, addressing both physiological and psychological symptoms. *Administer intravenous lorazepam 1mg* - While **benzodiazepines** like lorazepam can reduce acute anxiety, they are generally avoided as first-line immediate management for panic attacks due to the risk of **dependence** and sedation, which can complicate assessment. - Non-pharmacological interventions like breathing exercises are preferred for acute symptom control, especially given the recurrent nature of the attacks. *Prescribe propranolol 40mg orally* - **Propranolol**, a beta-blocker, can alleviate some physical symptoms of anxiety like **tachycardia** and tremors, but it does not directly address the core psychological component or the **hyperventilation** in an acute panic attack. - Its onset of action is not immediate enough for acute crisis management, and it's typically used for longer-term management of performance anxiety or as an adjunct for physical symptoms. *Refer urgently for cardiology assessment* - The **normal ECG** and **normal Troponin** levels effectively rule out an acute cardiac event such as a myocardial infarction or unstable angina, especially in a relatively young patient with a history of similar episodes. - Urgent cardiology assessment is unnecessary given the clear indicators pointing away from primary cardiac pathology. *Administer oxygen via face mask* - The patient's **oxygen saturation of 99%** on air indicates no hypoxia, rendering supplemental oxygen unnecessary and potentially harmful. - Administering oxygen can exacerbate the **respiratory alkalosis** caused by hyperventilation, potentially worsening symptoms like dizziness and paresthesias, and may heighten health anxiety.

Question 60: A 42-year-old woman presents to her GP with a 3-month history of persistent worry about her health, finances, work performance, and family relationships. She reports feeling restless, easily fatigued, and having difficulty concentrating. She experiences muscle tension particularly in her neck and shoulders, and has difficulty falling asleep most nights. Her PHQ-9 score is 8 and GAD-7 score is 14. She is keen to try non-pharmacological treatment initially. What is the most appropriate first-line intervention?

A. Refer for individual cognitive behavioural therapy
B. Recommend guided self-help based on CBT principles (Correct Answer)
C. Prescribe propranolol 40mg three times daily
D. Refer for psychodynamic psychotherapy
E. Prescribe low-dose amitriptyline 10mg at night

Explanation: ***Recommend guided self-help based on CBT principles*** - This is consistent with **NICE guidelines** for Generalised Anxiety Disorder (GAD), which recommend a **stepped-care approach** starting with **low-intensity psychological interventions** for moderate anxiety. - The patient's **GAD-7 score of 14** indicates moderate anxiety, and her preference for **non-pharmacological treatment** makes guided self-help an ideal first-line option. *Refer for individual cognitive behavioural therapy* - **Individual CBT** is a **high-intensity psychological intervention** typically reserved for patients with severe GAD or those who have not responded to low-intensity treatments. - It is not usually the first-line recommendation for moderate GAD, especially when less intensive, equally effective options are available. *Prescribe propranolol 40mg three times daily* - **Propranolol**, a beta-blocker, primarily targets **physical symptoms of anxiety** like palpitations, tremors, and sweating, but does not address the core psychological worry component of GAD. - It is not recommended as a monotherapy first-line treatment for GAD and goes against the patient's explicit preference for **non-pharmacological intervention**. *Refer for psychodynamic psychotherapy* - **Psychodynamic psychotherapy** is generally not considered an **evidence-based first-line treatment** for Generalised Anxiety Disorder according to most clinical guidelines. - Guidelines strongly advocate for **CBT-based interventions** due to their robust evidence base for treating GAD. *Prescribe low-dose amitriptyline 10mg at night* - **Amitriptyline**, a tricyclic antidepressant (TCA), is not a first-line pharmacological treatment for GAD due to its significant **side-effect profile** and potential for toxicity. - If pharmacological treatment were indicated, **SSRIs (Selective Serotonin Reuptake Inhibitors)** would be the preferred first-line choice, but the patient explicitly prefers non-pharmacological options.

Question 61: A 58-year-old woman with bipolar affective disorder presents with a 5-week history of low mood, loss of interest in activities, poor sleep, and reduced appetite. She reports feeling guilty about past mistakes and has fleeting thoughts of self-harm. Her current medications include lithium carbonate 800mg daily. Her most recent lithium level taken 2 weeks ago was 0.7 mmol/L (therapeutic range 0.6-1.0). What is the most appropriate initial pharmacological management?

A. Add fluoxetine to her current lithium treatment
B. Add quetiapine to her current lithium treatment (Correct Answer)
C. Switch from lithium to sodium valproate
D. Add lamotrigine to her current lithium treatment
E. Increase lithium dose to achieve level of 1.0 mmol/L

Explanation: ***Add quetiapine to her current lithium treatment***- For an acute episode of **bipolar depression**, quetiapine is a first-line pharmacological treatment option that can be used alone or as an **adjunctive agent** to mood stabilizers.- Clinical guidelines, such as **NICE**, recommend quetiapine due to its established efficacy in treating depressive symptoms without a high risk of switching to **mania**.*Add fluoxetine to her current lithium treatment*- While antidepressants can be used in bipolar depression, they generally carry a risk of **precipitating mania** or **rapid cycling**, especially when not combined with an adequate mood stabilizer or antipsychotic.- If an antidepressant is considered, the fixed combination of **fluoxetine and olanzapine** is specifically recommended for bipolar depression, rather than fluoxetine alone as an add-on to lithium.*Switch from lithium to sodium valproate*- The patient's **lithium level (0.7 mmol/L)** is within the therapeutic range, indicating that lithium is likely effective as a mood stabilizer for maintenance, and the current depressive episode is a breakthrough.- Switching medications during an acute episode can lead to destabilization, and **sodium valproate** is primarily effective for **acute mania** and prophylaxis, not typically a first-line agent for acute bipolar depression.*Add lamotrigine to her current lithium treatment*- **Lamotrigine** is highly effective for the **prevention of depressive episodes** in bipolar disorder but requires a very **slow titration** over several weeks to minimize the risk of serious skin rashes like **Stevens-Johnson syndrome**.- Due to its slow titration schedule, it is not suitable for the **rapid management** of an acute depressive episode, where quicker symptom resolution is needed.*Increase lithium dose to achieve level of 1.0 mmol/L*- The patient's current **lithium level (0.7 mmol/L)** is already within the recommended therapeutic range (0.6-1.0 mmol/L) for maintenance, and for treating acute depression, a higher level isn't necessarily more effective.- Increasing the dose to the upper end of the therapeutic range might not provide significant additional antidepressant effect and could increase the risk of **lithium toxicity** and side effects without adequate clinical justification.

Question 62: What is the recommended first-line pharmacological treatment for panic disorder according to NICE guidelines?

A. Selective serotonin reuptake inhibitors (Correct Answer)
B. Benzodiazepines for short-term use
C. Beta-blockers for symptom control
D. Tricyclic antidepressants
E. Pregabalin

Explanation: ***Selective serotonin reuptake inhibitors*** - **SSRIs** are the **first-line pharmacological treatment** for panic disorder according to **NICE guidelines** due to their proven efficacy in reducing the frequency of **panic attacks** and treating comorbid **agoraphobia**. - They work by increasing **serotonin levels** in the brain, helping to regulate **mood** and **anxiety**; common examples include **sertraline**, **paroxetine**, or **fluoxetine**. *Benzodiazepines for short-term use* - While effective for acute symptom relief, **NICE guidelines** advise against routine use of **benzodiazepines** in panic disorder due to the high risk of **dependence**, **withdrawal symptoms**, and **sedation**. - They do not address the underlying pathology and are associated with a lack of **long-term efficacy** compared to **antidepressants** for sustained panic disorder management. *Beta-blockers for symptom control* - **Beta-blockers** target physical symptoms of anxiety like **palpitations**, **tremors**, and **tachycardia** by blocking adrenergic receptors. - However, they do not alleviate the psychological symptoms or prevent **panic attacks**, and thus are not recommended as a first-line treatment for **panic disorder** itself. *Tricyclic antidepressants* - While some **TCAs** (e.g., **imipramine**, **clomipramine**) can be effective in treating panic disorder, they are generally considered **second-line** due to a less favorable **side effect profile**. - Their side effects, such as **anticholinergic effects**, **cardiac toxicity** in overdose, and lower tolerability, make them less preferred than **SSRIs** as first-line therapy. *Pregabalin* - **Pregabalin** is approved for **generalized anxiety disorder (GAD)** and neuropathic pain, but it is not a first-line treatment for **panic disorder**. - There is insufficient evidence to recommend its primary use for the management of **panic attacks** or anticipatory anxiety in panic disorder according to major guidelines.

Question 63: A 58-year-old man with recurrent depressive disorder has been taking citalopram 40mg daily for 3 years with good effect. He now presents with worsening depressive symptoms over 8 weeks despite good adherence. His wife reports he has been drinking 4-6 units of alcohol daily for the past 3 months since retiring from work. What is the most important initial management step?

A. Increase citalopram to maximum tolerated dose
B. Switch to venlafaxine 150mg daily
C. Address alcohol consumption with brief intervention (Correct Answer)
D. Add mirtazapine 15mg at night for augmentation
E. Refer to community mental health team for assessment

Explanation: ***Address alcohol consumption with brief intervention***- Alcohol is a potent **CNS depressant** that frequently causes or exacerbates **depressive symptoms**; the patient's decline matches the timeline of increased drinking.- Before escalating pharmacological therapy, **modifiable factors** such as substance use must be addressed, as alcohol reduces the efficacy of antidepressants.*Increase citalopram to maximum tolerated dose*- Citalopram 40mg is already the **maximum recommended dose** in many clinical guidelines due to the risk of **QT prolongation**.- Increasing the dose would be ineffective and potentially dangerous without first managing the underlying **alcohol-induced mood disruption**.*Switch to venlafaxine 150mg daily*- Switching to an **SNRI** is considered for **treatment-resistant depression**, but this patient's relapse is likely secondary to a new lifestyle factor.- Pharmacological switching is premature until the impact of **excessive alcohol consumption** is mitigated.*Add mirtazapine 15mg at night for augmentation*- **Augmentation therapy** is indicated for patients who do not respond to monotherapy despite appropriate trials and absence of external triggers.- Introducing more polypharmacy increases the risk of **drug-alcohol interactions** and side effects without addressing the root cause.*Refer to community mental health team for assessment*- While specialist referral is an option for complex cases, the **primary care physician** should first manage straightforward contributing factors like **alcohol use**.- Initial management focuses on **brief interventions** and psychoeducation before concluding that a specialist/tertiary intervention is required.

Question 64: According to current evidence, what is the mechanism by which SSRIs exert their therapeutic effect in generalised anxiety disorder that differs from their mechanism in depression?

A. Enhanced GABA-A receptor sensitivity in the amygdala
B. Desensitization of presynaptic 5-HT1A autoreceptors in the raphe nuclei (Correct Answer)
C. Direct antagonism of corticotropin-releasing hormone receptors
D. Increased neurogenesis in the hippocampus
E. Modulation of the hypothalamic-pituitary-adrenal axis

Explanation: ***Desensitization of presynaptic 5-HT1A autoreceptors in the raphe nuclei*** - SSRIs initially increase synaptic serotonin, which activates **presynaptic 5-HT1A autoreceptors** in the raphe nuclei, leading to feedback inhibition and limiting serotonin release. - Over 2 to 4 weeks, chronic SSRI administration causes these **5-HT1A autoreceptors** to desensitize and downregulate, allowing for a sustained increase in **serotonergic transmission** and the onset of clinical benefit for both anxiety and depression. *Enhanced GABA-A receptor sensitivity in the amygdala* - Enhanced **GABA-A receptor sensitivity** is the primary mechanism of action for **benzodiazepines**, which provide acute relief by facilitating GABAergic inhibitory transmission. - **SSRIs** do not directly bind to or alter the sensitivity of the **GABA-A receptor** complex to exert their therapeutic effects. *Direct antagonism of corticotropin-releasing hormone receptors* - While **corticotropin-releasing hormone (CRH)** is involved in the stress response, **SSRIs** do not act as direct **CRH receptor antagonists**. - Research into **CRH antagonists** is a separate area of drug development for anxiety and depression, distinct from **serotonin reuptake inhibition**. *Increased neurogenesis in the hippocampus* - While **BDNF-mediated neurogenesis** is a proposed long-term effect of antidepressants, particularly in **Major Depressive Disorder**, it is not the primary differentiating mechanism for generalized anxiety disorder. - This process is linked more closely to the reversal of hippocampal atrophy seen in chronic depression rather than the initial **anxiolytic** pathway. *Modulation of the hypothalamic-pituitary-adrenal axis* - **SSRIs** may lead to a secondary normalization of the **hypothalamic-pituitary-adrenal (HPA) axis** over time, but this is a consequence of improved neurotransmission rather than the primary mechanism of action. - Direct HPA modulation is not the specific pharmacological driver that defines the **therapeutic onset** of SSRIs in Generalized Anxiety Disorder.

Question 65: A 27-year-old woman with panic disorder has developed significant agoraphobia. She has been housebound for 3 months, unable to use public transport or visit shops. She completed a 12-week course of CBT focusing on cognitive restructuring but remains severely impaired. She is taking sertraline 150mg daily. What psychological intervention would be most appropriate at this stage?

A. Psychodynamic psychotherapy exploring childhood experiences
B. Acceptance and commitment therapy focusing on values
C. CBT with specific focus on graded exposure therapy (Correct Answer)
D. Mindfulness-based cognitive therapy in a group setting
E. Eye movement desensitization and reprocessing therapy

Explanation: ***CBT with specific focus on graded exposure therapy*** - For **panic disorder with agoraphobia**, the behavioral component of **CBT**, specifically **graded exposure**, is the most effective evidence-based intervention to target avoidance. - Since the patient only completed **cognitive restructuring**, she specifically requires a systematic hierarchy of **exposure to feared situations** to overcome being housebound. *Psychodynamic psychotherapy exploring childhood experiences* - This modality focuses on **unconscious conflicts** and lacks robust clinical evidence for the rapid treatment of **agoraphobic avoidance**. - It is generally considered a second-line or adjunctive approach rather than a primary treatment for **Panic Disorder**. *Acceptance and commitment therapy focusing on values* - **ACT** emphasizes psychological flexibility and **mindfulness**, which can be beneficial, but it is not the first-line gold standard for **severe agoraphobia**. - It lacks the direct, systematic **desensitization** evidence that **graded exposure** therapy provides for housebound patients. *Mindfulness-based cognitive therapy in a group setting* - **MBCT** is primarily indicated for the prevention of **relapse in recurrent depression** rather than the treatment of acute **panic-related avoidance**. - The **group setting** may be too high a hurdle for a patient who is currently **housebound** and unable to access public spaces. *Eye movement desensitization and reprocessing therapy* - **EMDR** is highly effective and specifically indicated for **Post-Traumatic Stress Disorder (PTSD)**. - There is no clinical indication for **EMDR** in a standard case of **panic disorder** or agoraphobia without a clear traumatic origin.

Question 66: A 44-year-old woman presents with low mood, anhedonia, and fatigue for 8 weeks. She describes mood that is consistently low throughout the day. Her sleep is poor with early morning wakening. She has passive suicidal thoughts but no intent or plans. Medical history includes hypothyroidism treated with levothyroxine. Recent thyroid function tests show TSH 12.3 mU/L (normal 0.4-4.0). What is the most appropriate initial management?

A. Commence sertraline 50mg daily and review in 2 weeks
B. Adjust levothyroxine dose and reassess mood in 6-8 weeks (Correct Answer)
C. Commence sertraline and refer for cognitive behavioural therapy
D. Refer for urgent psychiatric assessment given suicidal thoughts
E. Adjust levothyroxine dose and commence sertraline simultaneously

Explanation: ***Adjust levothyroxine dose and reassess mood in 6-8 weeks*** - The patient's **elevated TSH (12.3 mU/L)** indicates **suboptimally treated hypothyroidism**, a common cause of depressive symptoms, fatigue, and cognitive dysfunction. - Addressing the **underlying medical condition** by adjusting levothyroxine to achieve a **euthyroid state** is the priority before attributing symptoms solely to primary depression.*Commence sertraline 50mg daily and review in 2 weeks* - Initiating an **antidepressant (SSRI)** without first correcting the **thyroid dysfunction** is premature and may lead to unnecessary medication. - The depressive symptoms are likely secondary to **hypothyroidism** and may resolve once the thyroid hormone levels are optimized.*Commence sertraline and refer for cognitive behavioural therapy* - While **CBT** and antidepressants are effective for primary depression, they do not address the **organic cause** of depression in this case (hypothyroidism). - It is crucial to manage the **physical cause** first, as the mood symptoms might resolve without psychiatric intervention.*Refer for urgent psychiatric assessment given suicidal thoughts* - The patient has **passive suicidal thoughts** without intent or a plan, which, while serious, does not typically warrant an **urgent psychiatric assessment** over addressing a clear medical cause in primary care. - **Risk assessment** and appropriate safety planning should be done in primary care, but the immediate focus is on correcting the **metabolic imbalance**.*Adjust levothyroxine dose and commence sertraline simultaneously* - Administering both treatments concurrently complicates the assessment of which intervention is responsible for any improvement, or if one is causing side effects. - It's best practice to **sequentially address issues**, starting with the most identifiable medical cause, to avoid polypharmacy and potential adverse effects.

Question 67: A 36-year-old man with panic disorder has been taking escitalopram 10mg daily for 8 weeks with partial response. He continues to experience 2-3 panic attacks weekly. His adherence is good and he has no significant side effects. What is the most appropriate next step in his pharmacological management?

A. Increase escitalopram to 20mg daily (Correct Answer)
B. Add propranolol 40mg as needed for acute attacks
C. Switch to venlafaxine 75mg daily
D. Add pregabalin 150mg daily
E. Continue current dose and review in 4 weeks

Explanation: ***Increase escitalopram to 20mg daily***- In **panic disorder**, if a patient shows a **partial response** after an adequate trial of 6–8 weeks, the first-line recommendation is to **increase the dose** to the maximum licensed level.- Escitalopram is often effective at higher doses for anxiety disorders than for depression, and **optimizing the current SSRI** should occur before switching medications.*Add propranolol 40mg as needed for acute attacks*- **Propranolol** is a beta-blocker primarily used for **performance anxiety** and physical symptoms but is not recommended for treating the core pathology of **panic disorder**.- It does not prevent panic attacks or lead to long-term remission of the underlying psychiatric condition.*Switch to venlafaxine 75mg daily*- **Venlafaxine** (an SNRI) is a valid treatment option, but switching is only indicated after a failed trial at the **maximum tolerated dose** of an SSRI.- Switching at this stage is premature since the patient is already tolerating the current **escitalopram** well and just needs a dose adjustment.*Add pregabalin 150mg daily*- **Pregabalin** is licensed and effective for **generalized anxiety disorder (GAD)** but is not a first-line or standard treatment for **panic disorder**.- Adding an adjunct should only be considered if the patient fails multiple monotherapy trials at **optimized dosages**.*Continue current dose and review in 4 weeks*- After **8 weeks** of treatment, the medication has reached a steady state, and further improvement on the same low dose is unlikely.- Delaying a dose increase Prolongs the patient's distress, as **clinical guidelines** suggest titration is necessary if symptoms persist beyond the initial 6–8 week window.

Question 68: Which of the following patient presentations would most clearly indicate a need for same-day specialist psychiatric assessment rather than routine primary care management of depression?

A. A 52-year-old with severe depression who is not eating and has lost 8kg in 3 weeks (Correct Answer)
B. A 38-year-old with depression and a history of three previous episodes
C. A 61-year-old with depression and mild cognitive impairment
D. A 28-year-old with postnatal depression 6 weeks after delivery with PHQ-9 score of 15
E. A 45-year-old with moderate depression and PHQ-9 score of 17 who has failed two SSRIs

Explanation: ***A 52-year-old with severe depression who is not eating and has lost 8kg in 3 weeks***- Significant **biological symptoms** such as the inability to eat and rapid, substantial **weight loss** indicate a psychiatric emergency requiring immediate intervention.- This presentation suggests **melancholic depression** or potential **depressive stupor**, necessitating a same-day specialist assessment to evaluate the need for **urgent hospitalization** or intensive nutritional support.*A 38-year-old with depression and a history of three previous episodes*- While a history of **recurrent depression** increases the risk of future episodes, it does not inherently signal an immediate crisis in the absence of acute risk factors.- Recurrent episodes are typically managed in **primary care** through long-term **maintenance pharmacotherapy** or routine secondary care referral.*A 61-year-old with depression and mild cognitive impairment*- The presence of **mild cognitive impairment (MCI)** with depression requires thorough evaluation to differentiate between **pseudodementia** and neurodegenerative disease.- This assessment is usually conducted through **routine memory clinic** or geriatric psychiatry referrals rather than an emergency same-day assessment.*A 28-year-old with postnatal depression 6 weeks after delivery with PHQ-9 score of 15*- A **PHQ-9 score of 15** indicates moderately severe depression, which warrants close monitoring and treatment but not necessarily immediate specialist intervention unless **suicidal ideation** or **psychosis** is present.- Most cases of **postnatal depression** are managed effectively within **primary care** or community perinatal mental health teams on a non-emergency basis.*A 45-year-old with moderate depression and PHQ-9 score of 17 who has failed two SSRIs*- This patient meets the criteria for **treatment-resistant depression**, which justifies a referral for specialist advice on **augmentation strategies** or alternative classes of medications.- Although specialized input is needed, **failed trials of SSRIs** in a stable patient do not constitute a medical emergency requiring **same-day assessment**.

Question 69: A 31-year-old woman presents to the emergency department with her fourth panic attack in 2 weeks. She describes sudden onset intense fear with palpitations, chest tightness, and fear of dying. Physical examination and ECG are normal. She is extremely distressed and requesting medication. What is the most appropriate immediate management?

A. Administer diazepam 5mg orally
B. Provide reassurance and breathing techniques (Correct Answer)
C. Commence sertraline 50mg and arrange GP follow-up
D. Administer propranolol 40mg orally
E. Arrange urgent psychiatric assessment

Explanation: ***Provide reassurance and breathing techniques***- For an **acute panic attack**, the most appropriate immediate management is providing **reassurance** and teaching **controlled breathing** or grounding techniques.- Panic attacks are typically **self-limiting** (resolving within 20-30 minutes); non-pharmacological support is prioritized as it empowers the patient to manage symptoms.*Administer diazepam 5mg orally*- **Benzodiazepines** are generally avoided in the acute setting of panic disorder because they carry a high risk of **dependence** and do not address the underlying cause.- Clinical guidelines, such as **NICE**, specifically recommend against the routine use of benzodiazepines for the management of panic disorder.*Commence sertraline 50mg and arrange GP follow-up*- While **SSRIs** like sertraline are first-line for the long-term management of **panic disorder**, they take weeks to become effective and are not for **immediate** symptom relief.- Initiating maintenance medication like an SSRI is more appropriate in a **primary care** setting after a comprehensive diagnostic review, rather than in the emergency department.*Administer propranolol 40mg orally*- **Propranolol** is a beta-blocker that may help with **peripheral autonomic symptoms** (like palpitations) but does not treat the core psychological distress of a panic attack.- It is not considered first-line for acute management and is less effective than behavioral interventions for stopping an active attack.*Arrange urgent psychiatric assessment*- An uncomplicated panic attack in a patient without **suicidal ideation**, psychosis, or immediate risk to others does not require an **urgent psychiatric assessment**.- Most patients can be safely discharged with advice to follow up with their **General Practitioner** for psychological or pharmacological therapy planning.

Question 70: A 48-year-old woman with severe depression and significant psychomotor retardation is commenced on phenelzine by a psychiatrist. After 3 weeks, she reports improvement but develops a severe throbbing headache, sweating, and neck stiffness after eating aged cheese. Her blood pressure is 190/110 mmHg. What is the underlying mechanism of this reaction?

A. Accumulation of acetylcholine at muscarinic receptors
B. Excessive serotonin activity at 5-HT1A receptors
C. Accumulation of tyramine leading to noradrenaline release (Correct Answer)
D. Direct stimulation of dopamine receptors in the chemoreceptor trigger zone
E. Inhibition of GABA transmission in the central nervous system

Explanation: ***Accumulation of tyramine leading to noradrenaline release*** - Phenelzine is a **monoamine oxidase inhibitor (MAOI)**, preventing the breakdown of **tyramine**, a sympathomimetic amine found in **aged cheese** and other fermented foods. - The resulting systemic accumulation of **tyramine** displaces massive amounts of **noradrenaline** from presynaptic vesicles, leading to a life-threatening **hypertensive crisis** with symptoms like severe headache, sweating, and elevated blood pressure. *Accumulation of acetylcholine at muscarinic receptors* - This mechanism is typically associated with **cholinesterase inhibitors** or organophosphate poisoning, causing a **cholinergic crisis**. - Symptoms include salivation, lacrimation, miosis, and bradycardia, which are distinct from the presented sympathetic overdrive. *Excessive serotonin activity at 5-HT1A receptors* - This describes **serotonin syndrome**, often caused by combining MAOIs with other serotonergic drugs like **SSRIs**. - While it can involve hypertension, its hallmark features include **neuromuscular hyperactivity** (e.g., hyperreflexia, clonus, tremor), which are not the primary symptoms here. *Direct stimulation of dopamine receptors in the chemoreceptor trigger zone* - This mechanism is primarily associated with **dopamine agonists** or certain antiemetics, leading to nausea and vomiting. - It does not explain the profound **vasoconstriction** and hypertensive crisis triggered by a dietary interaction. *Inhibition of GABA transmission in the central nervous system* - Decreased **GABAergic** activity is linked to conditions like **seizures** and anxiety, or withdrawal syndromes from central depressants. - This mechanism is unrelated to the specific drug-food interaction involving **MAOIs** and dietary **tyramine** that causes a hypertensive reaction.

Question 71: A 34-year-old man presents with a 7-month history of constant excessive worry about work performance, finances, and his family's health. He reports muscle tension, irritability, difficulty concentrating, and fatigue. He avoids social situations where he might be judged. His GAD-7 score is 16. He has tried self-help materials without benefit. What is the most appropriate initial management step?

A. Commence sertraline 50mg daily
B. Refer for individual cognitive behavioural therapy
C. Commence pregabalin 75mg twice daily
D. Offer low-intensity psychological intervention (Correct Answer)
E. Refer to community mental health team

Explanation: ***Offer low-intensity psychological intervention*** - According to **NICE guidelines**, for patients with **Generalised Anxiety Disorder (GAD)** whose symptoms significantly impair function or who have not improved with active monitoring and basic self-help, low-intensity psychological interventions are the next appropriate step (Step 2). - These interventions include **individual non-facilitated self-help**, **guided self-help**, or **psychoeducational groups**, aiming to provide practical strategies for managing worry and anxiety. *Commence sertraline 50mg daily* - **Pharmacological treatment**, such as an **SSRI** like **sertraline**, is generally considered a **Step 3** intervention for GAD, typically offered if low-intensity psychological interventions are ineffective or unacceptable. - While effective, medication is not the initial management step when low-intensity psychological interventions have not yet been formally offered or fully explored. *Refer for individual cognitive behavioural therapy* - **Individual cognitive behavioural therapy (CBT)** is a **high-intensity psychological intervention** (Step 3) for GAD, usually reserved for patients who have not responded to low-intensity interventions. - It is a more intensive and specialized treatment, not typically the very first step after unsuccessful self-help in a moderate case. *Commence pregabalin 75mg twice daily* - **Pregabalin** is an alternative pharmacological treatment for GAD but is generally recommended for patients who have not responded to or cannot tolerate **SSRIs** or **SNRIs**. - It is not considered a first-line pharmacological option and certainly not the initial management step before psychological interventions are exhausted. *Refer to community mental health team* - Referral to a **Community Mental Health Team (CMHT)** is typically reserved for more **severe, complex, or treatment-resistant mental health conditions**, or where there is significant risk. - While the patient has moderate-severe GAD, the initial management in a stepped-care model often falls within primary care or IAPT (Improving Access to Psychological Therapies) services before specialist secondary care referral.

Question 72: A 55-year-old woman with recurrent depression has been stable on sertraline 100mg daily for 18 months following her third depressive episode. She asks about stopping her antidepressant as she feels completely well. Her previous episodes occurred at ages 35 and 48, both requiring 6-month treatment courses. What is the most appropriate advice regarding continuation of antidepressant therapy?

A. Continue sertraline for at least another 6 months then review
B. Continue sertraline indefinitely given three episodes (Correct Answer)
C. Gradually reduce sertraline over 4 weeks and monitor
D. Switch to a lower maintenance dose of sertraline 50mg daily
E. Continue sertraline for a total of 2 years from remission then stop

Explanation: ***Continue sertraline indefinitely given three episodes*** - Clinical guidelines recommend long-term or **indefinite maintenance therapy** for patients who have experienced **three or more depressive episodes** due to a very high risk of relapse (approx. 90%). - The patient is at a high risk for a fourth episode; therefore, continuing the treatment that successfully achieved stability is the most effective **relapse prevention strategy**. *Continue sertraline for at least another 6 months then review* - This approach is typically reserved for a **single episode** of depression, where treatment is continued for 6–9 months following **remission**. - Given the history of three episodes, a simple 6-month extension is insufficient to address the patient's long-term **recurrence risk**. *Gradually reduce sertraline over 4 weeks and monitor* - Discontinuing medication after multiple episodes significantly increases the likelihood of a **relapse** within a short period. - This strategy does not align with best practices for **recurrent Major Depressive Disorder**, which prioritize stability over cessation. *Switch to a lower maintenance dose of sertraline 50mg daily* - Guidelines specify that the **effective dose** used to achieve remission should be the same dose used for **maintenance therapy**. - Reducing the dose increases the risk of **sub-therapeutic levels**, which can lead to breakthrough symptoms and eventual relapse. *Continue sertraline for a total of 2 years from remission then stop* - While 2 years is often cited as a minimum for recurrent depression, the presence of **three discrete episodes** frequently warrants treatment beyond this fixed timeframe. - Stopping at exactly 2 years does not account for the patient's specific history and the high statistical probability of **future recurrence**.

Question 73: A 29-year-old woman with panic disorder has been taking propranolol 40mg three times daily as needed for the past 4 weeks. She reports that while it helps reduce her palpitations during panic attacks, she continues to experience frequent attacks with intense fear, dizziness, and depersonalization. What is the most appropriate modification to her management?

A. Increase propranolol to 80mg three times daily
B. Continue propranolol and add alprazolam for acute attacks
C. Discontinue propranolol and commence an SSRI (Correct Answer)
D. Continue propranolol and add venlafaxine
E. Switch propranolol to atenolol for better beta-blockade

Explanation: ***Discontinue propranolol and commence an SSRI*** - **SSRIs** are the **first-line pharmacological treatment** for panic disorder as they effectively target the core psychological symptoms, such as intense fear, dizziness, and depersonalization, and reduce attack frequency. - While **beta-blockers** like propranolol can alleviate peripheral **somatic symptoms** (e.g., palpitations), they do not address the central fear, **dizziness**, or **depersonalization** central to panic attacks, indicating the need for a more comprehensive treatment. *Increase propranolol to 80mg three times daily* - Increasing the dose of a **beta-blocker** will only enhance its peripheral effects and will not treat the underlying **pathophysiology of panic disorder** or reduce the frequency of attacks. - Higher doses increase the risk of side effects such as **bradycardia**, **hypotension**, and **fatigue** without providing further benefit for the psychological aspects of panic. *Continue propranolol and add alprazolam for acute attacks* - While **benzodiazepines** (like alprazolam) can acutely reduce anxiety, they are generally avoided for long-term or regular use in panic disorder due to the significant risk of **dependence**, tolerance, and withdrawal. - This approach would only provide symptomatic relief without addressing the long-term management and prevention of attacks, which an **SSRI** would achieve. *Continue propranolol and add venlafaxine* - While **SNRIs** (like venlafaxine) are effective treatments for panic disorder, **SSRIs** are typically considered first-line due to a generally more favorable side effect profile and established efficacy. - Continuing propranolol is unnecessary as an effective **SSRI** or **SNRI** will manage both the somatic and psychological components, rendering the beta-blocker redundant. *Switch propranolol to atenolol for better beta-blockade* - Switching to a different **beta-blocker** (atenolol) will not address the core issue that beta-blockers primarily manage **peripheral symptoms** and do not effectively treat the central psychological symptoms of panic disorder. - Atenolol, like propranolol, is a beta-blocker and shares the same limitations in treating **panic disorder**, offering no significant advantage for the patient's core symptoms.

Question 74: A 42-year-old man with generalised anxiety disorder has been experiencing muscle tension, restlessness, and sleep disturbance for 8 months. He has tried two SSRIs (sertraline and escitalopram) at therapeutic doses for adequate durations without benefit. He declines further psychological therapy having completed CBT previously. What is the most appropriate next pharmacological management according to NICE guidelines?

A. Switch to mirtazapine
B. Switch to pregabalin
C. Add buspirone to current SSRI
D. Switch to duloxetine (Correct Answer)
E. Add low-dose quetiapine to current SSRI

Explanation: ***Switch to duloxetine*** - According to **NICE guidelines** for the management of **Generalized Anxiety Disorder (GAD)**, if two SSRIs have been ineffective, an alternative SSRI or an **SNRI** such as **venlafaxine** or **duloxetine** should be offered. - The patient's failure on two SSRIs (sertraline and escitalopram) at therapeutic doses makes switching to an **SNRI** the most appropriate next pharmacological step. *Switch to mirtazapine* - **Mirtazapine** is generally not recommended as a first-line or sequential treatment for **GAD** according to established guidelines like NICE. - It is more commonly used for **major depressive disorder**, especially when associated with insomnia due to its sedating properties, not typically for GAD after SSRI failure. *Switch to pregabalin* - While **pregabalin** is an effective treatment for GAD, NICE guidelines typically recommend it after trials of **SSRIs** and **SNRIs** have been unsuccessful. - Due to concerns regarding **dependence** and **potential for abuse**, it is usually reserved for later stages of treatment, or when other options are contraindicated or not tolerated. *Add buspirone to current SSRI* - **Buspirone** is primarily considered as a monotherapy for GAD or as an alternative in specific circumstances, not typically as an **augmentation agent** in primary care after SSRI failure. - Its efficacy as an add-on therapy is less established compared to switching to an SNRI in the current scenario. *Add low-dose quetiapine to current SSRI* - Augmentation with **atypical antipsychotics** like **quetiapine** is not recommended by NICE for the routine management of GAD due to potential for significant side effects. - Such strategies are usually considered only in **specialist mental health settings** for severe, treatment-resistant cases, given risks like **weight gain** and **metabolic syndrome**.

Question 75: A 38-year-old woman presents with a 6-week history of low mood, anhedonia, disturbed sleep, and poor concentration. She has lost 4kg in weight. On examination, she appears tearful and psychomotor retarded. She denies suicidal ideation. She has no past psychiatric history. Her PHQ-9 score is 18. Which classification best describes the severity of her depressive episode according to ICD-10 criteria?

A. Moderate depressive episode (Correct Answer)
B. Severe depressive episode with psychotic symptoms
C. Recurrent depressive disorder, current episode moderate
D. Mild depressive episode
E. Severe depressive episode without psychotic symptoms

Explanation: ***Moderate depressive episode*** - A **moderate depressive episode** is diagnosed when at least two of the three **core symptoms** (depressed mood, anhedonia, loss of energy) are present, along with at least 3-4 other symptoms, leading to significant distress or functional impairment. - The patient exhibits two core symptoms (**low mood**, **anhedonia**) and several other symptoms including **disturbed sleep**, **poor concentration**, **weight loss**, and **psychomotor retardation**, totaling more than 5 symptoms, consistent with a moderate episode and a PHQ-9 score of 18. *Severe depressive episode with psychotic symptoms* - This classification requires the presence of **hallucinations** or **delusions**, which are explicitly absent in this patient's presentation. - While the patient has significant symptoms, the **absence of psychotic features** means this specific diagnosis is inappropriate. *Recurrent depressive disorder, current episode moderate* - This diagnosis applies only when there is a history of at least two prior depressive episodes, with periods of complete or partial recovery in between. - The case clearly states the patient has **no past psychiatric history**, indicating this is her first depressive episode, ruling out a recurrent disorder. *Mild depressive episode* - A **mild depressive episode** typically involves two core symptoms and only two additional symptoms, with the patient generally able to continue most daily activities with some effort. - The presence of **psychomotor retardation**, significant **weight loss**, and a PHQ-9 score of 18 (indicating significant severity) exceeds the criteria for a mild episode. *Severe depressive episode without psychotic symptoms* - A **severe depressive episode** usually involves all three core symptoms and a total of at least eight symptoms, leading to extreme distress and near-total inability to function socially or occupationally, often with **suicidal ideation**. - Although the patient has significant symptoms, the absence of suicidal ideation, and the overall symptom count align more closely with the **moderate** category, as not all three core symptoms (loss of energy is not explicitly mentioned as a primary complaint distinct from psychomotor retardation) and 8 symptoms are clearly met for severe.

Question 76: According to current NICE guidelines, what is the recommended minimum treatment duration with antidepressants following remission of symptoms in a patient experiencing their first episode of depression?

A. 2 months
B. 6 months (Correct Answer)
C. 12 months
D. 18 months
E. 24 months

Explanation: ***6 months*** - For a **first episode** of depression, NICE guidelines recommend continuing antidepressant treatment at the **same dose** that achieved remission for a minimum of **6 months** post-remission. - This duration is crucial to significantly **reduce the risk of relapse**, which remains high immediately after symptoms subside. *2 months* - Stopping treatment at 2 months is considered premature and is linked to a **high rate of symptom recurrence**. - This timeframe encompasses the **acute phase** of treatment but fails to provide the necessary support for the **continuation phase**. *12 months* - While some clinicians may choose a longer duration, it is not the **minimum** requirement for a first uncomplicated episode according to **NICE standards**. - This duration is more reflective of guidelines provided by other bodies like the **WHO**, but does not align with the specific 6-month NICE benchmark. *18 months* - Extension to 18 months is not standard for a first episode and would unnecessarily increase the **medication burden** and potential for **side effects**. - This period does not correspond to any specific milestone in the standard **stepped-care model** for depression management. *24 months* - A duration of **2 years (24 months)** is specifically recommended for patients at higher risk of relapse, such as those with **recurrent depression** (two or more episodes). - Applying this to a first episode exceeds the recommended minimum and is reserved for cases with **significant functional impairment** or chronic symptoms.

Question 77: A 27-year-old woman with panic disorder has been experiencing nocturnal panic attacks approximately twice weekly for the past 2 months, waking her from sleep. She also has daytime panic attacks. She is not currently on any medication. What is the most important differential diagnosis to exclude before attributing these episodes solely to panic disorder?

A. Obstructive sleep apnoea (Correct Answer)
B. Nocturnal epilepsy
C. Nightmares associated with post-traumatic stress disorder
D. Gastro-oesophageal reflux disease
E. Night terrors (sleep terrors)

Explanation: ***Obstructive sleep apnoea*** - **Obstructive sleep apnoea (OSA)** can cause sudden awakenings with intense fear, **breathlessness**, and **choking sensations** that perfectly mimic nocturnal panic attacks. - It is a critical medical diagnosis to exclude because it requires specific treatment like **CPAP** to prevent long-term **cardiovascular complications**. *Nocturnal epilepsy* - These episodes usually present with **stereotyped motor movements**, tongue biting, or urinary incontinence, rather than isolated autonomic arousal. - Patients with **nocturnal epilepsy** typically experience **post-ictal confusion** or drowsiness, which is not characteristic of waking from a panic attack with clear recall. *Nightmares associated with post-traumatic stress disorder* - **PTSD nightmares** involve the recall of specific **vivid traumatic content**, whereas nocturnal panic attacks typically lack a specific dream narrative or identifiable trigger within the dream. - Diagnosis requires a history of a **traumatic event** and other cardinal symptoms like **hyperarousal** and avoidance during the day. *Gastro-oesophageal reflux disease* - While **GERD** can cause nocturnal awakening with coughing, a choking sensation, or chest pain, it is usually accompanied by **heartburn**, regurgitation, or a sour taste in the mouth. - It rarely presents with the full constellation of **autonomic symptoms** (palpitations, sweating, tremors, dread) that characterize a panic attack. *Night terrors (sleep terrors)* - **Sleep terrors** typically occur during **slow-wave sleep** (NREM N3), and the individual usually has **no memory** of the event upon waking, often appearing disoriented and unresponsive. - In contrast, a patient experiencing a **nocturnal panic attack** transitions into full wakefulness and maintains clear memory of the distressing symptoms and the intense fear experienced.

Question 78: Which of the following best describes the neurobiological basis for the delayed therapeutic response to SSRIs in depression compared to their immediate effect on synaptic serotonin levels?

A. Time required for sufficient drug accumulation to reach therapeutic plasma levels
B. Gradual desensitization of presynaptic serotonin autoreceptors increasing serotonin transmission (Correct Answer)
C. Progressive increase in serotonin synthesis by tryptophan hydroxylase
D. Slow penetration of SSRIs across the blood-brain barrier
E. Time needed for metabolism of SSRIs to their active metabolites

Explanation: ***Gradual desensitization of presynaptic serotonin autoreceptors increasing serotonin transmission***- Initial use of SSRIs causes an increase in serotonin that activates **5-HT1A autoreceptors**, which provide **negative feedback** to inhibit further serotonin release.- Over 2-6 weeks, these autoreceptors **downregulate and desensitize**, allowing for sustained increases in synaptic serotonin and downstream **neuroplastic changes** like increased **BDNF** expression.*Time required for sufficient drug accumulation to reach therapeutic plasma levels*- **Steady-state plasma levels** of SSRIs are typically achieved within a few days, yet the clinical response still lags for several weeks.- Clinical delay is related to **cellular adaptations** in the brain rather than simple **pharmacokinetic accumulation** in the blood.*Progressive increase in serotonin synthesis by tryptophan hydroxylase*- SSRIs primarily act by inhibiting the **serotonin transporter (SERT)**, not by increasing the rate of **serotonin synthesis**.- While synthesis levels may fluctuate, it is the **reuptake inhibition** and subsequent receptor adaptation that drive the therapeutic outcome.*Slow penetration of SSRIs across the blood-brain barrier*- SSRIs are **lipophilic molecules** that readily cross the **blood-brain barrier** shortly after administration.- High concentrations are found in the **central nervous system** long before the patient experiences symptomatic relief from depression.*Time needed for metabolism of SSRIs to their active metabolites*- Most SSRIs are administered as **active compounds** and do not require conversion to an active form to exert their primary biochemical effect.- Even for SSRIs with **active metabolites** (like fluoxetine), the delay in clinical improvement is much longer than the hours or days required for metabolite formation.

Question 79: A 62-year-old man with newly diagnosed depression and mild cognitive impairment (MMSE 25/30) is being considered for antidepressant treatment. He lives alone and occasionally forgets to take his regular medications for hypertension. Which of the following factors should most influence the choice of antidepressant?

A. The speed of onset of therapeutic effect
B. The medication's anticholinergic profile (Correct Answer)
C. The once-daily dosing schedule
D. The cost of the medication
E. The sedative properties of the medication

Explanation: ***The medication's anticholinergic profile***- In elderly patients with **mild cognitive impairment** (MMSE 25/30), medications with **anticholinergic activity** can significantly worsen memory, increase confusion, and elevate the risk of **delirium or falls**.- Antidepressants like **tricyclic antidepressants (TCAs)** (e.g., amitriptyline) or paroxetine should be avoided as they antagonize **acetylcholine**, which is crucial for cognitive function.*The speed of onset of therapeutic effect*- Most standard antidepressants take approximately **2 to 4 weeks** to show clinical benefit, and this timeline is relatively consistent across different classes like **SSRIs** or **SNRIs**.- While important for patient distress, speed of onset is not the primary clinical concern compared to the potential for causing further **cognitive decline** in a vulnerable patient.*The once-daily dosing schedule*- While simple dosing (once-daily) supports **medication adherence** in a patient who is forgetful, many modern antidepressants already utilize once-daily regimens.- Adherence can be managed with tools like **pill organizers** or caregiver assistance, but the **pharmacodynamic effects** of a drug on the patient's cognition are a more critical concern.*The cost of the medication*- Financial considerations are important for long-term compliance and access, but **patient safety** and the prevention of further **cognitive impairment** take clinical precedence.- Generic versions of safe options like **sertraline** or **escitalopram** are widely available and cost-effective for most patients.*The sedative properties of the medication*- While **sedation** might be useful for patients with comorbid insomnia, it can also increase the risk of **gait instability** and evening confusion (sundowning) in the elderly.- Preventing **anticholinergic-induced cognitive worsening** remains the most critical priority for a patient already showing a declining **MMSE score**, as sedation is a separate, though also important, concern.

Question 80: A 44-year-old woman with panic disorder describes that her attacks always occur in crowded places such as shopping centres and public transport. She has started avoiding these situations. She is keen to address this issue. Her panic attacks are well-controlled on sertraline 100mg daily. What is the most appropriate additional intervention?

A. Increase sertraline to 150mg to prevent attacks in feared situations
B. Prescribe propranolol 40mg to take before entering feared situations
C. Offer graded exposure therapy targeting the avoided situations (Correct Answer)
D. Add pregabalin 75mg twice daily for anticipatory anxiety
E. Prescribe alprazolam 0.5mg as required for use in feared situations

Explanation: ***Offer graded exposure therapy targeting the avoided situations*** - The patient's symptoms describe **agoraphobia**, characterized by marked anxiety about, or avoidance of, situations where escape might be difficult or help unavailable during a panic attack, despite controlled panic attacks. - **Graded exposure therapy** is the most effective behavioral intervention for agoraphobia, facilitating **habituation** and **extinction learning** by gradually confronting feared situations. *Increase sertraline to 150mg to prevent attacks in feared situations* - The patient's **panic attacks are already well-controlled** on the current sertraline dose, indicating that increasing medication is unlikely to address the primary issue of **agoraphobic avoidance**. - While SSRIs treat panic disorder, **behavioral interventions** are crucial for overcoming learned avoidance patterns associated with agoraphobia. *Prescribe propranolol 40mg to take before entering feared situations* - **Propranolol** is a beta-blocker that can reduce the **physical symptoms of anxiety** (e.g., palpitations, tremor) but does not address the underlying cognitive fear or **avoidance behaviors** of agoraphobia. - Using it as a **safety behavior** before exposure can inadvertently prevent the patient from learning that anxiety naturally subsides, hindering the effectiveness of exposure therapy. *Add pregabalin 75mg twice daily for anticipatory anxiety* - **Pregabalin** is an anxiolytic, but it is typically a second- or third-line agent and not the most appropriate primary intervention for **agoraphobic avoidance** when panic attacks are controlled. - It does not directly facilitate the **exposure and extinction learning** necessary to overcome specific phobic situations and can add unnecessary polypharmacy. *Prescribe alprazolam 0.5mg as required for use in feared situations* - **Benzodiazepines** like alprazolam carry significant risks of **dependence** and **withdrawal**, and their use can reinforce avoidance behaviors by acting as a **safety pill**. - Their use can interfere with the long-term effectiveness of **exposure-based therapy** by preventing the patient from fully engaging with and habituating to anxious feelings.

Question 81: A 35-year-old woman with moderate depression has been taking citalopram 20mg daily for 5 weeks. She reports some improvement in sleep and appetite but continues to experience low mood and anhedonia. She asks when she should expect to feel better. What is the most appropriate response regarding expected timeframe for therapeutic response?

A. Maximum therapeutic benefit usually occurs within 2 weeks of starting treatment
B. Continue current dose for at least another 1-2 weeks as full response may take 6-8 weeks (Correct Answer)
C. Lack of response by 5 weeks indicates treatment failure and medication should be changed
D. Improvement in physical symptoms suggests likely response but mood symptoms may take 12 weeks
E. Increase dose to 40mg now as 20mg is likely insufficient

Explanation: ***Continue current dose for at least another 1-2 weeks as full response may take 6-8 weeks*** - Antidepressants like **SSRIs** (Citalopram) typically require an adequate trial of **4 to 8 weeks** at a therapeutic dose to evaluate full efficacy.- Improvement in **biological symptoms** (sleep and appetite) at 5 weeks is a positive prognostic sign that mood and **anhedonia** may soon follow.*Maximum therapeutic benefit usually occurs within 2 weeks of starting treatment*- While side effects appear quickly, the **therapeutic lag** means clinical mood improvement rarely peaks within the first 2 weeks.- Only **neurovegetative symptoms** might show early shifts, but core psychological symptoms take significantly longer due to needed **downregulation of receptors**.*Lack of response by 5 weeks indicates treatment failure and medication should be changed*- A change in medication is considered **premature** before reaching the 6-to-8-week mark, especially if the patient is showing partial improvement.- Clinical guidelines recommend a minimum of **6 weeks** at a therapeutic dose before declaring a **non-response** and switching classes.*Improvement in physical symptoms suggests likely response but mood symptoms may take 12 weeks*- Although recovery is gradual, characterizing the standard window for initial therapeutic assessment as **12 weeks** is longer than the standard 6–8 week guideline for initial response.- Waiting 12 weeks without a dose adjustment or review would delay the optimization of treatment for a patient with **persistent depression**.*Increase dose to 40mg now as 20mg is likely insufficient*- **Citalopram 20mg** is a standard therapeutic dose; increasing it before the 8-week assessment increases the risk of **dose-dependent side effects** (e.g., QTc prolongation).- Dose escalation is generally reserved for when there is **no response** or only a partial response after the full 6-to-8-week trial period has elapsed.

Question 82: A 51-year-old man presents with a 3-month history of excessive worry about multiple areas of his life including work, finances, and family health. He reports constant muscle tension, difficulty concentrating, irritability, and poor sleep. He struggles to control the worry. GAD-7 score is 17. He has no previous psychiatric history. What feature would most strongly indicate a need for urgent specialist referral rather than primary care management?

A. Severity of anxiety symptoms with GAD-7 score of 17
B. Duration of symptoms exceeding 6 months
C. Presence of active suicidal planning with intent (Correct Answer)
D. Comorbid symptoms of depression
E. Failure to respond to an initial trial of SSRI treatment

Explanation: ***Presence of active suicidal planning with intent*** - The presence of **active suicidal planning** with intent is a **psychiatric emergency** that overrides routine primary care management, necessitating an **urgent specialist referral** for safety and risk assessment. - While passive ideation might be managed in primary care, **clear intent and planning** indicate a high risk of self-harm requiring immediate secondary care intervention. *Severity of anxiety symptoms with GAD-7 score of 17* - A **GAD-7 score of 17** indicates severe anxiety, but this level of severity can often be initiated and managed within a **primary care setting** using standard protocols like CBT or SSRIs. - High symptom severity alone is not an automatic trigger for **urgent** referral unless it is associated with significant diagnostic uncertainty or immediate risk. *Duration of symptoms exceeding 6 months* - A duration of **6 months** or more is a standard diagnostic criterion for **Generalized Anxiety Disorder (GAD)** under DSM-5 and ICD-11 guidelines. - This timeframe establishes the **chronicity** of the condition but does not inherently signify a need for **urgent specialist escalation**; rather, it confirms the diagnosis often managed in primary care. *Comorbid symptoms of depression* - It is clinically common for GAD to coexist with **depressive symptoms**, and these cases are typically managed in primary care by addressing both conditions simultaneously. - Unless the **comorbid depression** presents with severe functional impairment, psychotic features, or active suicidal ideation with intent, it does not mandate an immediate specialist referral. *Failure to respond to an initial trial of SSRI treatment* - Failure of a **first-line treatment** (like an SSRI) is a common clinical scenario that usually prompts a switch to a different medication or **psychological therapy** within primary care. - Specialist referral for **treatment resistance** usually occurs after the failure of multiple sequential interventions, rather than as an urgent requirement after a single trial.

Question 83: A 33-year-old woman with panic disorder has been taking paroxetine 40mg daily for 6 months with good control of symptoms. She has just discovered she is 8 weeks pregnant. She is concerned about medication risks and asks about continuing treatment. What is the most appropriate management?

A. Stop paroxetine immediately and start CBT
B. Switch to sertraline as it has better safety data in pregnancy
C. Continue paroxetine and arrange detailed fetal cardiac scanning (Correct Answer)
D. Reduce paroxetine dose to 20mg daily to minimize fetal exposure
E. Stop all medication and monitor symptoms closely

Explanation: ***Continue paroxetine and arrange detailed fetal cardiac scanning*** - While paroxetine has a known association with an increased risk of **congenital cardiac malformations**, particularly if exposed during the first trimester, at 8 weeks gestation, the critical period of **organogenesis** is largely complete. - The risk of **maternal relapse** or **discontinuation syndrome** from abruptly stopping an effective antidepressant can be more harmful than continued exposure, necessitating a **detailed fetal cardiac scan** to monitor for potential structural abnormalities. *Stop paroxetine immediately and start CBT* - Immediate cessation of paroxetine can precipitate severe **discontinuation syndrome** and a high risk of **panic disorder relapse**, which can negatively impact both maternal and fetal well-being. - Stopping at 8 weeks does not reverse the **teratogenic risk** already incurred during the critical period of organogenesis, while creating new risks for the mother. *Switch to sertraline as it has better safety data in pregnancy* - Switching medications at this stage exposes the fetus to a **second drug** while the mother risks experiencing **withdrawal symptoms** from paroxetine, without mitigating the cardiac risk already established. - While **sertraline** is often preferred for new prescriptions in pregnancy, discontinuing an effective treatment and initiating another in a stable patient is generally not recommended unless the current treatment is failing. *Reduce paroxetine dose to 20mg daily to minimize fetal exposure* - Reducing the dose may render the treatment **subtherapeutic**, leading to a **relapse of panic symptoms** for the mother without necessarily eliminating the risk of malformation. - Physiological changes in pregnancy often require **maintaining or even increasing** SSRI doses due to altered pharmacokinetics, so dose reduction offers no proven safety benefit regarding malformation risk at this stage. *Stop all medication and monitor symptoms closely* - Discontinuing effective treatment for **panic disorder** carries a very high risk of **relapse**, which can lead to significant maternal distress, functional impairment, and adverse **neonatal outcomes**. - Monitoring without active treatment is generally insufficient for a patient with a severe enough panic disorder to require 40mg daily of paroxetine for control.

Question 84: What is the primary mechanism by which cognitive behavioural therapy achieves its therapeutic effect in panic disorder?

A. Gradual exposure to feared situations leading to habituation and reduced avoidance
B. Identifying and modifying catastrophic misinterpretations of bodily sensations (Correct Answer)
C. Restructuring early maladaptive schemas from childhood experiences
D. Teaching relaxation techniques to reduce physiological arousal during attacks
E. Enhancing insight into unconscious conflicts underlying anxiety symptoms

Explanation: ***Identifying and modifying catastrophic misinterpretations of bodily sensations***- The **cognitive model of panic disorder** posits that panic attacks are primarily driven by **catastrophic misinterpretations** of benign bodily sensations (e.g., chest pain as a heart attack, dizziness as fainting).- CBT specifically targets these **cognitive distortions** by teaching patients to identify, challenge, and modify their fearful thoughts, leading to a more realistic appraisal of internal cues.*Gradual exposure to feared situations leading to habituation and reduced avoidance*- While **exposure therapy** (including interoceptive and in vivo exposure) is an important component of CBT for panic disorder, it primarily addresses **conditioned fear responses** and **avoidance behaviors**, not the core cognitive misinterpretations.- This technique focuses on **habituation** to feared external or internal stimuli, whereas the primary mechanism involves restructuring thought patterns about bodily sensations.*Restructuring early maladaptive schemas from childhood experiences*- This approach is characteristic of **Schema-Focused Therapy**, which aims to identify and modify deeply ingrained, pervasive negative patterns (schemas) originating in childhood.- Standard CBT for panic disorder is more **present-focused**, concentrating on current cognitive distortions and behavioral patterns rather than extensively exploring early developmental experiences.*Teaching relaxation techniques to reduce physiological arousal during attacks*- **Relaxation techniques** (e.g., diaphragmatic breathing, progressive muscle relaxation) are often used as adjunctive tools to manage anxiety and physiological arousal.- However, over-reliance on relaxation can sometimes become a **safety behavior**, inadvertently reinforcing the belief that bodily sensations are dangerous and need to be controlled, rather than challenging the cognitive misinterpretation itself.*Enhancing insight into unconscious conflicts underlying anxiety symptoms*- This is the primary goal of **psychodynamic psychotherapy**, which seeks to uncover hidden emotional conflicts, past traumas, and defense mechanisms that contribute to anxiety symptoms.- CBT is a **structured, short-term, and present-oriented** therapy that focuses on conscious thought patterns and observable behaviors, distinctly different from the principles of psychodynamic approaches.

Question 85: A 47-year-old man with severe depression has not responded to adequate trials of sertraline, venlafaxine, and mirtazapine over the past 9 months. He has prominent psychomotor retardation, early morning wakening, and has lost 8kg in weight. He expresses passive suicidal ideation but has no active plans. What is the most appropriate next step in management?

A. Add lithium augmentation to current antidepressant
B. Refer for consideration of electroconvulsive therapy
C. Switch to a monoamine oxidase inhibitor
D. Commence combination therapy with venlafaxine and mirtazapine
E. Refer to secondary care for consideration of alternative treatments (Correct Answer)

Explanation: ***Refer to secondary care for consideration of alternative treatments*** - This patient meets the criteria for **treatment-resistant depression**, having failed three adequate antidepressant trials (SSRI, SNRI, and NaSSA) and presenting with **severe symptoms** like psychomotor retardation, significant weight loss, and early morning wakening. - **NICE guidelines** recommend referral to **secondary care mental health services** when primary care management has been unsuccessful, especially with biological features and **passive suicidal ideation**, to explore more advanced treatment options. *Add lithium augmentation to current antidepressant* - **Lithium augmentation** is a recognized strategy for treatment-resistant depression but is typically initiated and closely monitored by **specialist mental health services** due to its narrow therapeutic index. - It requires rigorous monitoring of **serum levels**, renal function, and thyroid function, which makes it unsuitable for initiation as a first next step in primary care for this complex case. *Refer for consideration of electroconvulsive therapy* - **Electroconvulsive therapy (ECT)** is highly effective for severe depression with **psychotic features** or **severe psychomotor retardation**, and is a specialist-level intervention. - While ECT might be considered, the immediate appropriate step is a **referral to specialists** who can perform a comprehensive assessment, including evaluating the suitability for ECT. *Switch to a monoamine oxidase inhibitor* - **MAOIs** are older antidepressants, usually considered second-line or third-line options due to significant **dietary restrictions** (tyramine-rich foods) and potential for severe drug interactions. - These medications require **specialist supervision** and are rarely initiated in primary care due to the risk of **hypertensive crisis** and complex management. *Commence combination therapy with venlafaxine and mirtazapine* - This combination, sometimes referred to as "**California Rocket Fuel**," targets multiple neurotransmitters and can be effective for severe depression but carries an increased risk of **serotonin syndrome** and other side effects. - Such complex augmentation strategies typically necessitate **secondary care assessment** and careful monitoring to evaluate patient suitability, manage potential side effects, and optimize the treatment response.

Question 86: A 28-year-old woman presents to the emergency department with sudden onset severe chest pain, breathlessness, trembling, and a feeling of impending doom that started 10 minutes ago. She has had three similar episodes in the past 2 months. Physical examination is unremarkable. ECG shows sinus tachycardia at 118 bpm. Troponin is negative. She is terrified she is having a heart attack. What is the most important immediate management step?

A. Administer oral diazepam 5mg for acute symptom relief
B. Arrange urgent cardiology assessment and echocardiogram
C. Provide reassurance and education about panic attacks (Correct Answer)
D. Start propranolol 40mg three times daily for symptom control
E. Commence escitalopram 10mg once daily

Explanation: ***Provide reassurance and education about panic attacks*** - The patient's presentation with sudden onset **severe chest pain**, **breathlessness**, **trembling**, and a **feeling of impending doom**, along with recurrent episodes and negative cardiac workup (unremarkable physical exam, **negative troponin**, sinus tachycardia), is classic for a **panic attack**. - The most important immediate step is **reassurance** and **education** to help the patient understand that her symptoms are anxiety-related and not life-threatening, thereby breaking the cycle of **catastrophic misinterpretation** of bodily sensations. *Administer oral diazepam 5mg for acute symptom relief* - While **benzodiazepines** can provide rapid symptom relief, they are generally reserved for severe cases or as a bridge to other treatments due to risks of **sedation**, **dependence**, and potential for masking symptoms. - Prioritizing non-pharmacological interventions like reassurance and psychoeducation in the acute setting empowers the patient and encourages coping skills without immediate medication reliance. *Arrange urgent cardiology assessment and echocardiogram* - Given the **negative troponin** and **sinus tachycardia** on ECG, and the absence of other concerning physical findings, an acute cardiac event has been effectively ruled out. - Further urgent cardiac investigations would likely reinforce the patient's **health anxiety** and delay appropriate management for the underlying panic disorder. *Start propranolol 40mg three times daily for symptom control* - **Beta-blockers** like propranolol can help mitigate some peripheral physical symptoms of anxiety such as **palpitations** and **tremor**, but they do not address the core psychological and cognitive components of a panic attack or disorder. - They are not considered a **first-line acute treatment** for panic attacks and are less effective than psychological interventions or SSRIs for overall panic disorder management. *Commence escitalopram 10mg once daily* - **SSRIs** like escitalopram are the **first-line pharmacological treatment** for long-term management of **panic disorder**, but they typically take several weeks to achieve therapeutic effects. - Initiating an SSRI is a long-term strategy, not the most important immediate step in the emergency department for an acute panic attack, where immediate symptom de-escalation and psychoeducation are paramount.

Question 87: A 56-year-old woman with recurrent depressive disorder has been taking escitalopram 20mg daily for 3 years following her second depressive episode. She has been completely well for the past 2.5 years and wishes to discontinue her medication. She has no current symptoms and her PHQ-9 score is 2. What is the most appropriate advice regarding discontinuation?

A. Stop escitalopram immediately as she has been symptom-free for over 2 years
B. Reduce to 10mg for 2 weeks then stop completely
C. Continue indefinitely as she has had two episodes
D. Gradually reduce the dose over at least 4 weeks while monitoring for symptoms (Correct Answer)
E. Switch to fluoxetine before stopping to minimize discontinuation effects

Explanation: ***Gradually reduce the dose over at least 4 weeks while monitoring for symptoms*** - For patients who have been on antidepressants for a long duration, **NICE guidelines** recommend a gradual **tapering** process over at least **4 weeks** to reduce the risk of discontinuation syndrome. - This approach allows for close monitoring of **relapse symptoms** and ensures that any **discontinuation symptoms** (like dizziness or nausea) are managed by adjusting the rate of reduction. *Stop escitalopram immediately as she has been symptom-free for over 2 years* - **Abrupt cessation** of SSRIs like escitalopram is associated with a high risk of **discontinuation syndrome**, causing flu-like symptoms, irritability, and sensory disturbances. - Immediate withdrawal does not allow for the clinical assessment of whether **depressive symptoms** will return as the drug levels drop. *Reduce to 10mg for 2 weeks then stop completely* - This constitutes a **rapid taper**, which may still be too abrupt for a patient who has been on the medication for **3 years**. - A more **prolonged taper** is preferred for long-term users to minimize the profound physiological shift in **serotonergic signaling**. *Continue indefinitely as she has had two episodes* - While **maintenance therapy** for at least 2 years is recommended after a second episode, the decision to continue **indefinitely** must be a **shared decision** and is not mandated if the patient is stable and wishes to stop. - Given the patient has been well for 2.5 years and has a low **PHQ-9 score**, a trial of discontinuation is a clinically reasonable request. *Switch to fluoxetine before stopping to minimize discontinuation effects* - **Fluoxetine** has a very long **half-life**, making it useful for tapering off drugs with short half-lives (like paroxetine), but this is not standard protocol for **escitalopram**. - Escitalopram can generally be tapered directly by decreasing the dose of the **original medication** without the need for a cross-taper.

Question 88: A 39-year-old man with a 5-month history of generalised anxiety disorder has been taking sertraline 100mg daily for 10 weeks with only partial response. He continues to experience significant worry, muscle tension, and sleep disturbance. His GAD-7 score remains at 14. He has not engaged with any psychological therapy. What is the most appropriate next step in management?

A. Switch to venlafaxine as an alternative pharmacological treatment
B. Augment sertraline with pregabalin
C. Offer cognitive behavioural therapy or applied relaxation (Correct Answer)
D. Increase sertraline to 150mg daily
E. Add short-term benzodiazepine therapy

Explanation: ***Offer cognitive behavioural therapy or applied relaxation*** - According to **NICE guidelines** for Generalised Anxiety Disorder (GAD), the stepped care model recommends offering **evidence-based psychological interventions** like **CBT** or **applied relaxation** alongside or after a drug trial. - This patient has had a partial response to an adequate dose and duration of an **SSRI (Sertraline)** but has not yet utilized any **psychological therapy**, making it the priority next step. *Switch to venlafaxine as an alternative pharmacological treatment* - While **Venlafaxine (an SNRI)** is a valid second-line pharmacological option, switching medications is usually reserved for when a patient has failed to respond to the initial trial or combined therapy, especially when psychological intervention has not been attempted. - **NICE guidelines** prioritize adding psychological therapy (like CBT) as a next step when there's a partial response to an SSRI, before switching to a different antidepressant. *Augment sertraline with pregabalin* - **Pregabalin** can be used as an alternative treatment if the patient cannot tolerate SSRIs or SNRIs, or as an augmentation strategy in severe or resistant GAD, but not typically as the *first* augmentation step when psychological therapy is untried. - Priority is given to **CBT** as a non-pharmacological addition before escalating polypharmacy, which increases the risk of side effects and dependency. *Increase sertraline to 150mg daily* - Although the dose of **Sertraline** can be titrated up to 200mg, the patient has already reached an adequate dose (100mg) for an adequate time (10 weeks) with a **GAD-7 score** that remains high, indicating a partial rather than complete non-response. - **NICE guidelines** recommend offering a high-intensity psychological intervention (like **CBT** or **applied relaxation**) in this scenario, rather than simply increasing the antidepressant dose further, especially as the patient has not engaged in any psychological therapy yet. *Add short-term benzodiazepine therapy* - **Benzodiazepines** are generally not recommended for the long-term management of GAD due to the high risk of **tolerance and dependence**, and they do not address the underlying cognitive and behavioral patterns of anxiety. - They may be used briefly for an acute crisis, but they are inferior to **CBT** as an adjunctive or standalone treatment for sustained symptom reduction and are not a recommended next step for partial response to SSRI without prior psychological therapy.

Question 89: A 42-year-old woman presents with a 6-week history of low mood, poor concentration, and disturbed sleep. She reports feeling tearful most days and has lost interest in her usual hobbies. She denies any suicidal thoughts. Her medical history includes well-controlled hypothyroidism on levothyroxine 100mcg daily. Recent thyroid function tests are within normal range. PHQ-9 score is 16. What is the most appropriate initial management?

A. Commence sertraline 50mg once daily
B. Refer urgently to secondary care mental health services
C. Increase levothyroxine dose to 125mcg daily
D. Offer a low-intensity psychosocial intervention such as guided self-help (Correct Answer)
E. Arrange review in 2 weeks with no specific intervention

Explanation: ***Offer a low-intensity psychosocial intervention such as guided self-help*** - A **PHQ-9 score of 16** indicates **moderate depression**, for which **NICE guidelines** recommend low-intensity psychological interventions as a first-line option. - Following the **stepped-care model**, these interventions are preferred initially for patients without high-risk features like active suicidal ideation. *Commence sertraline 50mg once daily* - While **SSRIs** like **sertraline** are effective for moderate depression, **psychological therapies** are often prioritized as the initial step, especially when there is no patient preference for medication or history of non-response to therapy. - **Antidepressant medication** is typically considered if psychosocial interventions are ineffective, or for more severe presentations of depression. *Refer urgently to secondary care mental health services* - **Urgent referral** to secondary care or crisis teams is indicated for patients with **active suicidal intent**, severe self-harm, psychotic symptoms, or severe functional impairment. - This patient explicitly **denies suicidal thoughts** and presents with moderate, not severe, depression, making primary care management appropriate. *Increase levothyroxine dose to 125mcg daily* - The patient's **recent thyroid function tests** are **within the normal range**, confirming her **hypothyroidism is well-controlled** and not contributing to her depressive symptoms. - Increasing **levothyroxine** without clinical indication could lead to **iatrogenic hyperthyroidism**, causing adverse effects and failing to address the depression. *Arrange review in 2 weeks with no specific intervention* - This approach, known as **watchful waiting**, is reserved for patients with **subthreshold** or **mild depressive symptoms** (e.g., PHQ-9 < 10) and minimal functional impairment. - A **PHQ-9 score of 16** signifies **moderate depression** requiring active clinical intervention, not just observation, to prevent worsening symptoms.

Question 90: A 34-year-old woman with panic disorder and moderate agoraphobia has been taking sertraline 150mg daily for 6 months with good control of panic attacks (reduced from daily to monthly). However, she remains significantly limited by avoidance of situations where escape might be difficult, including public transport, crowds, and enclosed spaces. She has not received any psychological therapy. Evaluating her current management, which intervention would be expected to provide the greatest additional benefit in addressing her residual functional impairment?

A. Increase sertraline to 200mg daily to target residual anxiety symptoms
B. Add CBT with graded in vivo exposure to feared situations (Correct Answer)
C. Add pregabalin 75mg twice daily for residual anxiety
D. Add propranolol 10mg as required before entering feared situations
E. Switch to venlafaxine 150mg daily which may have superior efficacy

Explanation: ***Add CBT with graded in vivo exposure to feared situations*** - Although **Sertraline** has successfully reduced the frequency of panic attacks, **agoraphobic avoidance** is a behavioral pattern that typically requires **Cognitive Behavioral Therapy (CBT)**, specifically **exposure therapy**, to resolve. - **Graded in vivo exposure** is the most effective intervention for reducing functional impairment related to avoidance by facilitating **habituation** to feared situations and correcting catastrophic misinterpretations of bodily sensations. *Increase sertraline to 200mg daily to target residual anxiety symptoms* - The patient is already on a high dose (150mg) with good control of the primary **panic attacks**, and further titration is unlikely to fully resolve established **avoidance behaviors**. - High-dose SSRI monotherapy without behavioral intervention often leaves patients with persistent **functional impairment** due to avoidance, even if panic attacks are controlled. *Add pregabalin 75mg twice daily for residual anxiety* - While **Pregabalin** can be effective for generalized anxiety disorder, it is not a first-line or primary augmentation strategy for **panic disorder with agoraphobia**, particularly for addressing avoidance. - Adding more medication focuses on **symptom suppression** rather than directly addressing the **learned behavioral avoidance** through exposure and fear extinction. *Add propranolol 10mg as required before entering feared situations* - **Beta-blockers** like propranolol primarily mask peripheral **autonomic symptoms** (e.g., palpitations, tremor) and do not address the core cognitive or behavioral components of **agoraphobia**. - Using medication "as required" for feared situations can act as a **safety behavior**, which paradoxically prevents the necessary process of **habituation** and learning that feared situations are not dangerous. *Switch to venlafaxine 150mg daily which may have superior efficacy* - Switching to another antidepressant like **Venlafaxine** is generally considered when the initial medication is ineffective, but **Sertraline** has already shown good efficacy in reducing panic attack frequency. - The residual impairment is not due to a lack of antidepressant efficacy but rather the untreated **agoraphobic avoidance**, which is best addressed with **psychological intervention**.

Question 91: A 50-year-old woman presents with low mood, reduced energy, and anhedonia for 7 weeks. She also describes feeling extremely anxious most days, with palpitations, tremor, heat intolerance, and unintentional weight loss of 6 kg. On examination, her pulse is 102 bpm and irregular, she has a fine tremor, and a smooth goitre is palpable. What is the most appropriate initial investigation to guide management?

A. PHQ-9 depression questionnaire
B. Thyroid function tests (TSH, free T4, free T3) (Correct Answer)
C. ECG to assess for atrial fibrillation
D. 24-hour urinary free cortisol
E. MRI brain to exclude organic pathology

Explanation: ***Thyroid function tests (TSH, free T4, free T3)*** - The patient exhibits classic signs of **hyperthyroidism**, including anxiety, palpitations, tremor, heat intolerance, unintentional **weight loss**, and a **goitre**, alongside an irregular pulse. - Since psychiatric symptoms like **low mood**, **reduced energy**, and **anhedonia** can be secondary to thyroid dysfunction, establishing a biochemical diagnosis is the priority to guide appropriate medical management. *PHQ-9 depression questionnaire* - While the patient reports **low mood** and **anhedonia**, this tool only screens for the severity of depressive symptoms and does not address the underlying **organic cause**. - Initiating psychiatric treatment without ruling out **hyperthyroidism** would be inappropriate given the prominent physical examination findings. *ECG to assess for atrial fibrillation* - An ECG is indicated given the **irregular pulse** of 102 bpm to assess for cardiac arrhythmias like **atrial fibrillation**, a known complication of hyperthyroidism. - However, it is a diagnostic tool for a *complication* rather than the primary **underlying etiology**, which thyroid function tests would identify. *24-hour urinary free cortisol* - This test is used to screen for **Cushing's syndrome**, which typically presents with **weight gain**, central obesity, hypertension, and proximal muscle weakness. - The patient’s clinical picture of **weight loss**, tachycardia, and heat intolerance is much more consistent with **thyrotoxicosis** than Cushing's. *MRI brain to exclude organic pathology* - A brain MRI is generally reserved for patients with **focal neurological deficits**, seizures, or symptoms highly suggestive of a **space-occupying lesion**. - It is not a standard initial investigation for a patient with clear systemic signs of **thyroid disease** and a palpable goitre.

Question 92: A 42-year-old man with generalised anxiety disorder has completed 12 weeks of individual CBT with good engagement but minimal symptom improvement. His GAD-7 score remains at 16 (moderate-severe anxiety). He has tried sertraline previously but discontinued it after 3 weeks due to gastrointestinal side effects. What is the most appropriate next step in his management?

A. Refer for psychodynamic psychotherapy
B. Offer pregabalin 150mg twice daily
C. Restart sertraline with antiemetic cover
D. Offer an alternative SSRI such as escitalopram or an SNRI such as duloxetine (Correct Answer)
E. Add buspirone to augment psychological therapy

Explanation: ***Offer an alternative SSRI such as escitalopram or an SNRI such as duloxetine*** - According to **NICE guidelines** for GAD, if an initial SSRI is not tolerated or is ineffective after a sufficient trial, the next step is to offer an **alternative SSRI** or an **SNRI** (e.g., duloxetine or venlafaxine). - The patient's previous trial of **sertraline** was brief (3 weeks) due to **gastrointestinal side effects**, making a switch to a different agent a reasonable strategy to find a tolerable and effective pharmacological treatment. *Refer for psychodynamic psychotherapy* - While psychological therapies are important, **CBT** and **applied relaxation** are the primary evidence-based psychological interventions recommended for GAD; **psychodynamic psychotherapy** lacks a strong evidence base for this condition. - Given the patient has already completed 12 weeks of CBT with minimal improvement and has not had a full trial of effective medication, the next step typically involves optimizing pharmacological treatment. *Offer pregabalin 150mg twice daily* - **Pregabalin** is a recommended treatment option for GAD, but it is usually considered after trials of both **SSRIs** and **SNRIs** have been unsuccessful or not tolerated. - Since the patient has only briefly tried one SSRI and SNRIs are still an option, pregabalin is not the immediate next step in the treatment algorithm. *Restart sertraline with antiemetic cover* - Restarting a medication that caused significant **gastrointestinal side effects** leading to early discontinuation is likely to result in poor **adherence** and distress for the patient. - Guidelines generally advise switching to a different antidepressant with a potentially different **side effect profile** rather than attempting to manage the side effects of a previously failed agent. *Add buspirone to augment psychological therapy* - **Buspirone** is not considered a first-line treatment for GAD in UK guidelines and is not typically used as an **augmentation agent** to psychological therapy. - The immediate focus should be on establishing a successful **monotherapy** with an appropriately chosen antidepressant before considering augmentation strategies, especially given the lack of robust evidence for this specific approach.

Question 93: A 37-year-old woman with recurrent depressive disorder has experienced three episodes in the past 6 years, each requiring treatment with antidepressants and each followed by full remission. She is currently well on citalopram 40mg daily, having been symptom-free for 18 months. She asks about stopping her medication. Which factor in her history would most strongly indicate the need for long-term maintenance antidepressant therapy?

A. Age under 40 years at current episode
B. History of three or more depressive episodes (Correct Answer)
C. Duration of current remission exceeding 12 months
D. Previous good response to the same antidepressant
E. Female gender and associated hormonal factors

Explanation: ***History of three or more depressive episodes*** - Guidelines (e.g., **NICE**) strongly recommend long-term maintenance antidepressant therapy for individuals with **three or more prior depressive episodes**, as the risk of relapse is significantly high, often exceeding **70-80%**. - For these patients, maintenance treatment should ideally continue for **at least 2 years**, or even indefinitely in some cases, to effectively prevent future relapses. *Age under 40 years at current episode* - While an **early age of onset** (under 40) is recognized as a risk factor for future depressive episodes, it is not as strong an indicator for the necessity of long-term maintenance therapy as the **total number of previous episodes**. - This factor alone, without a high number of recurrent episodes, does not typically mandate indefinite antidepressant treatment. *Duration of current remission exceeding 12 months* - A sustained period of **remission** (such as 18 months) indicates that the current antidepressant treatment is effective, but it does not mitigate the inherent **high risk of recurrence** associated with a history of multiple depressive episodes. - Discontinuing medication based on prolonged remission in a patient with recurrent depression is a common trigger for **relapse**. *Previous good response to the same antidepressant* - This factor is highly valuable for guiding the **choice of medication** for maintenance therapy, confirming its efficacy for the individual patient. - However, it does not determine the fundamental **clinical need** for maintenance treatment; that decision is primarily driven by the patient's history of recurrence. *Female gender and associated hormonal factors* - While **female gender** is linked to a higher prevalence of depression and potential hormonal influences, it is not a primary or independent criterion for deciding the **duration of maintenance antidepressant therapy** in clinical practice guidelines. - The decision for long-term treatment is predominantly based on the **severity and recurrence pattern** of depressive episodes rather than demographic factors.

Question 94: Which neurotransmitter system dysfunction is most consistently implicated in the pathophysiology of major depressive disorder based on neuroimaging and cerebrospinal fluid studies?

A. Reduced gamma-aminobutyric acid (GABA) in the prefrontal cortex
B. Excessive glutamate activity in the hippocampus
C. Decreased serotonin metabolite 5-HIAA in cerebrospinal fluid (Correct Answer)
D. Elevated dopamine in the mesolimbic pathway
E. Reduced noradrenaline in the locus coeruleus

Explanation: ***Decreased serotonin metabolite 5-HIAA in cerebrospinal fluid*** - Low levels of **5-hydroxyindoleacetic acid (5-HIAA)** in the cerebrospinal fluid are the most consistent and replicated neurochemical findings indicating reduced **serotonergic activity** in depression. - This finding supports the **monoamine hypothesis** and is closely linked to suicidal behavior and mood dysregulation in patients with major depressive disorder. *Reduced gamma-aminobutyric acid (GABA) in the prefrontal cortex* - While some studies show lower **GABA levels** in depression, this finding is less consistent across neuroimaging studies compared to serotonergic markers. - GABAergic dysfunction is often more specifically associated with **anxiety symptoms** or comorbid anxiety disorders rather than core depressive pathology. *Excessive glutamate activity in the hippocampus* - Excessive **glutamate** is associated with the **neurotoxicity hypothesis** of stress and hippocampal atrophy, but direct evidence in CSF is variable. - While ketamine (a glutamate modulator) treats depression, primary glutamate excess is not as consistently demonstrated as the **monoamine deficit**. *Elevated dopamine in the mesolimbic pathway* - Elevated dopamine is typically associated with **psychosis** or mania; in contrast, depression is generally linked to **dopaminergic deficiency**, contributing to **anhedonia**. - Dysregulation of the **mesolimbic reward system** is a feature of depression, but the most consistent biomarker remains serotonin metabolites. *Reduced noradrenaline in the locus coeruleus* - Although **noradrenaline** is implicated in depression (the basis for SNRIs), studies measuring its metabolites like **MHPG** in CSF show inconsistent results. - Noradrenaline dysfunction often correlates with deficits in **attention and physical energy**, but it lacks the robust evidence base of the **serotonin system**.

Question 95: A 29-year-old woman with panic disorder has been taking escitalopram 10mg daily for 12 weeks. Her panic attacks have reduced from daily to once weekly, but she still experiences significant anticipatory anxiety about having attacks in public places. She is motivated for further treatment. According to evidence-based practice, what is the most appropriate next step to optimise her treatment outcome?

A. Increase escitalopram to 20mg daily
B. Add propranolol 10mg as required before anxiety-provoking situations
C. Add diazepam 5mg twice daily for ongoing anxiety
D. Refer for cognitive behavioural therapy with graded exposure (Correct Answer)
E. Switch to paroxetine as it has better evidence for panic disorder

Explanation: ***Refer for cognitive behavioural therapy with graded exposure***- Combining **pharmacotherapy (SSRIs)** with **cognitive behavioural therapy (CBT)** is more effective for panic disorder than medication alone, particularly when addressing **anticipatory anxiety** and **avoidance behavior**.- CBT techniques like **interoceptive exposure** and **graded exposure** help the patient process feared bodily sensations and public situations that medication alone often fails to resolve.*Increase escitalopram to 20mg daily*- While increasing the dose is a common pharmacological step, this patient has already had a **partial response** over 12 weeks, and the residual symptoms are heavily **cognitive/behavioral**.- Evidence suggests that at this stage, adding **specialized psychotherapy** provides a more significant clinical benefit than simply escalating the **SSRI dose**.*Add propranolol 10mg as required before anxiety-provoking situations*- **Beta-blockers** like propranolol are generally not recommended for the core treatment of **panic disorder** as they do not address the underlying psychopathology or anticipate attacks effectively.- These medications focus on **peripheral somatic symptoms** (like palpitations) but do not help with the **catastrophic misinterpretations** central to panic disorder.*Add diazepam 5mg twice daily for ongoing anxiety*- **Benzodiazepines** should be avoided for long-term management of panic disorder due to the high risk of **tolerance, dependence**, and withdrawal issues.- Guidelines generally recommend against their use for chronic anxiety as they can interfere with the efficacy of **exposure-based therapies** by preventing the patient from habituating to anxiety.*Switch to paroxetine as it has better evidence for panic disorder*- Most **SSRIs**, including escitalopram and paroxetine, have comparable efficacy in treating panic disorder, and the patient has already shown a **reduction in attack frequency** on her current regimen.- Switching medications is usually reserved for cases of **treatment failure** or intolerable side effects, whereas this patient is a **partial responder** who needs behavioral intervention.

Question 96: A 54-year-old man with severe depression and significant suicidal ideation is started on venlafaxine. Three weeks into treatment at 150mg daily, his mood has improved slightly but he continues to report low mood and suicidal thoughts. Blood pressure monitoring shows readings of 158/98 mmHg on two separate occasions (baseline 128/82 mmHg). He has no previous history of hypertension. What is the most appropriate next step in management?

A. Stop venlafaxine and switch to mirtazapine (Correct Answer)
B. Continue venlafaxine and add amlodipine for blood pressure control
C. Reduce venlafaxine dose to 75mg daily and review in 2 weeks
D. Continue venlafaxine at current dose and monitor blood pressure more frequently as hypertension may be transient
E. Arrange urgent psychiatric admission for electroconvulsive therapy

Explanation: ***Stop venlafaxine and switch to mirtazapine*** - **Venlafaxine**, a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), is known to cause **dose-dependent hypertension** due to its norepinephrinergic effects, especially at doses of 150mg or higher. - Switching to **mirtazapine** is appropriate as it lacks the hypertensive side effect profile and is effective for **severe depression** with suicidal ideation due to its sedating and anxiolytic properties. *Continue venlafaxine and add amlodipine for blood pressure control* - It is clinically inappropriate to prescribe a second medication to treat the **side effects** of the first when an equally effective alternative class is available. - Managing the patient with **polypharmacy** increases the risk of further side effects and complications in a patient already struggling with severe depression. *Reduce venlafaxine dose to 75mg daily and review in 2 weeks* - While a lower dose may reduce **blood pressure**, it is likely to be sub-therapeutic for a patient with **severe depression** and significant **suicidal ideation**. - Dose reduction may delay the stabilization of the patient's mental health, which is a critical priority given the risk of self-harm. *Continue venlafaxine at current dose and monitor blood pressure more frequently as hypertension may be transient* - The hypertension associated with SNRIs is typically sustained rather than **transient**; persistent readings of 158/98 mmHg pose an immediate **cardiovascular risk**. - Current clinical guidelines recommend either reducing the dose or discontinuing the drug if blood pressure increases significantly during treatment. *Arrange urgent psychiatric admission for electroconvulsive therapy* - **Electroconvulsive therapy (ECT)** is generally reserved for life-threatening depression or cases resistant to multiple pharmacological trials, not as a first-line response to a medication's side effect. - The patient has shown a **slight improvement** in mood on venlafaxine, suggesting that optimized pharmacotherapy should be explored before resorting to invasive treatments.

Question 97: A 46-year-old woman presents with a 4-month history of persistent worry about multiple aspects of her life including her children's safety, finances, and work performance. She reports feeling restless, experiencing muscle tension, having difficulty concentrating, and poor sleep. She finds it extremely difficult to control her worry. Her symptoms occur most days and significantly impair her social functioning. Physical examination and routine blood tests including thyroid function are normal. What is the most appropriate first-line treatment?

A. Low-intensity psychological intervention such as guided self-help based on CBT principles
B. High-intensity psychological intervention such as individual CBT (Correct Answer)
C. Sertraline 50mg once daily
D. Diazepam 5mg three times daily
E. Propranolol 40mg twice daily

Explanation: ***High-intensity psychological intervention such as individual CBT*** - For patients with **Generalized Anxiety Disorder (GAD)** causing significant functional impairment, NICE guidelines recommend **high-intensity psychological interventions** (CBT or applied relaxation) as a first-line option. - Individual **Cognitive Behavioral Therapy (CBT)** specifically targets the cognitive processes of excessive worry and the somatic symptoms of restlessness and muscle tension. *Low-intensity psychological intervention such as guided self-help based on CBT principles* - These interventions are typically the first step in a **stepped-care model** for milder cases of GAD with less functional impairment. - Since this patient presents with symptoms that **significantly impair social functioning**, high-intensity therapy is more appropriate to address the severity of the case. *Sertraline 50mg once daily* - Selective Serotonin Reuptake Inhibitors (**SSRIs**) like sertraline are effective for GAD, but psychological interventions are generally preferred as the initial offering if accessible. - Pharmacological treatment is usually reserved for those who **decline psychological therapy**, fail to respond to it, or have a strong preference for medication. *Diazepam 5mg three times daily* - **Benzodiazepines** are not recommended for long-term management of GAD due to the high risk of **dependence**, tolerance, and cognitive side effects. - They should only be used as a **short-term measure** (max 2-4 weeks) during an acute crisis to manage severe symptoms. *Propranolol 40mg twice daily* - **Beta-blockers** like propranolol may alleviate **autonomic symptoms** of anxiety, such as palpitations or tremors, but they do not treat the psychological core of worry. - Propranolol is not considered a first-line treatment for GAD and has no significant effect on the long-term resolution of the disorder.

Question 98: A 33-year-old woman with a first episode of moderate depression achieved remission after 8 months of treatment with sertraline 100mg daily. She has no previous psychiatric history and no family history of mood disorders. She has been symptom-free for 9 months and wishes to discontinue medication. What is the most appropriate approach to stopping her antidepressant?

A. Reduce sertraline by 50mg every week until discontinued
B. Switch to fluoxetine 20mg for 2 weeks then stop due to its longer half-life
C. Stop sertraline immediately as she has been well for 9 months
D. Reduce sertraline by 25mg every 1-2 weeks while monitoring for symptoms (Correct Answer)
E. Continue indefinitely as relapse risk remains elevated

Explanation: ***Reduce sertraline by 25mg every 1-2 weeks while monitoring for symptoms*** - A **gradual taper** is essential to minimize the risk of **discontinuation syndrome** and allows the clinician to monitor for the return of depressive symptoms. - For a first episode of depression with a 9-month symptom-free period, this **incremental reduction** (25% of dose) follows clinical guidelines for safe cessation. *Reduce sertraline by 50mg every week until discontinued* - This approach is considered **too rapid**, as reducing the dose by 50% weekly significantly increases the likelihood of withdrawal effects like **dizziness** and **paresthesia**. - Faster tapers are generally reserved for situations involving **severe adverse reactions** or when switching to another agent within the same class. *Switch to fluoxetine 20mg for 2 weeks then stop due to its longer half-life* - A **fluoxetine bridge** is typically reserved for antidepressants with very short half-lives, such as **paroxetine** or **venlafaxine**, to mitigate severe withdrawal. - Sertraline has an intermediate half-life, making a direct taper clinically appropriate without the added complexity of **switching medications**. *Stop sertraline immediately as she has been well for 9 months* - **Abrupt discontinuation** of SSRIs is contraindicated due to the high risk of **SSRI discontinuation syndrome**, even if the patient feels completely recovered. - Sudden cessation prevents the brain from adapting to the reappearance of normal **serotonin reuptake** levels, leading to physical and psychological distress. *Continue indefinitely as relapse risk remains elevated* - **Indefinite treatment** is usually only indicated for patients with a **recurrent history** (3 or more episodes) or significant risk factors for relapse. - For a **first episode** with no family history and successful maintenance, guidelines suggest stopping after 6-9 months of stable remission.

Question 99: A 38-year-old man with panic disorder presents to the emergency department during a panic attack. He reports intense chest pain, breathlessness, dizziness, paraesthesia in his fingers, and a feeling of impending doom. Examination reveals a respiratory rate of 32 breaths per minute. Arterial blood gas analysis shows: pH 7.51, PaCO2 3.2 kPa, PaO2 13.1 kPa, HCO3- 24 mmol/L. What is the most appropriate immediate management?

A. Administer high-flow oxygen via non-rebreather mask
B. Administer intravenous lorazepam 2mg stat
C. Encourage breathing into a paper bag
D. Provide reassurance and coach slow, controlled breathing techniques (Correct Answer)
E. Arrange urgent cardiology review for acute coronary syndrome

Explanation: ***Provide reassurance and coach slow, controlled breathing techniques*** - This patient is experiencing **hyperventilation** secondary to a panic attack, leading to **respiratory alkalosis** (pH 7.51, low PaCO2); initial management should always be non-pharmacological. - Coaching the patient to perform **slow, controlled breathing** (6-10 breaths per minute) is the most effective way to normalize PaCO2 levels and reduce physical symptoms like **paraesthesia**. *Administer high-flow oxygen via non-rebreather mask* - High-flow oxygen is contraindicated because the patient already has an **elevated PaO2** (13.1 kPa) and is successfully blowing off carbon dioxide. - Increasing oxygen delivery would not address the **respiratory alkalosis** and is unnecessary in the absence of hypoxia. *Administer intravenous lorazepam 2mg stat* - **Benzodiazepines** are generally reserved as second-line therapy for severe cases that do not respond to psychological interventions or breathing exercises. - Reassurance and breathing techniques are preferred first-line interventions to avoid potential **sedation** and dependence issues associated with pharmacological therapy. *Encourage breathing into a paper bag* - This historical practice is **no longer recommended** as it carries risks of inducing **hypoxia** and hypercapnia if the diagnosis is incorrect (e.g., myocardial infarction or asthma). - Current clinical guidelines and evidence-based practice favor **controlled breathing techniques** over the use of paper bags to manage hyperventilation. *Arrange urgent cardiology review for acute coronary syndrome* - While chest pain is present, the clear history of **panic disorder** and ABG evidence of **respiratory alkalosis** strongly point toward a psychiatric cause. - Although organic pathology must be ruled out in a first presentation, this patient's known diagnosis and **hyperventilation symptoms** prioritize immediate behavioral stabilization.

Question 100: What is the neurobiological mechanism that explains why selective serotonin reuptake inhibitors (SSRIs) typically require 2-4 weeks to produce clinical improvement in depression despite achieving serotonin reuptake inhibition within hours?

A. Time required for the drug to reach therapeutic plasma concentrations
B. Gradual downregulation of presynaptic 5-HT1A autoreceptors increasing serotonergic neurotransmission (Correct Answer)
C. Slow accumulation of serotonin in the synaptic cleft over several weeks
D. Time needed for hepatic enzyme induction to produce active metabolites
E. Progressive increase in serotonin synthesis by tryptophan hydroxylase

Explanation: ***Gradual downregulation of presynaptic 5-HT1A autoreceptors increasing serotonergic neurotransmission*** - Initial use of SSRIs causes an acute increase in serotonin which activates **presynaptic 5-HT1A autoreceptors**, leading to a negative feedback loop that temporarily reduces serotonin release. - Sustained treatment over 2-4 weeks leads to the **desensitization and downregulation** of these autoreceptors, allowing for increased serotonergic neuron firing and subsequent greater release of serotonin into the synaptic cleft, which ultimately produces the clinical antidepressant effect. *Time required for the drug to reach therapeutic plasma concentrations* - This is incorrect because most SSRIs achieve **steady-state plasma concentrations** within a few days of consistent dosing. - The delayed clinical effect is due to **neuroadaptive changes** in the brain, not simply the time it takes for the drug to accumulate in the bloodstream. *Slow accumulation of serotonin in the synaptic cleft over several weeks* - SSRIs inhibit the **serotonin reuptake transporter (SERT)** quite rapidly, leading to an increase in extracellular serotonin concentrations in the somatodendritic region within hours. - The delay is not in the accumulation of serotonin itself, but in the **adaptive changes** of the receptors to this altered serotonin level. *Time needed for hepatic enzyme induction to produce active metabolites* - Most SSRIs are pharmacologically active in their **parent form** and do not require hepatic enzyme induction to become active. - While some SSRIs have **active metabolites** (e.g., fluoxetine to norfluoxetine), their formation does not explain the consistent 2-4 week delay observed across the entire class. *Progressive increase in serotonin synthesis by tryptophan hydroxylase* - SSRIs primarily exert their action by blocking the **reuptake of serotonin**, thereby increasing its availability in the synaptic cleft, rather than by directly stimulating its synthesis. - There is no significant evidence that SSRIs cause a **progressive increase in serotonin synthesis** via tryptophan hydroxylase that would account for the clinical delay.

Question 101: A 41-year-old woman with moderate depression has been taking citalopram 40mg daily for 10 weeks with good response. Her PHQ-9 score has improved from 18 to 6. She now wishes to stop treatment as she feels completely well. What is the most appropriate management advice regarding continuation of antidepressant therapy?

A. Continue treatment for at least 6 months from the point of remission then consider gradual withdrawal (Correct Answer)
B. Stop citalopram immediately as she has achieved remission
C. Switch to psychological therapy and discontinue citalopram over 2 weeks
D. Continue treatment for a further 4 weeks then stop abruptly
E. Reduce citalopram to 20mg daily and continue indefinitely

Explanation: ***Continue treatment for at least 6 months from the point of remission then consider gradual withdrawal***- According to **NICE guidelines**, for a first episode of depression, patients who respond well to antidepressants should continue therapy for **at least 6 months** after achieving remission to significantly reduce the **risk of relapse**.- Maintaining the antidepressant at the **full effective dose** that led to remission during this continuation phase is crucial for ensuring stability and preventing symptom recurrence.*Stop citalopram immediately as she has achieved remission*- Stopping antidepressant medication immediately after achieving symptomatic remission carries a **very high relapse risk**, as the brain's neurochemical balance requires more time to stabilize.- **Abrupt cessation** can also lead to **antidepressant discontinuation syndrome**, characterized by symptoms such as dizziness, nausea, headaches, and flu-like symptoms.*Switch to psychological therapy and discontinue citalopram over 2 weeks*- While **psychological therapy** is an excellent adjunctive treatment for depression, it does not replace the critical **continuation phase** of pharmacotherapy necessary for preventing relapse after a first episode.- A **2-week taper** is generally too rapid for discontinuing an antidepressant like citalopram after 10 weeks of effective treatment, increasing the risk of both relapse and withdrawal symptoms.*Continue treatment for a further 4 weeks then stop abruptly*- Continuing treatment for only **4 weeks** after remission is insufficient; the high risk of **recurrent depressive symptoms** persists if medication is stopped prematurely.- **Abruptly stopping** antidepressant therapy after such a short continuation phase is strongly discouraged due to the increased risk of **relapse** and severe **discontinuation symptoms**.*Reduce citalopram to 20mg daily and continue indefinitely*- **Indefinite continuation** of antidepressant therapy is typically reserved for patients with a history of **recurrent depressive episodes** (e.g., two or more episodes) or chronic severe depression, not usually a first episode.- Reducing the dose during the **continuation phase** is generally not recommended as the **remission-inducing dose** should be maintained to provide adequate protection against relapse.

Question 102: A 25-year-old woman presents with a 5-month history of experiencing sudden episodes of intense fear that peak within minutes. During these episodes she experiences palpitations, trembling, and a sensation of choking. She has been to the emergency department four times convinced she was having a heart attack. All cardiac investigations including ECG, troponin, and echocardiography have been normal. She now avoids crowded places and public transport. What feature would most strongly differentiate panic disorder from generalised anxiety disorder in this patient?

A. The presence of autonomic symptoms during episodes
B. The discrete, time-limited nature of the anxiety episodes (Correct Answer)
C. The development of avoidance behaviours
D. The duration of symptoms exceeding 3 months
E. The presence of excessive worry about physical health

Explanation: ***The discrete, time-limited nature of the anxiety episodes***- **Panic disorder** is uniquely characterized by **paroxysmal episodes** that have a sudden onset, peak rapidly (usually within 10 minutes), and are self-limiting.- In contrast, **generalized anxiety disorder (GAD)** involves a a **persistent, chronic** state of tension and worry that lacks these discrete, high-intensity spikes.*The presence of autonomic symptoms during episodes*- Autonomic symptoms such as **palpitations**, trembling, and sweating are common to both **panic attacks** and the somatic manifestations of **GAD**.- Because these symptoms overlap across many anxiety disorders, they cannot be used to reliably differentiate the two conditions.*The development of avoidance behaviours*- While avoidance is typical of **panic disorder with agoraphobia**, it can also occur in **GAD** as a way to avoid triggers of worry or stress.- Avoidance is a secondary behavioral response rather than a defining characteristic of the **core anxiety pattern** itself.*The duration of symptoms exceeding 3 months*- Both conditions are chronic; **panic disorder** requires 1 month of worry about attacks, while **GAD** requires persistent symptoms for at least **6 months**.- Duration does not distinguish the clinical manifestation as effectively as the **temporal pattern** of the anxiety (episodic vs. continuous).*The presence of excessive worry about physical health*- Excessive worry about health is a central feature of **GAD** (generalized worry) but also occurs in panic disorder as **catastrophic misinterpretation** of physical symptoms.- In **GAD**, this worry is usually wide-ranging and covers multiple life domains, whereas in panic disorder, it is specifically focused on the **imminent danger** of the attack.

Question 103: A 67-year-old man with a 6-week history of severe depression presents with persistent low mood, early morning wakening at 3 AM with inability to return to sleep, psychomotor retardation, and marked anhedonia. He has lost 8 kg in weight and reports feeling worse in the mornings with slight improvement as the day progresses. His PHQ-9 score is 22. What is the most appropriate initial pharmacological treatment?

A. Fluoxetine 20mg once daily
B. Mirtazapine 15mg once nightly (Correct Answer)
C. Sertraline 50mg once daily
D. Venlafaxine 37.5mg twice daily
E. Trazodone 50mg once nightly

Explanation: ***Mirtazapine 15mg once nightly*** - **Mirtazapine** is a noradrenergic and specific serotonergic antidepressant (NaSSA) that is ideal for patients with **melancholic features**, specifically addressing **insomnia** and **weight loss** through its sedative and appetite-stimulating effects. - Its pharmacological profile makes it a preferred option for elderly patients who present with **psychomotor retardation** and **poor nutrition** associated with severe depression. *Fluoxetine 20mg once daily* - As an SSRI with a **long half-life** and activating properties, it may initially worsen **insomnia** and **early morning wakening**. - It is frequently associated with **decreased appetite**, which would be detrimental to a patient who has already lost **8 kg**. *Sertraline 50mg once daily* - While often a first-line SSRI, it lacks the specific **sedative properties** needed to immediately address this patient's severe **sleep disturbance**. - Like other SSRIs, it carries a risk of **gastrointestinal side effects** that could complicate the patient's existing weight loss and nutritional status. *Venlafaxine 37.5mg twice daily* - This SNRI is generally reserved for **treatment-resistant depression** or cases where SSRIs have failed, rather than as the first-line choice for insomnia-predominant cases. - It can cause **increased blood pressure** and significant withdrawal symptoms, making it less suitable as an initial choice in a 67-year-old before trying more targeted options. *Trazodone 50mg once nightly* - **Trazodone** is primarily utilized in low doses as an adjunct for **insomnia** rather than as a primary monotherapy for **severe depression** with a PHQ-9 score of 22. - At therapeutic antidepressant doses, it is often poorly tolerated due to excessive **orthostatic hypotension** and sedation.

Question 104: A 36-year-old woman with panic disorder has been taking escitalopram 10mg daily for 5 months with excellent response. She is now planning a pregnancy with her partner. She has had no panic attacks for 3 months and her GAD-7 score is 4. What is the most appropriate management of her escitalopram at this stage?

A. Continue escitalopram 10mg daily throughout pregnancy planning and pregnancy
B. Stop escitalopram immediately and monitor for relapse
C. Gradually reduce and stop escitalopram before attempting conception (Correct Answer)
D. Switch to sertraline before conception as it is safer in pregnancy
E. Reduce escitalopram to 5mg daily before attempting conception

Explanation: ***Gradually reduce and stop escitalopram before attempting conception***- For patients with **panic disorder** who have been asymptomatic for several months (remission), NICE guidelines suggest a trial of medication discontinuation prior to conception if the patient is stable.- This patient has been **symptom-free for 3 months** and has a low **GAD-7 score**, making her a good candidate for a gradual taper to minimize neonatal exposure and withdrawal.*Continue escitalopram 10mg daily throughout pregnancy planning and pregnancy*- While some medications are continued for high-risk **recurrent depression**, panic disorder in full remission offers an opportunity to minimize **fetal exposure**.- Continuing therapy is reserved for patients at **high risk of relapse** or those who have failed previous attempts to stop medication.*Stop escitalopram immediately and monitor for relapse*- Abrupt cessation of SSRIs can trigger **discontinuation syndrome**, characterized by dizziness, nausea, and irritability.- A **gradual reduction** over several weeks is necessary to distinguish withdrawal symptoms from a true **relapse** of panic disorder.*Switch to sertraline before conception as it is safer in pregnancy*- While **sertraline** is often preferred in pregnancy, there is no clinical benefit to switching a patient who is already stable on **escitalopram** if the goal is to stop treatment.- Switching introduces a risk of **instability** and new side effects during a critical planning period for pregnancy.*Reduce escitalopram to 5mg daily before attempting conception*- Maintaining a **sub-therapeutic dose** provides neither full protection against relapse nor the benefit of being medication-free for the fetus.- Current clinical practice favors either maintaining the **effective dose** or aiming for complete **discontinuation** when the patient is in remission.

Question 105: A 53-year-old woman with severe depression has been referred for electroconvulsive therapy (ECT) after failing multiple medication trials. She has significant psychomotor retardation, poor oral intake, and nihilistic delusions. Which medication should be discontinued before starting ECT due to the risk of prolonged seizures?

A. Lithium (Correct Answer)
B. Venlafaxine
C. Olanzapine
D. Lorazepam
E. Fluoxetine

Explanation: ***Lithium*** - **Lithium** is known to increase the risk of **prolonged seizures** and **postictal delirium** when combined with ECT. - Discontinuation, typically 24-48 hours before treatment, is recommended to prevent increased **neurotoxicity** and significant cognitive side effects. *Venlafaxine* - **Venlafaxine**, an **SNRI**, is generally safe to continue during ECT and may even **enhance the clinical response**. - It does not significantly lower the **seizure threshold** or contribute to prolonged seizure activity during ECT. *Olanzapine* - **Olanzapine**, an **atypical antipsychotic**, is often continued, especially in cases of **psychotic depression** or **nihilistic delusions**. - It does not cause **prolonged seizures** or typically interfere with the safety or efficacy of electrical stimulation. *Lorazepam* - **Lorazepam**, a **benzodiazepine**, is an **anticonvulsant** that would raise the **seizure threshold**, potentially making ECT ineffective. - It is usually held or tapered before ECT to ensure a **therapeutic seizure**, rather than causing prolonged seizures. *Fluoxetine* - **Fluoxetine**, an **SSRI**, is generally safe to continue during ECT and does not have a documented association with **prolonged seizure duration**. - While it can theoretically lower the seizure threshold slightly, it does not carry the high risk of **delirium** and neurotoxicity seen with lithium.

Question 106: A 44-year-old man with depression and panic disorder presents with symptoms of both conditions. His depression is moderate in severity (PHQ-9 score 16) and panic attacks occur 2-3 times per week with associated avoidance behaviour. He has no other medical conditions. What is the most appropriate management approach?

A. Treat the depression first with an SSRI, then address panic disorder separately once depression improves
B. Start an SSRI which will treat both conditions simultaneously (Correct Answer)
C. Offer CBT for panic disorder first, then review depression symptoms
D. Start an SSRI for depression and a benzodiazepine for panic attacks
E. Refer to specialist mental health services for dual diagnosis management

Explanation: ***Start an SSRI which will treat both conditions simultaneously*** - **Selective Serotonin Reuptake Inhibitors (SSRIs)** are the first-line pharmacotherapy for both **major depressive disorder** and **panic disorder**, allowing for streamlined management of comorbidities. - NICE guidelines suggest that when depression and anxiety disorders coexist, clinicians should prioritize treating the most disabling condition or treat both **simultaneously** using an agent effective for both. *Treat the depression first with an SSRI, then address panic disorder separately once depression improves* - Sequential treatment is unnecessary and inefficient since **SSRIs** provide therapeutic benefit for the symptoms of both conditions at the same time. - Delaying treatment for **panic disorder** may lead to persistent avoidance behavior and reduced quality of life despite improvements in mood. *Offer CBT for panic disorder first, then review depression symptoms* - While **Cognitive Behavioral Therapy (CBT)** is effective, moderate depression (PHQ-9 of 16) often requires immediate intervention to improve the patient's capacity to engage in psychological therapy. - Treating the **panic symptoms** in isolation fails to address the neurochemical and functional impact of the comorbid **moderate depression**. *Start an SSRI for depression and a benzodiazepine for panic attacks* - **Benzodiazepines** are generally avoided in long-term management due to the significant risk of **dependence**, tolerance, and withdrawal symptoms. - Routine use of benzodiazepines for **panic disorder** is not recommended by guidelines because they do not address the underlying pathology as effectively as **SSRIs**. *Refer to specialist mental health services for dual diagnosis management* - Primary care clinicians are typically equipped to manage **uncomplicated comorbid depression and panic disorder** without an immediate specialist referral. - **Dual diagnosis** usually refers to the co-occurrence of mental illness and **substance misuse**, which is not indicated in this patient's clinical presentation.

Question 107: A 61-year-old woman with recurrent depression has been taking mirtazapine 45mg at night for 4 years with excellent control of her symptoms. She now presents with drowsiness, confusion, and general malaise. Blood tests show: sodium 118 mmol/L, potassium 4.2 mmol/L, serum osmolality 245 mOsm/kg, urine osmolality 520 mOsm/kg, urine sodium 45 mmol/L. She takes no other regular medications. What is the most likely cause of her hyponatraemia?

A. Primary polydipsia
B. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (Correct Answer)
C. Adrenal insufficiency
D. Hypothyroidism
E. Cerebral salt wasting syndrome

Explanation: ***Syndrome of inappropriate antidiuretic hormone secretion (SIADH)*** - The patient presents with **hypotonic hyponatraemia** (sodium 118, serum osmolality 245), inappropriately **concentrated urine** (urine osmolality 520 >100 mOsm/kg), and **elevated urine sodium** (45 mmol/L >20 mmol/L), all characteristic findings of SIADH. - **Mirtazapine**, an antidepressant, is known to cause SIADH by increasing ADH release or enhancing its renal effects, even after prolonged use. *Primary polydipsia* - Primary polydipsia is characterized by excessive water intake leading to **dilute urine** (urine osmolality typically <100 mOsm/kg) as the kidneys try to excrete the excess water. - This patient's **urine osmolality of 520 mOsm/kg** is highly concentrated, ruling out primary polydipsia as the cause of her hyponatraemia. *Adrenal insufficiency* - Adrenal insufficiency can cause hyponatraemia, but it typically presents with **hyperkalaemia** due to aldosterone deficiency, which is not seen here (potassium 4.2 mmol/L). - Patients are also often **hypovolaemic** and may have symptoms of hypotension or hyperpigmentation, none of which are described. *Hypothyroidism* - Severe **hypothyroidism** can lead to hyponatraemia, but it is usually associated with other classic symptoms such as fatigue, cold intolerance, and bradycardia, and would typically show a **high TSH**. - The acute presentation of confusion and drowsiness, combined with the specific electrolyte imbalance, points more strongly towards drug-induced SIADH rather than hypothyroidism as the primary cause. *Cerebral salt wasting syndrome* - **Cerebral salt wasting syndrome** is almost exclusively associated with **acute intracranial pathology** (e.g., subarachnoid hemorrhage, brain tumor) and is characterized by **hypovolaemia** due to increased natriuresis. - This patient has no history of neurological injury or signs of hypovolaemia, and the biochemical picture is more consistent with euvolaemic hyponatraemia seen in SIADH.

Question 108: A 27-year-old man presents with recurrent panic attacks occurring 3-4 times per week for the past 2 months. He describes intense fear with palpitations, sweating, and a feeling of impending doom. Between attacks, he worries constantly about having another attack. He has started avoiding crowded places. He has no other medical history. What is the most appropriate first-line treatment according to NICE guidelines?

A. Cognitive behavioural therapy (CBT) focused on panic (Correct Answer)
B. Sertraline 50mg daily
C. Propranolol 40mg as required before situations that trigger anxiety
D. Diazepam 5mg as required during panic attacks
E. Applied relaxation therapy

Explanation: ***Cognitive behavioural therapy (CBT) focused on panic*** - According to **NICE guidelines**, **CBT** is a highly recommended first-line psychological intervention for **panic disorder**, often preferred or offered alongside medication. - CBT helps patients identify and challenge **catastrophic misinterpretations** of bodily sensations and develop coping strategies, directly addressing the core symptoms of panic. *Sertraline 50mg daily* - While **SSRIs** like sertraline are considered first-line pharmacological options for panic disorder, NICE guidelines suggest discussing both **CBT** and medication to determine patient preference. - In a question asking for the

Question 109: A 35-year-old woman with moderate depression has been taking fluoxetine 40mg daily for 7 weeks with good response. She now presents at 8 weeks gestation with an unplanned but wanted pregnancy. She is concerned about continuing fluoxetine. What is the most appropriate advice regarding her antidepressant treatment?

A. Stop fluoxetine immediately as it is contraindicated in pregnancy
B. Continue fluoxetine as benefits likely outweigh risks given good response (Correct Answer)
C. Switch to sertraline as it is safer in pregnancy than fluoxetine
D. Gradually reduce and stop fluoxetine, then start CBT
E. Reduce fluoxetine to 20mg daily to minimize fetal exposure

Explanation: ***Continue fluoxetine as benefits likely outweigh risks given good response*** - In a patient stable on an **SSRI** with a good clinical response, the risk of **relapse of depression** during pregnancy often outweighs the potential risks of fetal exposure. - **Fluoxetine** is considered safe in pregnancy with extensive safety data; maintaining the established effective dose is prioritized to ensure **maternal mental stability**. *Stop fluoxetine immediately as it is contraindicated in pregnancy* - SSRIs are not **contraindicated** in pregnancy; sudden cessation carries a high risk of **discontinuation syndrome** and relapse. - Untreated depression is associated with poor **antenatal care**, low birth weight, and increased risk of **postnatal depression**. *Switch to sertraline as it is safer in pregnancy than fluoxetine* - While **sertraline** is often a preferred SSRI in pregnancy, switching a patient who is currently **stable and responsive** to fluoxetine is not routinely recommended as it risks destabilization. - There is no strong evidence that sertraline is clinically "safer" than fluoxetine to justify disrupting effective treatment, especially given fluoxetine's extensive safety data in pregnancy. *Gradually reduce and stop fluoxetine, then start CBT* - Although **Cognitive Behavioral Therapy (CBT)** is an excellent adjunct, relying solely on it after stopping a successful medication risks a severe **relapse** in moderate depression. - The decision to stop medication should be based on the patient's **psychiatric history** and risk of relapse, which is high if stopped shortly after achieving response. *Reduce fluoxetine to 20mg daily to minimize fetal exposure* - Reducing the dose below the **therapeutic level** that achieved remission increases the risk of recurrence without significantly eliminating fetal risk. - Sub-therapeutic dosing during pregnancy is generally discouraged; the goal is to use the **minimum effective dose**, which in this patient's case is 40mg.

Question 110: A 49-year-old woman with chronic generalised anxiety disorder has tried sertraline, venlafaxine, and duloxetine over the past 2 years with minimal benefit. She has also completed two courses of CBT with limited response. Her anxiety significantly impacts her work and relationships. Physical health screening is unremarkable. According to NICE guidelines, which medication option should be considered next?

A. Propranolol 40mg three times daily
B. Buspirone 5mg three times daily
C. Pregabalin 150mg twice daily (Correct Answer)
D. Hydroxyzine 25mg three times daily
E. Lorazepam 1mg twice daily

Explanation: ***Pregabalin 150mg twice daily***- According to **NICE guidelines**, when a patient with **Generalised Anxiety Disorder (GAD)** has not responded to initial treatments including two **SSRIs/SNRIs** (sertraline, venlafaxine, duloxetine) and **CBT**, **pregabalin** is the recommended next pharmacological step.- It is a **gamma-aminobutyric acid (GABA) analogue** specifically licensed for GAD, acting to modulate voltage-gated calcium channels and reduce neurotransmitter release, providing an anxiolytic effect.*Propranolol 40mg three times daily*- **Propranolol** is a **beta-blocker** primarily effective for managing the **physical symptoms of anxiety**, such as palpitations, tremor, and sweating, but it does not address the underlying psychological components of GAD.- **NICE guidelines** do not endorse beta-blockers as a primary or sequential treatment option for the psychological aspects of chronic GAD after the failure of multiple antidepressants and CBT.*Buspirone 5mg three times daily*- **Buspirone** acts as a 5-HT1A receptor partial agonist, but its evidence for efficacy in **chronic GAD**, particularly in treatment-resistant cases, is less robust compared to other recommended agents.- It is not typically recommended by **NICE guidelines** as a subsequent pharmacological option after the failure of multiple first-line treatments due to its generally lower efficacy and slower onset of action.*Hydroxyzine 25mg three times daily*- **Hydroxyzine** is a sedating antihistamine that may provide **short-term relief** for acute anxiety symptoms due to its sedative effects, but it is not suitable for chronic management.- Concerns regarding its long-term efficacy, sedative side effects, and potential for **QT prolongation** make it an inappropriate next-line treatment for chronic, treatment-resistant GAD as per NICE recommendations.*Lorazepam 1mg twice daily*- **Benzodiazepines** like **lorazepam** are highly effective for acute anxiety but carry significant risks of **dependence, tolerance, and withdrawal** with prolonged use.- **NICE guidelines** strongly advise against the long-term use of benzodiazepines for chronic GAD, reserving them only for **short-term (2-4 weeks)** management of severe acute crises, not as a sequential maintenance therapy.

Question 111: A 31-year-old man with panic disorder has been experiencing nocturnal panic attacks occurring 1-2 times per week, waking him from sleep. He is currently taking sertraline 100mg daily and has good control of his daytime panic symptoms. He asks whether these night-time episodes are truly panic attacks. Which feature would most strongly support that these are genuine nocturnal panic attacks?

A. They occur during REM sleep and he recalls vivid dreams
B. They occur during non-REM sleep without preceding dreams or triggers (Correct Answer)
C. They are preceded by sleep paralysis
D. They are associated with abnormal movements witnessed by his partner
E. They occur only in the early hours of the morning between 3-5am

Explanation: ***They occur during non-REM sleep without preceding dreams or triggers*** - **Nocturnal panic attacks** characteristically occur during **non-REM sleep**, most commonly in late **Stage 2** or early **Stage 3 (slow-wave) sleep**, often within the first few hours of sleep. - Unlike nightmares, these episodes are **not preceded by dreams** or specific psychological triggers; the individual awakens abruptly with intense **autonomic arousal** and fear. *They occur during REM sleep and he recalls vivid dreams* - Episodes occurring during **REM sleep** that are associated with vivid, frightening dream content are diagnostic of **nightmares**, not panic attacks. - Panic attacks are characterized by a sudden surge of physiological symptoms without the cognitive narrative typical of REM-related dream imagery. *They are preceded by sleep paralysis* - **Sleep paralysis** involves an inability to move or speak upon waking or falling asleep, often accompanied by **hypnagogic/hypnopompic hallucinations**. - While distressing, sleep paralysis is a distinct parasomnia and does not involve the intense autonomic activation and fear associated with a full-blown panic attack. *They are associated with abnormal movements witnessed by his partner* - Significant abnormal movements during sleep, especially complex or violent ones, are more indicative of a **parasomnia** (e.g., REM sleep behavior disorder, sleepwalking) or a **nocturnal seizure**. - Genuine panic attacks involve intense internal autonomic symptoms (e.g., palpitations, dyspnea, sweating) but do not typically manifest with complex motor automatisms. *They occur only in the early hours of the morning between 3-5am* - The **timing** of a nocturnal panic attack is not a definitive diagnostic feature; they can occur at any point during the sleep cycle, though often earlier in the night. - Events more consistently occurring in the early hours of the morning (late in the sleep cycle) are often associated with **REM-sleep phenomena**, like nightmares, as REM sleep predominates then.

Question 112: A 43-year-old woman presents with a 12-week history of persistent low mood, anhedonia, fatigue, and weight gain of 4kg. She reports feeling worse in the evenings and has been sleeping 10-11 hours per night. She has increased her appetite, particularly craving carbohydrates. She has no past psychiatric history. What is the most likely diagnosis?

A. Major depressive disorder with melancholic features
B. Major depressive disorder with atypical features (Correct Answer)
C. Hypothyroidism
D. Seasonal affective disorder
E. Adjustment disorder with depressed mood

Explanation: ***Major depressive disorder with atypical features*** - This diagnosis is characterized by **atypical features** such as **hypersomnia** (sleeping 10-11 hours), **increased appetite** (especially **carbohydrate craving**), and **weight gain** (4kg), all of which align with the patient's presentation. - Patients with atypical features often report **mood reactivity** and may experience a **reverse diurnal variation**, where symptoms feel worse in the **evenings**, consistent with the patient's report. *Major depressive disorder with melancholic features* - Melancholic depression typically presents with **insomnia** (often early morning awakening), **significant weight loss** or **anorexia**, and profound **anhedonia**, which are the opposite of this patient's symptoms. - Symptoms are usually **worse in the morning** and there is a marked **lack of mood reactivity**, differentiating it from the given case. *Hypothyroidism* - While **fatigue**, **low mood**, and **weight gain** can be present, the specific pattern of **hypersomnia** and **carbohydrate craving** is more indicative of atypical depression. - Hypothyroidism usually includes other physical signs like **cold intolerance**, **dry skin**, or **bradycardia**, which are not mentioned in the patient's history. *Seasonal affective disorder* - This diagnosis requires a clear **seasonal pattern** of depressive episodes, typically recurring for at least **two consecutive years**, which is not indicated in the vignette. - Although often presenting with atypical features, the defining criterion of **seasonal periodicity** is absent from the information provided. *Adjustment disorder with depressed mood* - This diagnosis requires an **identifiable psychosocial stressor** within three months of symptom onset, which is not mentioned in the patient's history. - The symptoms must not meet the full criteria for a **Major Depressive Episode**, whereas this patient's prolonged and severe symptoms (12 weeks of low mood, anhedonia, fatigue) clearly meet those criteria.

Question 113: What is the minimum duration for which antidepressant treatment should be continued after remission of a first episode of depression in an adult, according to NICE guidelines?

A. 4 weeks after remission
B. 3 months after remission
C. 6 months after remission (Correct Answer)
D. 12 months after remission
E. 24 months after remission

Explanation: ***6 months after remission*** - For a **first episode** of depression, **NICE guidelines** recommend continuing antidepressant therapy for at least **6 months** after remission to significantly reduce the **risk of relapse**. - The medication should be maintained at the **same dose** that was effective during the acute phase of treatment to ensure maximal preventative effect.*4 weeks after remission* - This duration is insufficient to ensure **neurochemical stabilization** and provides negligible protection against early relapse. - While initial symptomatic improvement may be seen in 2-4 weeks, stopping treatment this early almost guarantees a **high rate of recurrence**.*3 months after remission* - While longer than the acute phase, 3 months is still considered an **inadequate duration** for a first depressive episode according to clinical standards. - Studies show that stopping medication this early markedly increases the likelihood of symptoms returning shortly after cessation, as the brain has not fully recovered.*12 months after remission* - A duration of **12 months** or longer is often recommended for patients with **recurrent depression** (e.g., two or more previous episodes) or those with higher risk factors for relapse. - It is not the standard minimum requirement for a first, uncomplicated episode of depression in an adult, which typically requires a shorter maintenance phase.*24 months after remission* - **NICE guidelines** reserve a **2-year** (24 months) maintenance period for patients who have had **two or more severe depressive episodes**, frequent relapses, or those with chronic depression. - This extended timeframe is intended to provide long-term stability for chronic or severely recurrent cases.

Question 114: A 58-year-old man with severe recurrent depression has failed trials of three different antidepressants at adequate doses and durations. He has significant functional impairment and expresses feelings of hopelessness but denies active suicidal ideation. His past medical history includes well-controlled hypertension and type 2 diabetes. Which treatment option should be considered at this stage?

A. Electroconvulsive therapy (ECT)
B. Transcranial magnetic stimulation (TMS)
C. Lithium augmentation of current antidepressant (Correct Answer)
D. Deep brain stimulation
E. Cognitive behavioural therapy (CBT) alone without medication

Explanation: ***Lithium augmentation of current antidepressant*** - This patient meets the criteria for **Treatment-Resistant Depression (TRD)**, having failed three trials of antidepressants, and **Lithium augmentation** is a primary evidence-based strategy in this scenario. - Augmentation involves adding a second agent to enhance the therapeutic effect, and **Lithium** has strong evidence for reducing **hopelessness** and preventing further relapse in TRD. *Electroconvulsive therapy (ECT)* - While highly effective, ECT is typically reserved for **life-threatening** situations such as severe **suicidality**, **catatonia**, or when a rapid clinical response is indispensable. - This patient denies active **suicidal ideation**, making less invasive pharmacological augmentation like Lithium the more appropriate next step. *Transcranial magnetic stimulation (TMS)* - TMS is a non-invasive procedure used for depression, but it is often considered later in the treatment algorithm or when patients prefer to avoid medication side effects. - It is generally not the first-line recommendation in guideline-driven care compared to the established efficacy of **Lithium augmentation** for severe functional impairment. *Deep brain stimulation* - This is an **invasive/surgical** intervention that remains largely **experimental** and is not standard clinical practice for depression management. - It is only considered in highly specialized centers for **extreme treatment resistance** that has failed all other conventional somatic therapies. *Cognitive behavioural therapy (CBT) alone without medication* - **CBT monotherapy** is insufficient for severe recurrent depression with significant functional impairment and a history of multiple medication failures. - Guidelines suggest that **psychotherapy** should be used as an **adjunct** to medication in TRD, rather than replacing it, to address complex psychosocial stressors.

Question 115: A 39-year-old woman with panic disorder experiences sudden chest pain, breathlessness, and tingling in her hands while shopping. She is brought to A&E by ambulance. Her observations show: heart rate 110 bpm, blood pressure 145/88 mmHg, respiratory rate 26/min, oxygen saturation 99% on air. ECG shows sinus tachycardia. She has a history of similar episodes. What is the most likely cause of her hyperventilation-related symptoms?

A. Metabolic acidosis due to lactic acid accumulation
B. Respiratory alkalosis leading to decreased ionised calcium (Correct Answer)
C. Hypoxia causing peripheral paraesthesia
D. Hypercapnia resulting in cerebral vasoconstriction
E. Hypokalaemia secondary to catecholamine release

Explanation: ***Respiratory alkalosis leading to decreased ionised calcium***- Hyperventilation causes excessive exhalation of **carbon dioxide (CO2)**, leading to an increase in blood pH and the development of **respiratory alkalosis**.- Alkalosis promotes the binding of **calcium** to **albumin**, which reduces the concentration of **ionised calcium**, resulting in symptoms like **paraesthesia** and tingling.*Metabolic acidosis due to lactic acid accumulation*- Hyperventilation specifically results in **alkalosis** due to the loss of carbon dioxide, not **acidosis**.- Lactic acid accumulation is associated with anaerobic metabolism, which is not the physiological driver of acute **panic disorder** symptoms.*Hypoxia causing peripheral paraesthesia*- The patient's **oxygen saturation** is 99% on room air, which objectively rules out **hypoxia** as a cause of her symptoms.- Paraesthesia in hyperventilation is a direct result of **electrolyte shifts** rather than a lack of oxygen delivery to tissues.*Hypercapnia resulting in cerebral vasoconstriction*- Hyperventilation leads to **hypocapnia** (low CO2), not **hypercapnia** (high CO2).- It is **hypocapnia** that triggers **cerebral vasoconstriction**, potentially causing the lightheadedness often felt during a panic attack.*Hypokalaemia secondary to catecholamine release*- While catecholamines can cause a transient shift of potassium into cells, this is not the primary mechanism for **peripheral tingling** in panic attacks.- The characteristic **neuromuscular irritability** seen here is classically driven by the reduction in **ionised calcium** levels.

Question 116: A 24-year-old university student presents with a 4-month history of excessive, uncontrollable worry about academic performance, finances, and health. She reports difficulty concentrating, muscle tension, and poor sleep. She has no significant past medical history and takes no regular medications. Physical examination and routine blood tests are normal. Which initial management approach is most appropriate according to NICE guidelines?

A. Start sertraline 50mg daily immediately
B. Offer low-intensity psychological intervention and psychoeducation (Correct Answer)
C. Prescribe diazepam 2mg three times daily for 2 weeks
D. Refer directly to specialist mental health services
E. Start pregabalin 150mg twice daily

Explanation: ***Offer low-intensity psychological intervention and psychoeducation***- The patient's 4-month history of excessive, uncontrollable worry about various aspects of life, along with difficulty concentrating, muscle tension, and poor sleep, strongly suggests **Generalised Anxiety Disorder (GAD)**. Physical examination and routine blood tests being normal rule out other medical causes.- According to **NICE guidelines** for GAD, the initial recommended management (after simple psychoeducation, which is often combined) is to offer **low-intensity psychological interventions**, such as guided self-help, group psychoeducation, or low-intensity Cognitive Behavioural Therapy (CBT). This aligns with the **stepped-care model** before considering pharmacotherapy.*Start sertraline 50mg daily immediately*- While **SSRIs like sertraline** are a first-line pharmacological option for GAD (considered at Step 3 of the NICE stepped-care model), they are typically offered if **low-intensity psychological interventions** have been ineffective or if the patient expresses a strong preference for medication over psychological therapies.- Starting medication immediately as the very first step, without attempting psychological interventions, is generally not in line with the initial management recommendations for mild-to-moderate GAD.*Prescribe diazepam 2mg three times daily for 2 weeks*- **Benzodiazepines** like diazepam are not recommended for the long-term management of GAD due to a high risk of **dependence, tolerance, and withdrawal symptoms**.- Their use should be limited to very short-term (e.g., a few days) management of severe **crisis** or extreme agitation, and they are not a primary treatment for ongoing anxiety symptoms.*Refer directly to specialist mental health services*- Direct referral to **specialist mental health services** (Step 4 in NICE guidelines) is reserved for individuals with severe GAD, significant **functional impairment**, co-occurring severe mental health conditions, a high risk of self-harm, or those who have not responded to multiple interventions in primary care.- The current presentation does not meet criteria for immediate specialist referral, as initial interventions should be attempted in **primary care**.*Start pregabalin 150mg twice daily*- **Pregabalin** is an alternative pharmacological treatment for GAD, but it is typically considered after a patient has not responded to or cannot tolerate **SSRIs or SNRIs** (selective serotonin and noradrenaline reuptake inhibitors).- It is not an initial management strategy and should only be offered after attempting first-line psychological and pharmacological treatments.

Question 117: A 67-year-old man with moderate depression is being reviewed 6 weeks after starting citalopram 20mg daily. His PHQ-9 score has reduced from 18 to 10. He reports significant improvement in mood and sleep but continues to experience some residual symptoms including reduced concentration and low energy. He tolerates the medication well with no adverse effects. What is the most appropriate next step in management?

A. Continue citalopram 20mg daily and review in 2 weeks
B. Increase citalopram to 40mg daily (Correct Answer)
C. Switch to venlafaxine 75mg daily
D. Add mirtazapine 15mg at night
E. Reduce citalopram to 10mg daily and continue for 2 more weeks

Explanation: ***Increase citalopram to 40mg daily***- In patients with a **partial response** to an antidepressant after 4-6 weeks and continued **residual symptoms**, increasing the dose of the current well-tolerated medication is the most appropriate next step.- This strategy aims to achieve **full remission** by optimizing the therapeutic effect before considering alternative or augmentation therapies.*Continue citalopram 20mg daily and review in 2 weeks*- The patient has shown a **partial response** but still experiences significant residual symptoms, indicating that the current dose is not fully effective.- Continuing the same dose without adjustment fails to address the persistent symptoms and may delay the achievement of **full remission**.*Switch to venlafaxine 75mg daily*- Switching antidepressants is typically reserved for patients who have shown **no response** or have experienced intolerable side effects with the initial treatment.- Given the patient's **significant improvement** and good tolerability, switching at this stage would be premature.*Add mirtazapine 15mg at night*- **Augmentation therapy** is generally considered for **treatment-resistant depression** after monotherapy optimization (including dose escalation) has failed.- It adds complexity and potential for additional side effects, making it a later-line strategy.*Reduce citalopram to 10mg daily and continue for 2 more weeks*- Reducing the dose of an antidepressant is indicated for managing **adverse effects**, which this patient does not report.- Lowering the dose in a partially responsive patient would likely lead to a **worsening of depressive symptoms** and loss of achieved benefits.

Question 118: A 43-year-old woman presents with symptoms of depression including low mood, anhedonia, poor sleep, and reduced appetite for 6 weeks. During assessment, she mentions she has been taking St John's wort for the past 2 weeks, which she purchased from a health food shop. Her PHQ-9 score is 18. You decide pharmacological treatment with an SSRI is indicated. What is the most important consideration regarding her herbal medication?

A. St John's wort can be continued alongside SSRI treatment safely
B. St John's wort must be stopped immediately before starting SSRI due to serotonin syndrome risk (Correct Answer)
C. St John's wort should be tapered gradually over 4 weeks before starting SSRI
D. St John's wort has no interactions and can be ignored in treatment planning
E. St John's wort is contraindicated only with MAOIs, not SSRIs

Explanation: ***St John's wort must be stopped immediately before starting SSRI due to serotonin syndrome risk***- **St John's wort** has serotonergic properties and, when combined with **SSRIs**, significantly increases the risk of life-threatening **serotonin syndrome**.- Because she has only been taking the herbal remedy for **two weeks**, it can be discontinued immediately rather than requiring a prolonged tapering period.*St John's wort can be continued alongside SSRI treatment safely*- This combined use is **contraindicated** due to the high risk of **pharmacodynamic interactions** leading to neuromuscular and autonomic overactivity.- **St John's wort** is a potent **CYP450 enzyme inducer**, which can also alter the metabolism of many other co-administered medications.*St John's wort should be tapered gradually over 4 weeks before starting SSRI*- A **4-week taper** is unnecessary given the short duration of her herbal medicine use (2 weeks) and the clinical urgency to prevent **interaction risks**.- While a small **washout period** is advisable, delaying standard antidepressant treatment for a month would unnecessarily prolong her **PHQ-9 score of 18** (moderate-to-severe depression).*St John's wort has no interactions and can be ignored in treatment planning*- This is medically incorrect; it interacts with numerous drugs, including **warfarin**, **digoxin**, and **oral contraceptives**, by reducing their plasma levels.- Ignoring herbal supplements during assessment can lead to severe **adverse drug reactions** or treatment failure of standard medications.*St John's wort is contraindicated only with MAOIs, not SSRIs*- While it is indeed contraindicated with **MAOIs**, the risk extends to all **serotonergic agents**, including SSRIs and SNRIs.- Clinical guidelines emphasize that any agent that increases **synaptic serotonin** levels constitutes a risk when combined with St John's wort.

Question 119: A 36-year-old woman with generalised anxiety disorder has persistent moderate symptoms (GAD-7 score 12) despite completing 10 weeks of guided self-help and 14 sessions of individual CBT. She has declined medication throughout. She continues to experience excessive worry affecting multiple life domains and has significant functional impairment at work. What is the most appropriate next management step?

A. Refer for long-term psychodynamic psychotherapy
B. Repeat CBT with focus on remaining problem areas
C. Recommend sertraline and arrange close monitoring (Correct Answer)
D. Discharge with crisis contact details for future exacerbation
E. Refer to specialist anxiety disorders service

Explanation: ***Recommend sertraline and arrange close monitoring***- After failing both **low-intensity** (guided self-help) and **high-intensity** (CBT) psychological interventions, medication should be strongly recommended to address persistent **moderate symptoms**.- **Sertraline** is often the first-line SSRI recommended by NICE guidelines for GAD; the clinician must discuss its benefits to overcome the patient's previous refusal.*Refer for long-term psychodynamic psychotherapy*- Psychodynamic psychotherapy is not a standard recommended treatment for **generalized anxiety disorder** over established CBT protocols.- Focus should remain on **evidence-based** treatments for GAD that target the specific cognitive patterns of worry and rumination.*Repeat CBT with focus on remaining problem areas*- Completing **14 sessions** of CBT constitutes a full trial; repeating it immediately after failure is unlikely to result in significant clinical improvement.- Moving to the next step in the **stepped-care model** (pharmacology) is more appropriate than repeating failed Step 3 interventions.*Discharge with crisis contact details for future exacerbation*- Discharge is inappropriate because the patient has a **GAD-7 score of 12** and significant **functional impairment** at work.- Professional duty of care requires exploring further therapeutic options (medication) rather than abandoning treatment while the patient is symptomatic.*Refer to specialist anxiety disorders service*- Specialist referral is usually reserved for **treatment-refractory** cases that have failed both high-intensity psychological therapy and multiple pharmacological trials.- Pharmacological options must be thoroughly explored and exhausted in primary or secondary care before escalating to a **tertiary specialist service**.

Question 120: A 52-year-old woman with depression has been taking venlafaxine 150mg daily for 4 months with good response. She presents to the GP having abruptly stopped her medication 4 days ago due to a stomach upset. She now reports dizziness, electric shock sensations in her head, nausea, and feeling generally unwell. Her observations are: BP 128/78, HR 82, temperature 36.7°C. What is the most likely diagnosis?

A. Serotonin syndrome
B. Antidepressant discontinuation syndrome (Correct Answer)
C. Viral gastroenteritis with dehydration
D. Relapse of depressive episode
E. Hyponatraemia secondary to venlafaxine

Explanation: ***Antidepressant discontinuation syndrome***- Abrupt cessation of antidepressants, particularly those with a **short half-life** like **venlafaxine**, often leads to symptoms like **dizziness**, nausea, and flu-like sensations.- The pathognomonic reporting of **'electric shock sensations'** (brain zaps) and timing (2–4 days post-cessation) is classic for this syndrome.*Serotonin syndrome*- This condition is caused by **excessive serotonin** levels and typically presents with a triad of **autonomic instability**, altered mental status, and **neuromuscular hyperactivity** (e.g., clonus).- It occurs upon initiation or dose increase of serotonergic agents, not upon **discontinuation**.*Viral gastroenteritis with dehydration*- While a stomach upset was the reason for stopping the medication, it does not explain the neurological **'electric shock' sensations**.- The patient's **vital signs** (BP 128/78 and HR 82) are stable, which is inconsistent with significant **dehydration**.*Relapse of depressive episode*- A clinical relapse of **major depressive disorder** usually takes several weeks to manifest and presents with low mood and **anhedonia**.- The acute onset of physical and **sensory symptoms** within 4 days of stopping medication is indicative of withdrawal rather than a return of the primary psychiatric illness.*Hyponatraemia secondary to venlafaxine*- **Hyponatraemia** is a known side effect of daily SSRI/SNRI use, particularly in the elderly, but it occurs while the patient is **taking the drug**.- The specific sensory neurological symptoms described here are not typical for low sodium; **headaches**, confusion, or seizures are more common presentations.

Question 121: A 29-year-old woman with panic disorder reports that her panic attacks are always preceded by noticing her heart beating faster, which makes her think she is having a heart attack, leading to escalating anxiety and full panic symptoms. Which cognitive-behavioural model best explains this phenomenon?

A. Classical conditioning of fear response to cardiac sensations
B. Catastrophic misinterpretation of benign bodily sensations (Correct Answer)
C. Learned helplessness from repeated panic experiences
D. Interoceptive deficit leading to poor recognition of bodily states
E. Cognitive avoidance of anxiety-provoking thoughts

Explanation: ***Catastrophic misinterpretation of benign bodily sensations*** - This phenomenon is the core of **Clark's cognitive model** of panic, where normal physiological changes (like tachycardia) are wrongly perceived as **signs of an emergency** (heart attack). - This creates a **vicious cycle** where perception of a sensation leads to anxiety, which increases the sensation, eventually peaking in a **panic attack**. *Classical conditioning of fear response to cardiac sensations* - This focuses on **learned associations** between a stimulus and a response, but it lacks the **cognitive appraisal** component (thinking one is having a heart attack). - While it explains why sensations trigger a reflex, it does not account for the specific **catastrophic thoughts** described in the scenario. *Learned helplessness from repeated panic experiences* - This model is primarily associated with **depression**, where an individual feels they have **no control** over negative events. - It suggests a passive acceptance or **lack of motivation** rather than the active, escalating anxiety seen in panic disorder. *Interoceptive deficit leading to poor recognition of bodily states* - Patients with panic disorder actually demonstrate **interoceptive hypersensitivity**, meaning they are overly aware of internal bodily sensations, not deficient. - A deficit would imply an **inability to sense** heart rate changes, which contradicts the patient's report of noticing her heart beating faster. *Cognitive avoidance of anxiety-provoking thoughts* - This refers to **suppression** or moving focus away from distressing thoughts, often seen in **Generalized Anxiety Disorder (GAD)** or OCD. - The scenario describes a specific **misinterpretation and escalation** of symptoms rather than an attempt to ignore or avoid them.

Question 122: A 47-year-old man with severe depression (PHQ-9 score 23) has been treated with sertraline 200mg daily for 6 weeks, then venlafaxine 225mg daily for 8 weeks, both without significant improvement. He has declined psychological therapy. His depression includes prominent psychomotor retardation and early morning wakening. He has no active suicidal ideation. What is the most appropriate next step in management?

A. Augment venlafaxine with lithium carbonate (Correct Answer)
B. Switch to mirtazapine monotherapy
C. Augment venlafaxine with quetiapine
D. Refer for electroconvulsive therapy
E. Switch to tranylcypromine

Explanation: ***Augment venlafaxine with lithium carbonate*** - This patient meets the criteria for **treatment-resistant depression**, having failed two adequate trials of different antidepressants (**SSRI** and **SNRI**) at maximum doses. - **Lithium augmentation** has the most robust evidence base for treatment resistance and is recommended by clinical guidelines as a first-line augmentation strategy to enhance antidepressant response. *Switch to mirtazapine monotherapy* - While switching to a third monotherapy class is possible, clinical guidelines generally favor **augmentation strategies** after two failed trials to exploit synergistic pharmacological effects. - **Mirtazapine** is often used in combination with an SNRI (e.g., California Rocket Fuel) rather than as another monotherapy switch in refractory cases. *Augment venlafaxine with quetiapine* - Adding a **second-generation antipsychotic** like quetiapine is a valid evidence-based option for augmentation in treatment-resistant depression. - However, **lithium** is typically preferred as the first augmenting agent due to its longer-standing evidence base and specific mortality-reducing benefits. *Refer for electroconvulsive therapy* - **ECT** is generally reserved for patients with **life-threatening** depression, severe psychomotor retardation with poor oral intake, or high **suicide risk**. - Although this patient has psychomotor retardation, he is not acutely suicidal or physically endangered, making further pharmacological steps appropriate before ECT. *Switch to tranylcypromine* - **Tranylcypromine**, an irreversible MAOI, is typically reserved for highly resistant cases due to its complex dietary restrictions and **hypertensive crisis risk**. - It should only be initiated by specialists when standard augmentation strategies with **lithium** or antipsychotics have already been exhausted.

Question 123: A 34-year-old woman presents with a 4-month history of constant worry about her health, her children's safety, household finances, and work deadlines. She reports feeling restless, easily fatigued, difficulty concentrating, muscle tension, and poor sleep. Her GAD-7 score is 14. She has no past psychiatric history. She is a full-time teacher and feels these symptoms are significantly affecting her work performance. What is the most appropriate first-line treatment approach?

A. Low-intensity psychological intervention such as guided self-help (Correct Answer)
B. High-intensity CBT alone
C. Sertraline 50mg daily alone
D. High-intensity CBT with sertraline 50mg daily
E. Applied relaxation therapy

Explanation: ***Low-intensity psychological intervention such as guided self-help*** - The patient's **GAD-7 score of 14** indicates **moderate anxiety**, and according to **NICE guidelines** for Generalised Anxiety Disorder (GAD), **low-intensity psychological interventions** are the recommended first-line treatment in this step (Step 2). - **Guided self-help** allows the patient to actively participate in managing their symptoms with structured support, aligning with the initial conservative approach for moderate GAD. *High-intensity CBT alone* - **High-intensity CBT** is typically a **Step 3 intervention** in the stepped-care model, reserved for patients who have not responded to low-intensity treatments or those with **more severe anxiety**. - Starting immediately with high-intensity therapy bypasses the standard, less intensive interventions recommended for initial management of moderate GAD. *Sertraline 50mg daily alone* - While **SSRIs** like sertraline are effective for GAD, they are generally considered **Step 3 pharmacological interventions**, usually offered if psychological interventions are declined or have failed. - Guidelines prioritize **psychological interventions** as the initial approach for newly diagnosed GAD, particularly when symptoms are moderate. *High-intensity CBT with sertraline 50mg daily* - **Combination therapy** is typically reserved for cases of **severe GAD** or when monotherapy (either psychological or pharmacological) has been insufficient to achieve symptom control. - Initiating both high-intensity CBT and medication simultaneously is considered an **over-treatment** for a patient presenting with moderate GAD who is new to psychiatric care. *Applied relaxation therapy* - **Applied relaxation therapy** is categorized as a **high-intensity psychological intervention** (Step 3) for GAD, similar to full CBT. - As a Step 3 intervention, it is not the recommended first-line treatment for a patient with **moderate anxiety** who has not yet tried Step 2 interventions.

Question 124: What is the typical time course for response to SSRI treatment in panic disorder according to evidence-based guidelines?

A. Immediate improvement within 2-3 days
B. Gradual improvement starting at 2-4 weeks with full effect by 8-12 weeks (Correct Answer)
C. No improvement until week 6, then rapid response
D. Steady linear improvement throughout the first 4 weeks
E. Initial worsening for 2 weeks followed by improvement

Explanation: ***Gradual improvement starting at 2-4 weeks with full effect by 8-12 weeks*** - **SSRIs** for panic disorder typically show initial symptomatic relief after **2 to 4 weeks** of consistent dosing. - **Full therapeutic effect** and panic attack remission are usually assessed after **8 to 12 weeks** of treatment, as per clinical guidelines. *Immediate improvement within 2-3 days* - This rapid response time is characteristic of **benzodiazepines**, which act quickly but are not suitable for long-term panic disorder management due to dependence risk. - **SSRIs** require time for **neurotransmitter reuptake inhibition** to lead to receptor downregulation and other adaptive changes in the brain, thus immediate effects are not expected. *No improvement until week 6, then rapid response* - Response to **SSRIs** is generally **gradual**, not an abrupt onset after a prolonged period of no effect. - Lack of any improvement by week 4-6 usually prompts a reassessment of **dosage**, adherence, or diagnosis, rather than anticipating a sudden late response. *Steady linear improvement throughout the first 4 weeks* - The improvement with **SSRIs** is often not perfectly linear; there can be fluctuations and a delayed onset of noticeable benefits. - Many patients experience an **initial period of adaptation** or even transient side effects before a more consistent improvement phase begins. *Initial worsening for 2 weeks followed by improvement* - While some individuals may experience **transient anxiety** or **jitteriness** at the start of SSRI treatment (often called the "jitteriness syndrome"), this is a potential side effect, not the typical therapeutic time course. - Describing this as the expected course might discourage **medication adherence**; worsening is a possible side effect, not a universal or desired phase.

Question 125: A 42-year-old man presents with a 10-week history of persistent low mood, anhedonia, poor concentration, and fatigue. He reports passive suicidal ideation but no plans or intent. His PHQ-9 score is 16. He is a recovering alcoholic, abstinent for 2 years, and attends regular AA meetings. Physical examination is unremarkable. What is the most appropriate initial management approach?

A. Commence sertraline 50mg daily and arrange follow-up in 2 weeks
B. Refer for high-intensity CBT and review in 4 weeks
C. Commence mirtazapine 15mg at night and arrange weekly follow-up
D. Admit to psychiatric inpatient unit for stabilisation
E. Commence sertraline 50mg daily and refer for high-intensity CBT (Correct Answer)

Explanation: ***Commence sertraline 50mg daily and refer for high-intensity CBT*** - A **PHQ-9 score of 16** indicates **moderate depression**, for which NICE guidelines recommend a **combination** of antidepressant medication and high-intensity psychological intervention. - **Sertraline** is an appropriate first-line SSRI choice due to its safety profile, especially in patients with a history of alcohol-related issues. *Commence sertraline 50mg daily and arrange follow-up in 2 weeks* - This approach offers pharmacological treatment alone, which is less effective than **combination therapy** for moderate-to-severe depressive episodes. - While follow-up is necessary, the initial management plan must address the need for a **high-intensity psychological intervention** like CBT. *Refer for high-intensity CBT and review in 4 weeks* - For **moderate depression**, managing the patient with psychological therapy alone is generally insufficient without offering **concurrent antidepressant medication**. - Relying solely on CBT may delay the stabilization of mood and physiological symptoms like **anhedonia and fatigue** provided by pharmacological support. *Commence mirtazapine 15mg at night and arrange weekly follow-up* - **Mirtazapine** is often a second-line option and is typically reserved for patients who cannot tolerate SSRIs or have specific needs like **severe insomnia** or **weight loss**. - Although weekly follow-up is safe, **combination therapy** with psychological intervention is still standard practice for this severity level. *Admit to psychiatric inpatient unit for stabilisation* - **Inpatient admission** is not indicated as the patient reports only **passive suicidal ideation** and lacks active plans, intent, or means. - He possesses strong **protective factors**, including two years of alcohol abstinence and active engagement with **support groups** like AA.

Question 126: A 55-year-old woman with recurrent depressive disorder is currently in remission on fluoxetine 20mg daily, which she has been taking for 18 months following her third depressive episode. She asks about stopping her medication as she feels well. Her previous episodes occurred 3 years ago and 6 years ago, each lasting 4-6 months. What is the most appropriate advice regarding continuation of antidepressant therapy?

A. Continue fluoxetine for at least another 6 months then review
B. Continue fluoxetine for at least 2 years from achieving remission (Correct Answer)
C. Begin gradual dose reduction over 4 weeks
D. Switch to a lower dose of 10mg daily for maintenance
E. Continue fluoxetine indefinitely given the recurrent nature

Explanation: ***Continue fluoxetine for at least 2 years from achieving remission***- For patients with a history of **two or more depressive episodes**, like this patient with her third, NICE guidelines recommend continuing antidepressant therapy for at least **2 years** from achieving remission to significantly reduce the risk of relapse.- Maintaining the **full therapeutic dose** that led to remission (fluoxetine 20mg) is crucial for effective long-term prevention of future depressive episodes.*Continue fluoxetine for at least another 6 months then review*- A **6-month continuation period** is the standard recommendation for a **single episode** of depression after remission, not for recurrent cases.- Given this patient's history of **three depressive episodes**, a 6-month period is insufficient and would put her at a high risk of early relapse.*Begin gradual dose reduction over 4 weeks*- Initiating a **dose reduction** or stopping medication now is premature as the patient has not yet completed the recommended **2-year prophylaxis** period for recurrent depression.- Premature cessation of antidepressants in a patient with **recurrent depressive disorder** carries a very high risk of immediate or early relapse.*Switch to a lower dose of 10mg daily for maintenance*- Current practice guidelines advise against using a **lower

Question 127: A 38-year-old woman with panic disorder has been experiencing frequent panic attacks in crowded places. She has started avoiding supermarkets, public transport, and social gatherings. Her panic attacks are well controlled on sertraline 100mg daily, but the avoidance behaviour persists. What is the most appropriate psychological intervention to address her avoidance behaviour?

A. Mindfulness-based cognitive therapy
B. Brief dynamic interpersonal therapy
C. Graded exposure therapy (Correct Answer)
D. Acceptance and commitment therapy
E. Eye movement desensitisation and reprocessing

Explanation: ***Graded exposure therapy*** - This patient exhibits **agoraphobia** and significant **avoidance behavior** related to panic disorder, for which **graded exposure therapy** is the psychological treatment of choice. - It involves systematically and gradually exposing the patient to feared situations in a **hierarchical manner**, allowing for **habituation** and reduction of anxiety and avoidance.*Mindfulness-based cognitive therapy* - This intervention is primarily indicated for preventing **relapse in recurrent depression** and managing chronic pain or stress, rather than treating specific phobic avoidance.- It focuses on changing the patient's relationship with thoughts and feelings through **mindfulness practices**, not direct behavioral modification for agoraphobia.*Brief dynamic interpersonal therapy* - This is an evidence-based treatment primarily for **depression** that focuses on current interpersonal relationships and social functioning.- It is not considered a first-line or most appropriate treatment for **panic disorder with agoraphobia** or specific avoidance behaviors.*Acceptance and commitment therapy* - While it incorporates mindfulness and aims to increase **psychological flexibility**, it is not the primary gold-standard intervention for targeted avoidance in panic disorder with agoraphobia.- Unlike **graded exposure therapy**, its evidence base for directly correcting **agoraphobic avoidance behaviors** is less robust than standard CBT approaches that include exposure.*Eye movement desensitisation and reprocessing* - This specialized therapy is primarily used for the treatment of **Post-Traumatic Stress Disorder (PTSD)** and other trauma-related conditions.- It has no established role as a first-line treatment for **panic disorder with agoraphobia** or general avoidance of crowded places.

Question 128: A 50-year-old man with moderate depression has been taking citalopram 40mg daily for 7 weeks with minimal improvement. His PHQ-9 score remains at 17. He has been adherent to medication and denies any side effects. He declined psychological therapy initially due to work commitments. What is the most appropriate next step in pharmacological management?

A. Increase citalopram to 60mg daily
B. Add mirtazapine 15mg at night to the citalopram
C. Switch to venlafaxine 75mg daily (Correct Answer)
D. Continue citalopram for a further 4 weeks
E. Switch to fluoxetine 20mg daily

Explanation: ***Switch to venlafaxine 75mg daily*** - After a 6-8 week trial of a first-line **SSRI** at an adequate dose (citalopram 40mg daily) with minimal improvement, the recommended next step is to **switch antidepressants**, either to another SSRI or to a different class like an **SNRI**. - **Venlafaxine**, an **SNRI**, is a suitable second-line option for patients who have not responded to initial SSRI treatment, offering a different mechanism of action by inhibiting both **serotonin and norepinephrine reuptake**.*Increase citalopram to 60mg daily* - The **maximum licensed dose** for citalopram is **40mg daily** (or 20mg in the elderly) due to dose-dependent risks of **QT prolongation** and cardiac arrhythmias. - Increasing the dose beyond 40mg is contraindicated and would not be an appropriate clinical step according to relevant **NICE guidelines**.*Add mirtazapine 15mg at night to the citalopram* - **Augmentation strategies**, such as adding mirtazapine to an SSRI, are generally reserved for **treatment-resistant depression** after multiple monotherapy trials have failed. - Guidelines advise **switching monotherapy** first before moving to combination treatments to minimize side effect burden and potential drug interactions.*Continue citalopram for a further 4 weeks* - Clinical response to antidepressants is typically assessed at **4 weeks** and definitively at **6-8 weeks**; this patient has shown minimal improvement despite **7 weeks** of adherence. - Continuing a treatment that has already failed to produce a meaningful reduction in the **PHQ-9 score** over an adequate timeframe is unlikely to lead to further benefit and delays effective treatment.*Switch to fluoxetine 20mg daily* - While switching to another **SSRI** is a valid option, switching to a different drug class (like an **SNRI**) is often preferred when there has been a near-complete lack of response to the initial SSRI. - Given the patient's **moderate depression** and lack of response to a maximum tolerated dose of citalopram, a drug with a different mechanism of action might offer a better chance of efficacy.

Question 129: A 26-year-old woman presents to the emergency department with sudden onset breathlessness, chest pain, trembling, and fear of dying. Symptoms began 15 minutes ago while shopping. She has experienced three similar episodes in the past month. ECG shows sinus tachycardia at 115 bpm. Troponin, D-dimer, and chest X-ray are normal. She is currently symptom-free. What is the most appropriate immediate management?

A. Prescribe a 2-week supply of diazepam 5mg as required
B. Prescribe propranolol 40mg three times daily
C. Provide reassurance and psychoeducation about panic attacks (Correct Answer)
D. Commence escitalopram 10mg daily immediately
E. Arrange same-day psychiatric assessment

Explanation: ***Provide reassurance and psychoeducation about panic attacks*** - After ruling out life-threatening medical conditions like **myocardial infarction** or **pulmonary embolism** with normal investigations, the immediate priority is to reassure the patient. - **Psychoeducation** helps the patient understand that their symptoms, though distressing, are not dangerous and are part of a **panic attack**, reducing their **catastrophic misinterpretation** of physical sensations. *Prescribe a 2-week supply of diazepam 5mg as required* - **Benzodiazepines** carry a high risk of **dependence** and **withdrawal symptoms**, making them generally unsuitable for the routine or long-term management of panic disorder. - Current guidelines, such as those from NICE, specifically advise against the routine use of benzodiazepines for managing **panic disorder** due to these significant risks. *Prescribe propranolol 40mg three times daily* - **Beta-blockers** like propranolol primarily target **autonomic symptoms** such as **tachycardia** and **trembling**, but they do not address the core psychological component of a panic attack. - They are not considered a first-line treatment for **panic disorder** and are less effective than psychological therapies or SSRIs in treating the underlying condition. *Commence escitalopram 10mg daily immediately* - While **SSRIs** like escitalopram are a first-line pharmacological treatment for **panic disorder**, their therapeutic effects take several weeks to become evident and are not suitable for immediate symptom relief in an emergency setting. - Initiation of long-term pharmacotherapy should ideally occur in a primary care setting following a comprehensive assessment and diagnosis of **panic disorder**. *Arrange same-day psychiatric assessment* - An immediate **emergency psychiatric assessment** is generally not required for isolated **panic attacks** once acute medical causes have been excluded, especially if there are no signs of psychosis or immediate risk to self or others. - Appropriate follow-up for the management of recurrent panic attacks would typically involve referral to **primary care** for ongoing management or to **community mental health services** if specialized therapy is indicated.

Question 130: A 31-year-old man with generalised anxiety disorder has been experiencing excessive worry about work performance, finances, and family relationships for 8 months. He reports difficulty controlling the worry, muscle tension, poor concentration, and disturbed sleep. He declined medication initially. After completing a 10-week high-intensity CBT programme, his GAD-7 score has reduced from 18 to 15. What is the most appropriate next step in management?

A. Discharge with self-help materials
B. Repeat the CBT course with a different therapist
C. Commence sertraline and review in 4 weeks (Correct Answer)
D. Refer for psychodynamic psychotherapy
E. Commence pregabalin and review in 2 weeks

Explanation: ***Commence sertraline and review in 4 weeks*** - The patient's GAD-7 score of 15 indicates persistent moderate-to-severe anxiety despite completing a 10-week **high-intensity CBT** program, making pharmacological intervention necessary. - **Sertraline** is a **first-line selective serotonin reuptake inhibitor (SSRI)** recommended for Generalised Anxiety Disorder (GAD) by clinical guidelines, with a **4-week review** being appropriate to assess initial response and tolerability. *Discharge with self-help materials* - Discharge is inappropriate given the patient's ongoing significant symptoms and a GAD-7 score of 15, which indicates continued **clinical impairment**. - Self-help materials are part of **low-intensity interventions** (Step 2), which the patient has already progressed beyond by failing to improve with high-intensity therapy (Step 3). *Repeat the CBT course with a different therapist* - While therapist-client fit is important, there's no strong evidence to suggest that merely repeating an identical **10-week high-intensity CBT course** with a different therapist is the most effective next step after a previous failure. - Guidelines typically recommend **stepping up treatment** to a different modality, such as pharmacotherapy, when a primary psychological intervention is insufficient. *Refer for psychodynamic psychotherapy* - **Psychodynamic psychotherapy** is not a recommended first-line or second-line treatment option for Generalised Anxiety Disorder in most major clinical guidelines (e.g., **NICE**). - It lacks the robust evidence base demonstrated by **CBT** and **pharmacological treatments** like SSRIs for effective management of GAD. *Commence pregabalin and review in 2 weeks* - **Pregabalin** is generally considered a **second or third-line option** for GAD, typically used when first-line agents like SSRIs or SNRIs are ineffective or not tolerated. - **SSRIs** are the initial pharmacological treatment of choice due to their established efficacy and favorable risk-benefit profile compared to pregabalin's potential for **dependence** and specific side effects.

Question 131: A 44-year-old woman presents with a 6-week history of low mood, reduced energy, and weight loss. She describes feeling worthless and guilty about minor past events. Her PHQ-9 score is 21. She has no past psychiatric history and takes no regular medications. Physical examination and routine blood tests are normal. What is the most appropriate first-line pharmacological treatment?

A. Venlafaxine
B. Fluoxetine
C. Amitriptyline
D. Mirtazapine
E. Sertraline (Correct Answer)

Explanation: ***Sertraline*** - **Selective Serotonin Reuptake Inhibitors (SSRIs)** like sertraline are the recommended first-line pharmacological treatment for **moderate-to-severe depression** (PHQ-9 ≥20). - Sertraline is specifically favored due to its **cost-effectiveness**, lower risk of **drug-drug interactions**, and favorable safety profile. *Venlafaxine* - This is a **Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)** typically reserved for **treatment-resistant depression** after SSRIs have failed. - It is associated with a higher risk of **hypertension** and more severe withdrawal symptoms compared to first-line agents. *Fluoxetine* - While an SSRI, it is generally preferred in **children and young people** or when a long half-life is specifically desired. - In adult populations, **sertraline** or citalopram are often prioritized over fluoxetine in many clinical guidelines due to cost-effectiveness analyses. *Amitriptyline* - This is a **Tricyclic Antidepressant (TCA)** and is not first-line because of its high **toxicity in overdose** and significant side-effect burden. - Common side effects include **anticholinergic effects** like dry mouth, blurred vision, and potential cardiac arrhythmias. *Mirtazapine* - This **NaSSA (Noradrenergic and specific serotonergic antidepressant)** is often used as a second-line agent or in patients with prominent **insomnia or weight loss**. - Although effective, its side effects of **sedation and increased appetite** make it less common than SSRIs for initial treatment in most patients.

Question 132: A 36-year-old woman presents with symptoms suggestive of depression. She describes low mood, reduced appetite, poor sleep, and diminished interest in activities for the past 5 weeks. During assessment, which of the following symptoms would be classified as a 'biological' (somatic) symptom of depression according to ICD-10 criteria?

A. Reduced ability to experience pleasure (anhedonia)
B. Diurnal variation in mood with worsening in the morning (Correct Answer)
C. Feelings of worthlessness and guilt
D. Reduced concentration and attention
E. Recurrent thoughts of death

Explanation: ***Diurnal variation in mood with worsening in the morning*** - According to **ICD-10 criteria**, mood that is distinctly worse in the morning is a specific **somatic (biological) symptom** of depression. - Other recognized somatic symptoms include **early morning awakening**, significant **weight loss** (5% or more in a month), and objective **psychomotor agitation or retardation**. *Reduced ability to experience pleasure (anhedonia)* - Although it is a **core symptom** of depression, it is categorized as a psychological/emotional feature rather than a specific somatic symptom in the ICD-10 somatic syndrome classification. - It represents a lack of **emotional reactivity** to enjoyable surroundings but is distinct from the physiological changes like appetite or sleep disturbances. *Feelings of worthlessness and guilt* - These are considered **cognitive symptoms** of depression that reflect the patient's internal thought patterns and self-perception. - While they contribute to the diagnosis of a **depressive episode**, they do not fall under the **somatic syndrome** cluster. *Reduced concentration and attention* - This is a **cognitive impairment** symptom associated with depression that affects daily functioning and task performance. - It is not classified as a **biological symptom**, which typically involves alterations in **circadian rhythms** or physiological drives like hunger and sex. *Recurrent thoughts of death* - Suicidal ideation and thoughts of death are categorized as **psychological and behavioral** symptoms of severe depression. - These symptoms reflect the severity of the **depressive episode** but do not meet the criteria for **biological/somatic features** like diurnal mood variation.

Question 133: A 52-year-old man with chronic generalised anxiety disorder has failed to respond adequately to sertraline 150mg daily and two courses of CBT over the past 18 months. His GAD-7 score remains at 15 and symptoms significantly impact his work and relationships. He has no history of substance misuse. His renal function is normal. Which of the following would be the most appropriate next pharmacological option?

A. Switch to duloxetine
B. Add buspirone as augmentation
C. Switch to pregabalin (Correct Answer)
D. Add quetiapine as augmentation
E. Trial of benzodiazepines for 4 weeks

Explanation: ***Switch to pregabalin*** - **Pregabalin** is recommended by **NICE guidelines** for the treatment of **Generalised Anxiety Disorder (GAD)** if a patient cannot tolerate or does not respond to SSRIs or SNRIs. - It has a distinct mechanism of action as a **voltage-gated calcium channel** ligand, making it a suitable next step after the failure of **Sertraline** and **CBT**. *Switch to duloxetine* - **Duloxetine** is an **SNRI** often used for GAD, but switching between first-line pharmacological classes (SSRI to SNRI) is generally considered after multiple initial failures or as an alternative to **Pregabalin**. - In clinical practice, when an SSRI and intensive psychological therapy fail, **Pregabalin** is often prioritized due to its specific licensing and evidence base for treatment resistance. *Add buspirone as augmentation* - **Buspirone** is a 5-HT1A partial agonist that lacks robust evidence for effectiveness when used as an **augmentation agent** in treatment-resistant GAD. - It is not a preferred next step in UK clinical guidelines compared to switching to an established monotherapy like **Pregabalin**. *Add quetiapine as augmentation* - **Quetiapine** is an atypical antipsychotic that carries a significant risk of **metabolic side effects**, including weight gain and impaired glucose tolerance. - While used in specialist settings for refractory cases, it is not recommended for routine use in primary care or as a standard next step before trying **Pregabalin**. *Trial of benzodiazepines for 4 weeks* - **Benzodiazepines** are generally avoided in the long-term management of GAD due to high risks of **tolerance, dependence**, and withdrawal symptoms. - They are only indicated for **short-term crisis management** (usually 2-4 weeks max) and do not address the underlying pathology in chronic treatment-resistant cases.

Question 134: A 45-year-old woman with moderate depression started on sertraline 50mg daily attends for review after 2 weeks. She reports nausea, loose stools, and increased anxiety. These symptoms started 3 days after beginning the medication. Her mood has not yet improved. She is considering stopping the medication due to side effects. What is the most appropriate management approach?

A. Stop sertraline immediately and switch to mirtazapine
B. Reduce sertraline dose to 25mg daily for 1 week then increase to 50mg
C. Continue current dose with reassurance that side effects typically improve within 1-2 weeks (Correct Answer)
D. Add propranolol to manage anxiety symptoms
E. Stop sertraline and arrange to restart after 1 week washout period

Explanation: ***Continue current dose with reassurance that side effects typically improve within 1-2 weeks*** - Side effects like **nausea**, **loose stools**, and **increased anxiety** are very common when starting **SSRIs** and typically resolve as tolerance develops within the first **forty-eight hours to two weeks**. - Antidepressant **therapeutic benefits** usually take **2-4 weeks** to manifest, so the medication should not be discontinued before an adequate trial period has passed. *Stop sertraline immediately and switch to mirtazapine* - Switching medications is inappropriate until an **adequate trial** of the first-line agent has been completed or if side effects are truly **intolerable**. - **Mirtazapine** has a different side effect profile (e.g., sedation and weight gain) but is generally reserved for patients who do not tolerate or respond to **SSRIs**. *Reduce sertraline dose to 25mg daily for 1 week then increase to 50mg* - While **dose titration** can sometimes help, the patient is already at a standard starting dose, and reduction may unnecessarily delay the time to reaching a **therapeutic level**. - Reassurance is the preferred first step as most patients can successfully habituate to the **50mg dose** without tapering. *Add propranolol to manage anxiety symptoms* - **Propranolol** is used for the symptomatic relief of **physical anxiety symptoms** (like palpitations) but does not address the underlying transient side effects of SSRI initiation. - It is better to manage patient expectations and provide **psychoeducation** rather than adding a second medication for a temporary side effect. *Stop sertraline and arrange to restart after 1 week washout period* - A **washout period** is not indicated for early side effects and would only serve to prolong the patient's **depressive episode** and delay treatment efficacy. - Stopping and restarting often leads to a recurrence of the same **initial side effects**, which can negatively impact future **medication adherence**.

Question 135: A 33-year-old woman with panic disorder and agoraphobia has completed 12 weeks of cognitive behavioural therapy with exposure work. She reports significant improvement with reduced panic frequency and increased confidence in previously avoided situations. However, she still experiences occasional panic attacks (once every 2-3 weeks) and mild anticipatory anxiety. What is the most appropriate next step in her management?

A. Discharge with advice to self-manage using techniques learned
B. Offer further CBT sessions focusing on relapse prevention (Correct Answer)
C. Start an SSRI to address residual symptoms
D. Refer for psychodynamic psychotherapy
E. Prescribe diazepam for use during panic attacks

Explanation: ***Offer further CBT sessions focusing on relapse prevention*** - The patient has shown a **significant response** to Cognitive Behavioural Therapy (CBT), making it the most appropriate path to extend treatment to consolidate gains and manage **residual symptoms**. - Relapse prevention sessions target **anticipatory anxiety** and provide strategies to handle future setbacks, which are crucial for long-term maintenance after the initial 12 weeks.*Discharge with advice to self-manage using techniques learned* - Discharging the patient prematurely while she still experiences **active panic attacks** and anxiety increases the risk of a full clinical relapse. - Monitoring and **embedding skills** through a structured conclusion of therapy is necessary before moving to independent self-management.*Start an SSRI to address residual symptoms* - While **SSRIs** are first-line for panic disorder, they are typically introduced if psychological therapy fails or as an initial combined approach for severe cases. - Given the patient's **good progress** with psychotherapy alone, continuing the psychological approach is preferred over introducing medication side effects for mild residual symptoms.*Refer for psychodynamic psychotherapy* - **Psychodynamic psychotherapy** is not considered a first-line, evidence-based treatment for panic disorder and agoraphobia compared to CBT. - Shifting modalities when a patient is already **positively responding** to the current evidence-based framework is clinically counter-indicated.*Prescribe diazepam for use during panic attacks* - **Benzodiazepines** like diazepam are not recommended for long-term management as they can lead to **dependence and tolerance**. - They act as **safety behaviors**, which undermine the efficacy of CBT exposure work by preventing the patient from learning that panic sensations are not dangerous.

Question 136: A 59-year-old man with recurrent depressive disorder has been taking fluoxetine 40mg daily for 2 years following his third depressive episode. He has been well for 18 months and asks about stopping his medication. According to current NICE guidance, what is the minimum recommended duration of maintenance treatment after a third or subsequent episode of depression?

A. 6 months after remission
B. 12 months after remission
C. 18 months after remission
D. 24 months after remission
E. Indefinite treatment should be considered (Correct Answer)

Explanation: ***Indefinite treatment should be considered*** - For patients with **three or more episodes** of depression (recurrent depressive disorder), the risk of relapse is over **90%**, necessitating long-term maintenance. - NICE guidelines recommend that such patients continue antidepressant treatment for at least **2 years** at the dose that led to remission, with strong consideration for **indefinite therapy** to prevent further recurrences. *6 months after remission* - This duration is typically reserved for a **first-time episode** of depression to reduce the risk of immediate relapse. - It is insufficient for recurrent depression, where the risk of **clinical deterioration** is significantly higher. *12 months after remission* - While some guidelines suggest this for a **second episode** with specific risk factors, it is not the standard for a third or subsequent episode. - Discontinuing at this stage in high-risk patients often leads to **treatment failure** and a rapid return of symptoms. *18 months after remission* - This matches the patient's current duration of wellness, but it falls short of the minimum **24-month guideline** for high-risk individuals. - Stopping now would ignore the **cumulative risk** associated with having had three separate depressive episodes. *24 months after remission* - While antidepressant treatment must be continued for at least **2 years** following remission after a third episode, the ultimate recommendation for such high-risk patients is often to consider **indefinite treatment**. - 24 months serves as a benchmark for review, but the clinical focus remains on **long-term prevention** rather than a fixed end-date, making indefinite treatment the more comprehensive answer.

Question 137: A 37-year-old man with panic disorder describes that his panic attacks are always triggered by being in crowded places, particularly supermarkets and public transport. He has been avoiding these situations for 3 months. He has no unexpected panic attacks. His avoidance is significantly impacting his daily functioning. Which diagnosis best describes his presentation?

A. Panic disorder with agoraphobia
B. Agoraphobia without history of panic disorder (Correct Answer)
C. Specific phobia (situational type)
D. Social anxiety disorder
E. Generalised anxiety disorder with panic attacks

Explanation: ***Agoraphobia without history of panic disorder***- The patient experiences panic attacks that are exclusively **situationally bound** or triggered by specific environments like crowds and public transport, rather than **spontaneous/unexpected** attacks.- According to diagnostic criteria, if panic attacks only occur in response to agoraphobic triggers and there is no history of **unprovoked attacks**, the primary diagnosis is **Agoraphobia**.*Panic disorder with agoraphobia*- **Panic disorder** requires the presence of recurrent, **unexpected panic attacks** that occur "out of the blue."- Since this patient has **no unexpected attacks** and symptoms are strictly triggered by specific situations, this diagnosis is excluded.*Specific phobia (situational type)*- Specific phobia typically involves a fear of a **single, specific situation** (e.g., flying or heights) rather than a cluster of situations.- This patient avoids multiple distinct scenarios like **supermarkets AND public transport**, which fulfills the broader avoidance criteria of **agoraphobia**.*Social anxiety disorder*- Social anxiety is centered on a fear of **social scrutiny**, embarrassment, or being judged by others.- The patient's avoidance is driven by the fear of the **panic symptoms** themselves and the difficulty of escape, rather than a fear of negative evaluation by others.*Generalised anxiety disorder with panic attacks*- **GAD** is characterized by persistent, excessive worry regarding **multiple different domains** (e.g., work, health, finances) for at least 6 months.- This presentation is focused specifically on **situational triggers** and panic symptoms, not the pervasive "free-floating" anxiety typical of GAD.

Question 138: A 43-year-old woman presents with symptoms of depression including low mood, anhedonia, fatigue, and poor concentration for the past 4 weeks. She mentions she has tried St John's Wort purchased online for 2 weeks without benefit. Her PHQ-9 score is 18. You decide to prescribe an SSRI. What is the most important reason for advising her to stop St John's Wort before starting the SSRI?

A. St John's Wort reduces the effectiveness of SSRIs through hepatic enzyme induction
B. Risk of serotonin syndrome from combining serotonergic agents (Correct Answer)
C. St John's Wort can cause hypertensive crisis when combined with SSRIs
D. Both medications together increase bleeding risk significantly
E. The combination reduces compliance due to increased side effects

Explanation: ***Risk of serotonin syndrome from combining serotonergic agents*** - **St John's Wort** contains active compounds like **hypericin** and **hyperforin** that enhance serotonergic activity in the brain. - Combining it with an SSRI, which also increases serotonin levels, significantly raises the risk of **serotonin syndrome**, a potentially life-threatening condition. *St John's Wort reduces the effectiveness of SSRIs through hepatic enzyme induction* - While **St John's Wort** is a known inducer of **CYP3A4** and **P-glycoprotein**, which can reduce the plasma concentration and effectiveness of some SSRIs, this is a pharmacokinetic concern. - The immediate and most critical safety reason to avoid co-administration is the risk of excessive serotonergic activity leading to acute toxicity, rather than merely reduced drug efficacy. *St John's Wort can cause hypertensive crisis when combined with SSRIs* - **Hypertensive crisis** is a well-known risk when **Monoamine Oxidase Inhibitors (MAOIs)** are combined with tyramine-rich foods or certain medications, not typically associated with SSRIs and St John's Wort. - The primary severe adverse interaction between SSRIs and St John's Wort is related to **serotonin overload**, not a direct hypertensive crisis mechanism. *Both medications together increase bleeding risk significantly* - SSRIs can modestly increase **bleeding risk** by interfering with platelet function, and St John's Wort may also have some anticoagulant properties. - However, while a potential concern, the risk of **bleeding** is secondary to the immediate and severe danger of **serotonin syndrome** when considering the most important reason for stopping St John's Wort. *The combination reduces compliance due to increased side effects* - Increased side effects, such as gastrointestinal upset, anxiety, or insomnia, can indeed result from the combination and may reduce **patient compliance**. - Nevertheless, the paramount reason for advising cessation is to prevent a serious medical emergency like **serotonin syndrome**, which takes precedence over concerns about adherence.

Question 139: A 30-year-old woman with panic disorder has been taking sertraline 100mg daily for 10 weeks with good control of panic attacks. She is planning to become pregnant and asks about continuing her medication. She has had no panic attacks for 6 weeks. What is the most appropriate advice regarding her SSRI treatment in relation to pregnancy planning?

A. Continue sertraline as the benefits outweigh risks in pregnancy (Correct Answer)
B. Switch to paroxetine which has better safety data in pregnancy
C. Gradually discontinue sertraline before attempting conception
D. Switch to a tricyclic antidepressant which is safer in pregnancy
E. Reduce sertraline to the lowest effective dose before conception

Explanation: ***Continue sertraline as the benefits outweigh risks in pregnancy*** - **Sertraline** is one of the preferred **SSRIs** in pregnancy due to its extensive safety data and low placental transfer compared to other options. - Maintaining stability in **panic disorder** is crucial, as a relapse during pregnancy poses significant risks to both maternal well-being and fetal outcomes. *Switch to paroxetine which has better safety data in pregnancy* - **Paroxetine** is generally avoided in the first trimester because it is associated with an increased risk of **congenital cardiac malformations**. - It also has a higher risk of **discontinuation syndrome** compared to sertraline, making it a poor choice for switching. *Gradually discontinue sertraline before attempting conception* - Discontinuation poses a high risk of **relapse** of panic disorder, which can lead to poor maternal self-care and increased stress levels during pregnancy. - Decisions should be based on a **risk-benefit analysis** rather than a default recommendation to stop effective treatment. *Switch to a tricyclic antidepressant which is safer in pregnancy* - While **TCAs** like amitriptyline have a long history of use, they are not inherently "safer" than most **SSRIs** and can cause more side effects like sedation and anticholinergic effects. - Switching a patient who is already **clinically stable** on an effective SSRI to a different class is not routinely recommended and may cause unnecessary instability. *Reduce sertraline to the lowest effective dose before conception* - While the goal is always the **minimum effective dose**, the patient is already on a standard therapeutic dose (100mg) that has achieved stability; arbitrary reduction risks **sub-therapeutic levels**. - The priority should be maintaining **clinical remission** rather than focusing solely on dose reduction, which might lead to a return of panic attacks.

Question 140: A 54-year-old woman presents with a 3-month history of persistent worry, restlessness, and muscle tension. She worries excessively about her adult children's wellbeing, household finances, and minor health symptoms. She has difficulty controlling these worries. Her sleep is disturbed. She drinks 4 units of alcohol daily to help her relax. Blood tests including TFTs are normal. What aspect of her presentation requires addressing before initiating standard treatment for generalised anxiety disorder?

A. The need to exclude physical health conditions first
B. The duration of symptoms being less than 6 months
C. The presence of sleep disturbance requiring separate treatment
D. Her alcohol consumption pattern (Correct Answer)
E. Her age being over 50 years requiring dose adjustment

Explanation: ***Her alcohol consumption pattern*** - The patient is consuming **4 units of alcohol daily** to relax, which can exacerbate anxiety, cause **rebound anxiety**, and significantly interfere with the efficacy of standard GAD treatments. - Addressing **alcohol misuse** is a critical first step as it can mimic, worsen, or complicate anxiety symptoms, making effective treatment for GAD challenging until the substance use is managed. *The duration of symptoms being less than 6 months* - While **DSM-5 criteria** typically suggest 6 months for GAD, significant distress over "several months" (as per **ICD-10**) often warrants intervention. - Furthermore, the presence of **alcohol as self-medication** makes addressing substance use a more immediate clinical priority regardless of exact symptom duration. *The presence of sleep disturbance requiring separate treatment* - **Sleep disturbance** is a common and integral **somatic symptom** of Generalised Anxiety Disorder (GAD) itself, rather than an independent sleep disorder. - Effective treatment of the underlying **GAD** with psychological therapies or medication is expected to improve sleep quality without necessarily requiring separate hypnotics. *The need to exclude physical health conditions first* - The vignette states that **blood tests, including TFTs, are normal**, indicating that major physical causes for her anxiety symptoms, such as **hyperthyroidism**, have already been excluded. - While important in initial assessment, in this specific case, the physical screen is complete, making the **alcohol consumption** the next critical factor to address. *Her age being over 50 years requiring dose adjustment* - While a cautious "start low, go slow" approach is often adopted for older adults when prescribing psychotropics, age over 50 is not, in itself, a barrier or an immediate requirement for dose adjustment without other comorbidities or specific indications. - The more pressing issue before initiating GAD treatment is the **active alcohol consumption**, which poses a direct and immediate challenge to treatment effectiveness and safety.

Question 141: A 48-year-old man with a 6-week history of severe depression presents with low mood, anhedonia, significant weight loss, psychomotor retardation, and nihilistic delusions. He believes his internal organs are rotting. He has failed to respond to sertraline 150mg daily after 5 weeks. His wife is concerned about his deteriorating physical condition. What is the most appropriate next step in management?

A. Switch to venlafaxine and continue for 6 weeks
B. Add aripiprazole as augmentation therapy
C. Urgent psychiatric referral for consideration of electroconvulsive therapy (Correct Answer)
D. Add cognitive behavioural therapy to current medication
E. Switch to mirtazapine and add lithium augmentation

Explanation: ***Urgent psychiatric referral for consideration of electroconvulsive therapy*** - The patient presents with **severe depression with psychotic features**, specifically **Cotard syndrome** (nihilistic delusions), along with significant **psychomotor retardation** and **physical deterioration** (weight loss, wife's concern). - **Electroconvulsive therapy (ECT)** is the most effective and rapidly acting treatment for such presentations, especially in cases of severe depression with psychotic features, marked psychomotor retardation, and when rapid response is critical due to physical decline or treatment refractoriness. *Switch to venlafaxine and continue for 6 weeks* - While switching to another antidepressant, such as an **SNRI** like venlafaxine, is a common strategy for treatment-resistant depression, it is insufficient for a patient with **psychotic features** and **rapid physical decline**. - Antidepressant monotherapy is generally ineffective for **psychotic depression**, and the time frame of 6 weeks is too long given the patient's urgent condition. *Add aripiprazole as augmentation therapy* - **Antipsychotic augmentation** (e.g., with aripiprazole) is indeed a valid treatment for **psychotic depression** when added to an antidepressant. - However, given the severe symptoms, **psychomotor retardation**, and **deteriorating physical condition**, **ECT** offers a much faster and more definitive response, making it the preferred initial step in this emergency. *Add cognitive behavioural therapy to current medication* - **Cognitive behavioural therapy (CBT)** is an effective psychotherapy for many forms of depression but is typically not sufficient as a primary treatment for **severe psychotic depression**. - Patients with severe **psychomotor retardation** and **nihilistic delusions** often lack the cognitive capacity and engagement necessary to benefit from psychotherapy at this stage. *Switch to mirtazapine and add lithium augmentation* - Both **mirtazapine** (a tetracyclic antidepressant) and **lithium augmentation** are used in treatment-resistant depression, but this strategy is generally reserved for less acute situations. - This approach would take too long to achieve therapeutic effects and would not adequately address the **psychotic features** and urgent **physical deterioration** as effectively or rapidly as **ECT**.

Question 142: A 35-year-old woman with generalised anxiety disorder describes constant worry about her health, finances, and relationships for the past 8 months. She reports muscle tension, poor concentration, and irritability. She has tried relaxation techniques with limited benefit. Her PHQ-9 score is 8 and GAD-7 score is 16. What is the most appropriate first-line treatment according to current UK guidelines?

A. Diazepam 5mg three times daily for 2 weeks
B. Sertraline 50mg daily
C. Individual cognitive behavioural therapy (Correct Answer)
D. Propranolol 40mg three times daily
E. Pregabalin 150mg twice daily

Explanation: ***Individual cognitive behavioural therapy*** - For **Generalised Anxiety Disorder (GAD)** with a **GAD-7 score of 16** (moderate to severe), NICE guidelines recommend high-intensity psychological interventions like **CBT** as a first-line clinical option. - It provides long-term addressing of cognitive distortions and **maladaptive behaviors** without the side effect profile associated with pharmacotherapy. *Diazepam 5mg three times daily for 2 weeks* - **Benzodiazepines** are not recommended for the long-term management of GAD due to the high risk of **dependence and tolerance**. - They should only be considered for very short-term use during an acute **crisis** to manage extreme symptoms. *Sertraline 50mg daily* - While **SSRIs** are a first-line pharmacological option, UK guidelines often prioritize **high-intensity psychological interventions** if the patient is willing and resources are available. - If medication is chosen, **Sertraline** is the specific SSRI of choice, but it requires monitoring for initial increases in **suicidal ideation** and anxiety. *Propranolol 40mg three times daily* - **Beta-blockers** are not recommended for the treatment of the core symptoms of GAD, as they only mask the **peripheral autonomic features** like palpitations. - They do not address the underlying **psychological worry** or cognitive aspects of the disorder. *Pregabalin 150mg twice daily* - **Pregabalin** is considered a **second-line pharmacological treatment** if the patient cannot tolerate SSRIs or SNRIs. - It is not used as an initial first-line strategy due to different safety profiles and the efficacy of **CBT or SSRIs** as primary interventions.

Question 143: A 40-year-old man with moderate depression has been taking citalopram 20mg daily for 3 weeks. He reports minimal improvement in symptoms and asks about increasing the dose. Physical examination reveals no abnormalities. His blood pressure is 118/76 mmHg. What is the most appropriate management at this stage?

A. Increase citalopram to 40mg daily immediately
B. Continue current dose and review in 1-2 weeks (Correct Answer)
C. Switch to a different SSRI
D. Add mirtazapine as augmentation therapy
E. Refer for cognitive behavioural therapy while continuing medication

Explanation: ***Continue current dose and review in 1-2 weeks*** - Antidepressants like **SSRIs** typically require **4 to 6 weeks** of consistent use at a therapeutic dose to assess clinical efficacy; 3 weeks is too early for a full assessment. - Following current guidelines, the focus should be on **patience and adherence** to allow the medication to reach full therapeutic potential before altering the management plan.*Increase citalopram to 40mg daily immediately* - Increasing the dose prematurely can increase the risk of **dose-dependent side effects**, such as **QT interval prolongation**, without allowing time for the initial dose to work. - Dose escalation is usually only considered after an **adequate trial period** of 4-6 weeks shows insufficient response.*Switch to a different SSRI* - Switching is indicated only if the patient has a **complete lack of response** or intolerable side effects after a full 4-8 week trial. - Moving to another agent at 3 weeks ignores the possibility that the patient may still respond to the current course of **citalopram**.*Add mirtazapine as augmentation therapy* - **Polypharmacy** and augmentation are reserved for **treatment-resistant depression**, which is not yet diagnosed in this patient. - This strategy carries a higher burden of **side effects** and should not be initiated before maximizing or completing a monotherapy trial.*Refer for cognitive behavioural therapy while continuing medication* - While **CBT** is a valid treatment for depression, the primary clinical question concerns the immediate pharmacological management of the current SSRI trial. - Adding psychotherapy is beneficial but does not change the fact that the **biological response** to the medication still requires more time to be adequately evaluated.

Question 144: A 26-year-old woman presents with sudden onset palpitations, chest tightness, sweating, and fear of dying. These episodes last approximately 10 minutes and have occurred unexpectedly on four occasions over the past month. Between episodes she feels well. Physical examination and ECG are normal. What is the minimum number of panic attacks required to meet diagnostic criteria for panic disorder?

A. At least 2 panic attacks within a 1-month period
B. At least 3 panic attacks within a 1-month period
C. At least 4 panic attacks within a 1-month period
D. At least 2 panic attacks followed by 1 month of persistent worry (Correct Answer)
E. At least 1 panic attack followed by 1 month of persistent worry

Explanation: ***At least 2 panic attacks followed by 1 month of persistent worry*** - According to **DSM-5** and clinical guidelines, panic disorder requires recurrent (at least 2) **unexpected panic attacks** as a primary baseline. - Crucially, it must be followed by at least **one month** of persistent concern about additional attacks or a significant **maladaptive change in behavior** related to the attacks. *At least 2 panic attacks within a 1-month period* - While two attacks are necessary, the frequency alone is insufficient without the subsequent **anticipatory anxiety** or behavioral changes. - This option ignores the requirement for the **psychological impact** or worry that defines the clinical disorder. *At least 3 panic attacks within a 1-month period* - There is no specific diagnostic threshold requiring exactly three attacks in current **DSM or ICD** classifications. - Diagnosis focuses more on the **unexpected nature** of the attacks and the patient's ongoing reaction to them rather than a specific count beyond "recurrent." *At least 4 panic attacks within a 1-month period* - Older ICD-10 criteria mentioned four attacks in four weeks for "moderate" cases, but this is not the standard minimum for a general **Panic Disorder** diagnosis. - Modern criteria emphasize the **duration of worry** (1 month) rather than achieving a high frequency of attacks within that month. *At least 1 panic attack followed by 1 month of persistent worry* - A single panic attack is common in the general population; the diagnosis specifically requires **recurrent** (meaning more than one) attacks. - Without a minimum of **two unexpected attacks**, the criteria for a "disorder" of recurrent episodes are not met.

Question 145: A 51-year-old woman presents to her GP with a 5-week history of low mood, loss of appetite, early morning wakening, and difficulty concentrating. She reports feeling guilty about minor past events and has had thoughts that her family would be better off without her, though she has no specific plans to harm herself. Which of the following features would most strongly indicate severe depressive disorder rather than moderate depression?

A. Early morning wakening occurring at least 2 hours before usual time
B. Guilty ruminations about minor past events
C. Thoughts that her family would be better off without her
D. Marked psychomotor retardation observable by others (Correct Answer)
E. Duration of symptoms exceeding 4 weeks

Explanation: ***Marked psychomotor retardation observable by others*** - **Marked psychomotor retardation** (or agitation) is a significant biological marker that indicates a a **severe depressive episode** when it is clearly observable by others. - While patients with moderate depression may feel slowed down, the **observable nature** and intensity of this symptom distinguish severe from moderate impairment. *Early morning wakening occurring at least 2 hours before usual time* - This is considered a **somatic (biological) symptom** of depression, which can be present in both moderate and severe episodes. - While it points toward an **ICD-10 somatic syndrome**, it is not a defining threshold that separates moderate from severe classification on its own. *Guilty ruminations about minor past events* - **Excessive or inappropriate guilt** is a common core symptom of depression used to meet the diagnosis of a **major depressive episode**. - Although guilt can be more intense in severe cases (approaching **delusional intensity**), the presence of ruminations alone is characteristic of moderate depression. *Thoughts that her family would be better off without her* - These are categorized as **passive suicidal ideation** or death wishes, which are frequently seen in **moderate depression**. - To transition into the severe category based on this symptom, there would typically be active planning or a **high risk of harm**. *Duration of symptoms exceeding 4 weeks* - The minimum duration for a depressive episode diagnosis is typically **2 weeks**; exceeding 4 weeks does not determine the **severity status**. - Severity is determined by the **number and intensity of symptoms** and the degree of functional impairment, not the chronicity of the symptoms beyond the 2-week mark.

Question 146: A 29-year-old woman with panic disorder reports that her panic attacks always begin with noticing her heart beating faster, which she interprets as a sign of an impending heart attack. This triggers intense fear and further physical symptoms. Which cognitive-behavioural model component best describes this phenomenon?

A. Interoceptive conditioning
B. Safety-seeking behaviours
C. Catastrophic misinterpretation (Correct Answer)
D. Attentional bias
E. Hyperventilation syndrome

Explanation: ***Catastrophic misinterpretation*** - This refers to the cognitive process where **normal physiological sensations** (like a racing heart) are incorrectly perceived as signs of an **imminent medical emergency** or catastrophe. - According to **Clark's cognitive model**, this creates a **vicious cycle** where fear increases arousal, leading to more physical symptoms and further reinforcing the perceived threat. *Interoceptive conditioning* - This is a **behavioral concept** where low-level somatic sensations become **conditioned stimuli** that trigger a full-blown panic response through prior pairing. - Unlike catastrophic misinterpretation, it focuses on the **learned association** rather than the specific high-level cognitive thought or "meaning" assigned to the symptom. *Safety-seeking behaviours* - These are actions taken by the patient to **prevent a feared outcome**, such as sitting down quickly or checking their pulse to ensure they aren't dying. - While they maintain the disorder by preventing **disconfirmation of fears**, they are the consequence of the interpretation rather than the initial cognitive appraisal process. *Attentional bias* - This describes the **selective monitoring** or automatic scanning of the body for internal sensations that others might ignore. - While the patient demonstrates this by "noticing" her heart beating, the specific act of labeling it a "heart attack" moves beyond bias into **misinterpretation**. *Hyperventilation syndrome* - This is a **physiological state** characterized by over-breathing, which results in respiratory alkalosis and symptoms like dizziness or tingling. - It often accompanies panic attacks but is a **physical mechanism** of symptom production rather than a cognitive-behavioral model component explaining the user's interpretation.

Question 147: A 46-year-old woman presents with symptoms meeting criteria for both generalised anxiety disorder and moderate depressive episode. She has significant sleep disturbance, poor appetite with weight loss, and persistent worry. She requests treatment. According to best practice guidelines, which approach should be prioritized initially?

A. Treat the depression first as it is more responsive to pharmacotherapy
B. Treat the anxiety disorder first as it likely preceded the depression
C. Treat both conditions simultaneously with combined SSRI and CBT (Correct Answer)
D. Commence benzodiazepines for immediate anxiety relief before addressing depression
E. Refer to specialist services due to diagnostic complexity

Explanation: ***Treat both conditions simultaneously with combined SSRI and CBT*** - Comorbid **Generalized Anxiety Disorder (GAD)** and **Depression** are highly prevalent, and **best practice guidelines** recommend an integrated approach targeting both conditions concurrently. - **SSRIs** are effective first-line pharmacotherapy for both **GAD** and **depressive episodes**, while **Cognitive Behavioral Therapy (CBT)** addresses shared underlying cognitive and behavioral mechanisms. *Treat the depression first as it is more responsive to pharmacotherapy* - While depression often responds well to pharmacotherapy, neglecting the **generalized anxiety disorder** can lead to poorer overall outcomes and reduced treatment adherence. - An isolated focus on one disorder often fails to address the interwoven nature and shared symptomatology of comorbid anxiety and depression. *Treat the anxiety disorder first as it likely preceded the depression* - Although anxiety frequently predates depression, delaying treatment for a **moderate depressive episode** can exacerbate symptoms, increase distress, and raise the risk of **suicidality**. - Many effective treatments, particularly **SSRIs**, target both anxiety and depressive symptoms, making a sequential approach less optimal for comorbidity. *Commence benzodiazepines for immediate anxiety relief before addressing depression* - **Benzodiazepines** provide rapid symptom relief but carry risks of **dependence**, tolerance, and withdrawal, and are not effective for treating underlying depression. - They should generally be reserved for short-term use in severe acute anxiety or as an adjunct, not as a primary initial strategy in comorbid GAD and depression. *Refer to specialist services due to diagnostic complexity* - Comorbid **GAD** and **depression** are common presentations in primary care and often respond well to initial management by a general practitioner. - Referral to specialist services is usually indicated for **treatment-resistant** cases, significant safety concerns (e.g., high suicide risk), or diagnostic uncertainty regarding more complex conditions.

Question 148: A 37-year-old man with moderate depression has been taking sertraline 150mg daily for 8 weeks with 40% symptom improvement but remains functionally impaired. His GP considers next management steps. He has no other medical conditions and has not previously tried other antidepressants. Which strategy has the strongest evidence base for improving outcomes at this stage?

A. Continue sertraline at current dose for a further 4-6 weeks (Correct Answer)
B. Increase sertraline to 200mg daily
C. Switch to venlafaxine 150mg daily
D. Add mirtazapine 15mg at night to sertraline
E. Switch to cognitive behavioural therapy alone, discontinuing sertraline

Explanation: ***Continue sertraline at current dose for a further 4-6 weeks*** - A full trial of an antidepressant typically requires **8-12 weeks** at a therapeutic dose; given the patient's **40% symptom improvement** at 8 weeks, continued treatment at the same dose is likely to yield further benefits. - Clinical guidelines support maintaining the current regimen when there's evidence of **partial response**, as many patients achieve **full remission** with more time on the same dose. *Increase sertraline to 200mg daily* - Increasing the dose is generally considered when there is **minimal or no response** after an adequate trial, not when a patient has already shown significant partial improvement. - Higher doses can lead to an increased incidence of **dose-dependent side effects** without necessarily providing additional benefit when the current dose is already partially effective. *Switch to venlafaxine 150mg daily* - Switching to a different antidepressant is typically reserved for cases where the initial drug has proven **ineffective** or is not tolerated after a full trial, which is not the situation here. - Prematurely switching risks losing the **established partial response** and introduces a new set of potential **adverse effects** and withdrawal symptoms from sertraline. *Add mirtazapine 15mg at night to sertraline* - This **augmentation strategy** is usually reserved for **treatment-resistant depression**, generally defined as inadequate response to two or more full trials of monotherapy. - Initiating augmentation at this stage is overly aggressive given the patient's partial response and could increase the risk of **serotonergic side effects** without established need. *Switch to cognitive behavioural therapy alone, discontinuing sertraline* - Discontinuing a medication that is providing a **partial therapeutic effect** is generally not recommended for moderate depression, as it risks relapse or worsening symptoms. - For moderate depression, **cognitive behavioural therapy (CBT)** is most effective when used as **adjunctive therapy** alongside antidepressants, rather than as a replacement for an effective medication.

Question 149: A 33-year-old woman with panic disorder and agoraphobia has been receiving graded exposure therapy as part of CBT. After successfully managing short trips to local shops, she attempts a bus journey but experiences a severe panic attack and immediately returns home. She now refuses further exposure tasks. How should her therapist proceed?

A. Increase the hierarchy gradient by adding intermediate steps before attempting bus travel (Correct Answer)
B. Prescribe benzodiazepines to use before exposure tasks
C. Switch to medication-based treatment as psychological therapy has failed
D. Encourage immediate re-attempt of the bus journey to prevent avoidance consolidation
E. Discontinue exposure therapy and focus on cognitive restructuring techniques only

Explanation: ***Increase the hierarchy gradient by adding intermediate steps before attempting bus travel*** - A severe panic attack indicates the jump from local shops to bus travel was too large; the **anxiety hierarchy** must be adjusted to include more manageable steps to facilitate **habituation**. - Adding intermediate steps, such as sitting on a stationary bus or traveling one stop with a companion, helps rebuild **self-efficacy** and prevents the reinforcement of avoidance behavior. *Prescribe benzodiazepines to use before exposure tasks* - **Benzodiazepines** are generally contraindicated during exposure therapy as they act as a **safety behavior**, preventing the patient from experiencing the anxiety necessary for therapeutic habituation. - Using medication to suppress symptoms during exposure can lead to **state-dependent learning**, where the patient only feels capable when medicated. *Switch to medication-based treatment as psychological therapy has failed* - A single setback during **CBT** does not constitute treatment failure; setbacks are common and provide valuable clinical information about the patient's **fear hierarchy**. - First-line treatment for **panic disorder** with agoraphobia remains psychological, and adjustments to the existing protocol should be attempted before switching modalities. *Encourage immediate re-attempt of the bus journey to prevent avoidance consolidation* - Forcing an immediate re-attempt when the patient is in a state of high arousal and refusal risks **sensitization** rather than habituation, potentially traumatizing the patient further. - While preventing **avoidance consolidation** is important, it must be balanced with the patient's readiness to ensure the exposure remains **therapeutic** and not overwhelming. *Discontinue exposure therapy and focus on cognitive restructuring techniques only* - **Exposure therapy** is the most effective component for treating agoraphobic avoidance; removing it entirely would likely result in stagnant progress regarding her mobility. - **Cognitive restructuring** should complement exposure by challenging catastrophic misinterpretations of bodily sensations, but it cannot replace the behavioral experience of **extinction**.

Question 150: A 53-year-old woman with depression started on citalopram 20mg daily 10 days ago presents with confusion, agitation, tremor, hyperreflexia, and sweating. Temperature is 38.2°C. She also takes tramadol 100mg QDS for chronic back pain and St John's Wort which she didn't mention previously. What is the most likely diagnosis?

A. Neuroleptic malignant syndrome
B. Serotonin syndrome (Correct Answer)
C. Anticholinergic toxicity
D. Citalopram overdose
E. Meningitis

Explanation: ***Serotonin syndrome***- This condition is caused by the overstimulation of central and peripheral serotonin receptors due to the combination of **citalopram**, **tramadol**, and **St John's Wort**.- Key features include the triad of **neuromuscular hyperactivity** (hyperreflexia, tremor), **autonomic instability** (tachycardia, sweating, fever), and **altered mental status** (confusion, agitation).*Neuroleptic malignant syndrome*- Typically develops over days to weeks and is associated with **dopamine antagonists** (antipsychotics) rather than SSRIs.- Characterized by **"lead-pipe" muscle rigidity** and bradyreflexia, whereas serotonin syndrome presents with **hyperreflexia** and **clonus**.*Anticholinergic toxicity*- Patients present with the classic "red as a beet, dry as a bone" signs, including **dry skin** and **decreased bowel sounds**, unlike this patient's **diaphoresis**.- It lacks the **neuromuscular irritability** like hyperreflexia and tremor seen in serotonergic excess.*Citalopram overdose*- While an overdose can cause toxicity, the patient’s symptoms are triggered by the **pharmacodynamic interaction** of multiple serotonergic agents at therapeutic doses.- Isolated SSRI overdose is less likely to produce such severe **autonomic dysfunction** and **hyperreflexia** compared to the synergistic effects of multi-drug interactions.*Meningitis*- Presents with a classic triad of **fever, headache, and nuchal rigidity**, often accompanied by photophobia.- The specific findings of **hyperreflexia** and the recent addition of **serotonergic drugs** strongly point toward a toxicological rather than infectious etiology.

Question 151: A 49-year-old man with panic disorder has been taking sertraline 100mg daily for 4 months with good control of panic attacks. He now reports experiencing 4-5 panic attacks per week again, despite medication compliance. On further questioning, he reveals he has started drinking 6-8 units of alcohol daily over the past 6 weeks to 'calm his nerves'. What is the most likely explanation for his deteriorating symptoms?

A. Development of tolerance to sertraline requiring dose increase
B. Alcohol-induced enhancement of GABA transmission causing rebound anxiety (Correct Answer)
C. Hepatic enzyme induction by alcohol reducing sertraline levels
D. Emergence of treatment-resistant panic disorder
E. Alcohol withdrawal symptoms mimicking panic attacks

Explanation: ***Alcohol-induced enhancement of GABA transmission causing rebound anxiety*** - Alcohol acutely enhances **GABAergic** neurotransmission to provide temporary relief, but chronic use leads to **GABA receptor downregulation** and compensatory **glutamate hyperactivity**. - This neuroadaptation results in **rebound hyperexcitability** during periods of declining blood alcohol levels, which manifests as increased physiological anxiety and recurrent **panic attacks**. *Development of tolerance to sertraline requiring dose increase* - **Tolerance** to the therapeutic effects of **SSRIs** like sertraline is clinically rare once a stable and effective response has been achieved. - The sudden recurrence of symptoms specifically coincides with a significant change in lifestyle (heavy **alcohol consumption**), making pharmacological tolerance less likely. *Hepatic enzyme induction by alcohol reducing sertraline levels* - Alcohol primarily induces **CYP2E1**, whereas sertraline is metabolized mainly by **CYP2C19**, **CYP3A4**, and **CYP2B6**, minimizing the risk of a significant pharmacokinetic interaction. - Even if minor induction occurred, the profound neurochemical impact of 6-8 units of alcohol daily is a far more potent driver of **anxiety relapse** than a slight drop in serum drug levels. *Emergence of treatment-resistant panic disorder* - Treatment resistance is usually considered when there is non-response to adequate trials, not when a patient who was previously **stable** experiences a relapse due to a new **confounding factor**. - The patient’s clinical deterioration is temporally linked to the initiation of heavy drinking, suggesting a **substance-induced** exacerbation rather than a change in the primary disorder's nature. *Alcohol withdrawal symptoms mimicking panic attacks* - While **acute withdrawal** can mimic panic, the patient is drinking daily; the rebound anxiety described occurs frequently as alcohol levels fluctuate, even before formal withdrawal starts. - This option is less encompassing than the GABA/Glutamate rebound mechanism, which explains the **deteriorating baseline** of panic control specifically within the context of **co-occurring alcohol use**.

Question 152: A 41-year-old woman presents with a 2-month history of low mood, anhedonia, and significant psychomotor retardation. She has difficulty getting out of bed and has been off work for 3 weeks. PHQ-9 score is 23. She has no suicidal ideation. Her GP considers referral thresholds. Which action is most appropriate?

A. Initiate SSRI and review in 2 weeks in primary care
B. Refer urgently to crisis resolution home treatment team
C. Refer routinely to community mental health team for assessment
D. Refer to IAPT for high-intensity CBT
E. Initiate SSRI and refer to secondary care mental health services (Correct Answer)

Explanation: ***Initiate SSRI and refer to secondary care mental health services*** - The patient exhibits **severe depression** (PHQ-9 score 23) with significant **psychomotor retardation** and severe **functional impairment** (off work for 3 weeks, difficulty getting out of bed), necessitating both immediate pharmacological intervention and specialist management. - NICE guidelines recommend that for severe depression, especially with marked functional impairment or complex features, a combination of antidepressant medication and **referral to secondary care mental health services** is the most appropriate course of action for comprehensive assessment and management. *Initiate SSRI and review in 2 weeks in primary care* - While initiating an **SSRI** is appropriate, the **severity of her symptoms** (PHQ-9 23, psychomotor retardation, off work for 3 weeks) necessitates more than just primary care follow-up. - Severe depression with such **significant functional impairment** typically requires a multidisciplinary approach and the resources of secondary care for optimal management and monitoring. *Refer urgently to crisis resolution home treatment team* - Crisis resolution teams are for patients with **immediate acute risk**, such as active suicidal ideation, severe self-harm, or rapid deterioration requiring acute intervention to prevent hospital admission. - The patient explicitly states **no suicidal ideation**, and while severely depressed, her presentation does not meet the criteria for an urgent crisis referral, which is typically for more imminent safety concerns. *Refer routinely to community mental health team for assessment* - A routine referral would mean a delay in initiating treatment, which is not appropriate for **severe depression** with significant functional impairment where prompt intervention is crucial. - While referral to a **community mental health team (CMHT)** is part of the correct management, it should be concurrent with **initiation of an SSRI**, not just a referral for assessment. *Refer to IAPT for high-intensity CBT* - **IAPT (Improving Access to Psychological Therapies)** services are generally designed for mild to moderate depression and anxiety; this patient's **severe depression** and functional impairment exceed the typical scope for primary care IAPT. - While CBT can be beneficial, for **severe depression**, it is often more effective when delivered as part of a comprehensive treatment plan within **secondary care mental health services**, alongside pharmacological treatment and specialist oversight.

Question 153: A 35-year-old teacher with generalised anxiety disorder has been receiving CBT for 10 weeks with some improvement but continues to have significant functional impairment. She is reluctant to take medication but agrees to consider pharmacotherapy. She has no other medical conditions. According to NICE guidelines, which medication should be offered first-line?

A. Pregabalin 150mg twice daily
B. Diazepam 5mg three times daily
C. Sertraline 50mg daily (Correct Answer)
D. Propranolol 40mg twice daily
E. Buspirone 5mg three times daily

Explanation: ***Sertraline 50mg daily*** - According to **NICE guidelines (CG113)**, **Selective Serotonin Reuptake Inhibitors (SSRIs)** are the first-line pharmacological treatment for **Generalised Anxiety Disorder (GAD)** when psychological therapies are insufficient. - **Sertraline** is a recommended initial choice among SSRIs due to its effectiveness, generally favorable tolerability profile, and strong evidence base for managing GAD symptoms. *Pregabalin 150mg twice daily* - **Pregabalin** is an effective treatment for GAD but is considered a **second-line** option or an alternative if SSRIs or SNRIs are not tolerated or are ineffective. - It is not the initial pharmacotherapy recommended by NICE guidelines for a patient without contraindications to SSRIs. *Diazepam 5mg three times daily* - **Benzodiazepines** like diazepam are NOT recommended for the long-term management of GAD due to the significant risk of **dependence**, tolerance, and withdrawal symptoms. - They should only be used for **short-term crisis management** of severe anxiety, typically for no more than 2-4 weeks. *Propranolol 40mg twice daily* - **Beta-blockers** such as propranolol can help alleviate the **physical symptoms** of anxiety, such as palpitations and tremors. - However, they do not target the core psychological or cognitive symptoms of **Generalised Anxiety Disorder** and are not recommended as a first-line treatment for the disorder itself. *Buspirone 5mg three times daily* - **Buspirone** is an anxiolytic that acts on serotonin receptors but is generally less effective than SSRIs for GAD and has a slower onset of action. - It is typically considered a **third-line** or adjunctive treatment option, not a first-line agent, especially when SSRIs are appropriate.

Question 154: A 58-year-old woman with recurrent depressive disorder has been taking fluoxetine 40mg daily for 6 weeks with minimal improvement. She reports persistent low mood, poor sleep, and has lost 4kg in weight. She mentions that her mother responded well to a 'different type of antidepressant' years ago. Examination reveals a blood pressure of 168/95 mmHg. Which antidepressant change should be avoided?

A. Switch to sertraline 100mg daily
B. Switch to mirtazapine 30mg at night
C. Switch to vortioxetine 10mg daily
D. Switch to phenelzine 15mg three times daily (Correct Answer)
E. Switch to venlafaxine 75mg twice daily

Explanation: ***Switch to phenelzine 15mg three times daily*** - **Phenelzine** is a non-selective **monoamine oxidase inhibitor (MAOI)** that carries a high risk of **hypertensive crisis** and is contraindicated in patients with uncontrolled hypertension. - Switching from **fluoxetine** to an **MAOI** is particularly dangerous and requires a **5-week washout period** due to the long half-life of fluoxetine and the risk of **Serotonin Syndrome**. *Switch to sertraline 100mg daily* - This is an **SSRI** with a different side-effect profile that generally does not cause significant **blood pressure elevation**. - While the patient failed fluoxetine, switching to another **SSRI** is a common clinical step before moving to more complex classes. *Switch to mirtazapine 30mg at night* - **Mirtazapine** is a **noradrenergic and specific serotonergic antidepressant (NaSSA)** that often causes **weight gain** and **sedation**, which may benefit this patient’s weight loss and poor sleep. - It has a low risk of increasing **blood pressure** compared to SNRIs or MAOIs, making it a safer option for this patient. *Switch to vortioxetine 10mg daily* - **Vortioxetine** is a **multimodal** antidepressant that lacks the significant stimulatory effect on blood pressure seen with other classes. - It is often considered when patients have failed standard **SSRIs** and is generally well-tolerated in patients with cardiovascular comorbidities. *Switch to venlafaxine 75mg twice daily* - **Venlafaxine**, an **SNRI**, can cause dose-dependent **hypertension**, but it is generally easier to monitor and manage than an **MAOI**. - While it requires caution in patients with high blood pressure, it is not as strictly avoided or as pharmacologically complex to initiate as **phenelzine**.

Question 155: A 27-year-old woman presents to the emergency department with her third panic attack this month. She describes sudden onset of chest pain, palpitations, sweating, and a feeling of impending doom lasting 15-20 minutes. ECG shows sinus tachycardia. Troponin is negative. She is otherwise healthy. What is the most appropriate immediate management?

A. Admit for 24-hour cardiac monitoring
B. Prescribe propranolol 10mg PRN for future attacks
C. Provide reassurance, breathing techniques, and arrange GP follow-up (Correct Answer)
D. Commence sertraline 50mg daily immediately
E. Prescribe diazepam 5mg PRN for symptom relief

Explanation: ***Provide reassurance, breathing techniques, and arrange GP follow-up*** - After ruling out life-threatening cardiac causes with a **normal ECG** and **negative troponin**, reassurance is crucial to alleviate the patient's immediate fear of impending doom. - Teaching **breathing techniques** provides an immediate coping strategy, while arranging **GP follow-up** ensures appropriate long-term management for recurrent panic attacks. *Admit for 24-hour cardiac monitoring* - There is no clinical indication for admission as **acute cardiac pathology has been excluded** by the negative troponin and normal ECG in an otherwise healthy young woman. - Admitting the patient for further cardiac monitoring might inadvertently **reinforce her health anxiety** and validate a non-cardiac etiology. *Prescribe propranolol 10mg PRN for future attacks* - While **beta-blockers** like propranolol can help reduce some somatic symptoms such as palpitations and tremor, they do not address the underlying psychological component of panic disorder. - They are generally not considered **first-line for acute panic attack management** or long-term treatment, which focuses on psychological therapy or SSRIs. *Commence sertraline 50mg daily immediately* - **Selective Serotonin Reuptake Inhibitors (SSRIs)** are a first-line long-term treatment for panic disorder, but their initiation typically requires a full psychiatric assessment and ongoing monitoring. - Starting an antidepressant in the emergency department is not ideal, as SSRIs can cause an **initial increase in anxiety** and side effects, requiring careful titration and follow-up not feasible in an ED setting. *Prescribe diazepam 5mg PRN for symptom relief* - **Benzodiazepines** provide rapid relief for acute panic symptoms, but they carry a high risk of **dependence, tolerance, and withdrawal symptoms** with regular or frequent use. - Their use for recurrent panic attacks can prevent patients from learning **adaptive coping mechanisms** and is generally discouraged as a primary long-term management strategy due to these risks.

Question 156: A 44-year-old man with treatment-resistant depression has failed to respond to adequate trials of two different SSRIs and venlafaxine. His psychiatrist considers augmentation therapy. He has type 2 diabetes and stage 3 chronic kidney disease. Which augmentation strategy requires the most careful monitoring in this patient?

A. Addition of mirtazapine to current antidepressant
B. Addition of quetiapine to current antidepressant
C. Addition of lithium to current antidepressant (Correct Answer)
D. Addition of lamotrigine to current antidepressant
E. Addition of buspirone to current antidepressant

Explanation: ***Addition of lithium to current antidepressant***- **Lithium** is primarily excreted by the **kidneys**, and this patient has **Stage 3 Chronic Kidney Disease (CKD)**, which significantly reduces lithium clearance and increases the risk of toxicity.- It has a **narrow therapeutic index** and requires frequent monitoring of **serum lithium levels**, **renal function**, and **thyroid function**, especially in patients with pre-existing renal impairment.*Addition of mirtazapine to current antidepressant*- **Mirtazapine** is often used for augmentation but mainly carries risks of **weight gain** and **sedation**, which could complicate his diabetes management.- While it requires some dose adjustment in renal failure, it does not require the intensive **serum-level monitoring** that lithium necessitates.*Addition of quetiapine to current antidepressant*- **Quetiapine** is an atypical antipsychotic that can cause **metabolic syndrome**, potentially worsening this patient's **type 2 diabetes** control.- Although metabolic monitoring is required, it is not primarily renally cleared and is generally considered safer than lithium in the context of **Stage 3 CKD**.*Addition of lamotrigine to current antidepressant*- **Lamotrigine** is sometimes used for treatment-resistant depression but is primarily associated with a risk of **Stevens-Johnson Syndrome** rather than renal toxicity.- It is metabolized by the **liver** (glucuronidation), making it a less hazardous choice for a patient with **chronic kidney disease** compared to lithium.*Addition of buspirone to current antidepressant*- **Buspirone** is a 5-HT1A partial agonist used for augmentation that has a relatively **low side-effect profile** and does not require therapeutic drug monitoring.- While caution is advised in severe renal impairment, it does not pose the same acute risk of **nephrotoxicity** or accumulation-driven toxicity as **lithium**.

Question 157: A 31-year-old woman with panic disorder describes feeling increasingly anxious about having panic attacks in public places. She has started avoiding supermarkets and public transport. What psychological mechanism best explains the development of her avoidance behaviour?

A. Classical conditioning through association of neutral stimuli with panic symptoms
B. Operant conditioning through negative reinforcement of avoidance (Correct Answer)
C. Cognitive distortion through catastrophic misinterpretation of bodily sensations
D. Impaired habituation to anxiety-provoking stimuli
E. Dysfunctional schema activation in response to environmental triggers

Explanation: ***Operant conditioning through negative reinforcement of avoidance*** - This mechanism explains why avoidance behaviors are maintained. When the woman avoids public places (e.g., supermarkets), she immediately experiences a reduction in her **anxiety** about having a panic attack, which acts as a **negative reinforcer**. - The relief from anxiety strengthens the avoidance behavior, making her more likely to avoid similar situations in the future to prevent the unpleasant feeling of panic. *Classical conditioning through association of neutral stimuli with panic symptoms* - **Classical conditioning** explains how an initial fear response to a previously neutral stimulus (like a public place) is acquired, as it becomes associated with an unconditioned stimulus (panic attack). - However, it primarily describes the *acquisition* of fear to specific cues, not the **maintenance of avoidance behaviors** that *reduces* an already existing aversive state. *Cognitive distortion through catastrophic misinterpretation of bodily sensations* - This cognitive mechanism is central to the *initiation* of a panic attack, where innocuous bodily sensations (e.g., slight breathlessness) are misinterpreted as signs of imminent catastrophe. - While crucial in the **panic cycle**, it doesn't directly describe the **behavioral mechanism** that explains *why* the individual *avoids* certain situations *after* experiencing fear. *Impaired habituation to anxiety-provoking stimuli* - **Habituation** is the natural decrease in emotional or physiological response to a stimulus with repeated exposure. Impaired habituation suggests that the anxiety response doesn't diminish. - While relevant to the persistence of anxiety, it focuses on the *response itself* rather than the **behavioral strategy** (avoidance) employed to cope with or prevent that response. *Dysfunctional schema activation in response to environmental triggers* - **Dysfunctional schemas** are deep-seated, maladaptive patterns of thought and belief that influence how individuals interpret events, often seen in conditions like depression or personality disorders. - This is a broader cognitive concept that explains underlying vulnerability and processing biases, but it is less specific than **operant conditioning** in explaining the *reinforcement* of a particular behavioral pattern like avoidance in panic disorder.

Question 158: A 39-year-old man presents with a 5-month history of persistent worry about his health, finances, and family safety. He reports feeling 'on edge' constantly, has difficulty concentrating at work, and experiences muscle tension in his shoulders. He has no previous psychiatric history. What is the minimum duration of symptoms required for a diagnosis of generalised anxiety disorder according to ICD-11 criteria?

A. 2 weeks
B. 1 month
C. 3 months (Correct Answer)
D. 6 months
E. 12 months

Explanation: ***3 months***- According to **ICD-11 criteria**, the diagnosis of **Generalized Anxiety Disorder (GAD)** requires the presence of symptoms for at least **several months**, specifically a minimum of **3 months**.- This timeframe ensures that the persistent and chronic nature of excessive worry, characteristic of GAD, is captured for accurate diagnosis. *2 weeks*- A **2-week duration** is typically associated with the diagnostic criteria for conditions such as a **major depressive episode** or an **acute stress reaction**, not generalized anxiety disorder.- This timeframe is too short to fulfill the requirement for the pervasive and chronic pattern of worry characteristic of **GAD**. *1 month*- **One month** is a common duration requirement for other anxiety-related disorders, such as **Panic Disorder** or **Post-Traumatic Stress Disorder (PTSD)**.- However, for **Generalized Anxiety Disorder** under **ICD-11**, this duration is insufficient to establish the chronic and pervasive nature of the anxiety symptoms. *6 months*- A **6-month duration** is the diagnostic requirement for **Generalized Anxiety Disorder (GAD)** according to the **DSM-5 criteria**, which differs from the **ICD-11** standard.- It is a common distractor for those who may confuse the criteria between the two major diagnostic manuals. *12 months*- A **12-month duration** is not a standard diagnostic criterion for **Generalized Anxiety Disorder** or most other anxiety disorders in either **ICD-11** or **DSM-5**.- This timeframe is excessively long and would unnecessarily delay necessary diagnosis and intervention for patients experiencing chronic anxiety.

Question 159: A 62-year-old woman with moderate depressive disorder is being assessed for suitability for antidepressant therapy. She has a history of epilepsy controlled on carbamazepine. Which antidepressant should be avoided due to the increased risk of drug interaction lowering the seizure threshold?

A. Sertraline
B. Mirtazapine
C. Bupropion (Correct Answer)
D. Citalopram
E. Venlafaxine

Explanation: ***Bupropion***- **Bupropion** is strictly contraindicated in patients with a history of **epilepsy** because it is known to significantly **lower the seizure threshold** in a dose-dependent manner.- In patients taking **carbamazepine**, there is a complex interaction where carbamazepine induces the metabolism of bupropion, but the clinical focus remains the high inherent **seizure risk** associated with bupropion therapy.*Sertraline*- **Sertraline** is an SSRI and is generally considered to have a **low risk** of inducing seizures, making it a safer option for patients with controlled epilepsy.- While most SSRIs can technically affect the threshold, they do not carry the significant **pro-convulsant** warnings associated with bupropion.*Mirtazapine*- **Mirtazapine** has a relatively **low potential** for lowering the seizure threshold compared to older tricyclic antidepressants or bupropion.- It is often considered a viable alternative in patients where SSRIs are not tolerated, provided the **epilepsy** is stable.*Citalopram*- **Citalopram** is an SSRI that is frequently used in patients with epilepsy due to its **favorable safety profile** regarding seizure induction.- Like other SSRIs, it is preferred over bupropion as it does not carry a **dose-related seizure risk** of 0.4% or higher.*Venlafaxine*- **Venlafaxine** is an SNRI that carries a slight risk of seizures, but this risk is markedly **lower than bupropion** at therapeutic doses.- It is generally avoided only in cases of **uncontrolled epilepsy** or severe overdose scenarios, unlike bupropion which is avoided even in controlled cases.

Question 160: Which of the following neurotransmitter systems is primarily targeted by selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression?

A. Dopaminergic transmission in the mesolimbic pathway
B. Noradrenergic transmission in the locus coeruleus
C. Serotonergic transmission via inhibition of SERT (Correct Answer)
D. GABAergic transmission in the amygdala
E. Glutamatergic transmission via NMDA receptors

Explanation: ***Serotonergic transmission via inhibition of SERT*** - **SSRIs** (Selective Serotonin Reuptake Inhibitors) primarily block the **serotonin transporter (SERT)**, preventing the reuptake of serotonin from the synaptic cleft. - This action increases the concentration of **serotonin** in the synapse, enhancing serotonergic neurotransmission to alleviate depressive symptoms. *Dopaminergic transmission in the mesolimbic pathway* - This pathway is primarily associated with **reward, motivation**, and pleasure, and is a key target for antipsychotics or stimulants, not SSRIs. - While some indirect effects on dopamine may occur, SSRIs do not directly inhibit **dopamine reuptake** or act on dopamine receptors. *Noradrenergic transmission in the locus coeruleus* - This system is mainly involved in **arousal, attention**, and the stress response, and is the primary target for **SNRIs** (Serotonin-Norepinephrine Reuptake Inhibitors). - SSRIs have negligible affinity for the **norepinephrine transporter** and therefore do not directly affect noradrenergic transmission. *GABAergic transmission in the amygdala* - The **amygdala** plays a critical role in fear and anxiety, and **GABAergic transmission** is the primary inhibitory system. - This system is typically targeted by **benzodiazepines** to enhance inhibitory effects, not directly by SSRIs. *Glutamatergic transmission via NMDA receptors* - **Glutamate** is the main excitatory neurotransmitter, and **NMDA receptors** are targeted by novel, rapid-acting antidepressants like **ketamine**. - SSRIs do not primarily modulate glutamatergic transmission or directly act on **NMDA receptors** as their therapeutic mechanism.

Question 161: A 36-year-old woman presents with a 6-month history of excessive worry about various aspects of her life, difficulty sleeping, and muscle tension. She also describes experiencing 4-5 distinct episodes in the past month where she suddenly felt intense fear with palpitations, dizziness, and fear of dying, lasting about 15 minutes each. These episodes occur unpredictably. What is the most accurate diagnosis?

A. Generalised anxiety disorder
B. Panic disorder
C. Generalised anxiety disorder with panic attacks (Correct Answer)
D. Mixed anxiety and depressive disorder
E. Panic disorder with generalised anxiety

Explanation: ***Generalised anxiety disorder with panic attacks***- The patient presents with a 6-month history of **excessive worry** about various aspects of life, difficulty sleeping, and muscle tension, which are diagnostic criteria for **Generalised Anxiety Disorder (GAD)**.- Additionally, she describes 4-5 distinct episodes of intense fear with palpitations, dizziness, and fear of dying, occurring unpredictably and lasting about 15 minutes, which are characteristic of **panic attacks** superimposed on GAD.*Generalised anxiety disorder*- While the patient clearly demonstrates symptoms of **GAD**, including chronic worry and muscle tension, this diagnosis alone is insufficient as it fails to account for the discrete, **sudden panic attacks** she experiences.- A diagnosis of GAD would not fully capture the clinical picture, specifically the recurrent, intense episodes of **acute fear and somatic symptoms**.*Panic disorder*- **Panic disorder** requires recurrent, unexpected panic attacks and at least one month of persistent concern about having additional attacks or their consequences, or significant maladaptive change in behavior related to the attacks.- However, the patient's primary and more pervasive issue is the **chronic, excessive worry** about various aspects of her life, indicating GAD as the underlying and more dominant condition, with panic attacks as a comorbid feature rather than the sole diagnosis.*Mixed anxiety and depressive disorder*- This diagnosis is typically used when symptoms of both **anxiety and depression** are present but neither is sufficiently prominent or severe to meet the criteria for a specific anxiety or depressive disorder.- The patient's presentation clearly meets the full diagnostic criteria for **GAD and panic attacks**, and there is no mention of significant depressive symptoms such as **anhedonia** or persistent low mood.*Panic disorder with generalised anxiety*- The distinction between

Question 162: A 55-year-old woman with depression started on venlafaxine 6 weeks ago presents for review. She reports significant improvement in mood but has developed persistently elevated blood pressure (readings 155/95, 158/98, 152/96 mmHg on separate occasions). She has no previous history of hypertension. Her BMI is 26 and cardiovascular examination is otherwise normal. What is the most appropriate management?

A. Continue venlafaxine and commence amlodipine 5mg daily
B. Continue venlafaxine and commence ramipril 2.5mg daily
C. Reduce venlafaxine dose by half
D. Switch to sertraline 100mg daily (Correct Answer)
E. Continue venlafaxine and monitor blood pressure weekly

Explanation: ***Switch to sertraline 100mg daily***- **Venlafaxine**, a **Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)**, is known to cause **dose-dependent hypertension** due to its norepinephrinergic effects.- The most appropriate management for **iatrogenic hypertension** due to a medication is to discontinue or switch the offending agent to one that is **blood pressure neutral**, such as an **SSRI** like sertraline, especially when mood is stable.*Continue venlafaxine and commence amlodipine 5mg daily*- Adding an **antihypertensive** like amlodipine introduces unnecessary **polypharmacy** and potential drug interactions without addressing the root cause.- This approach treats the symptom rather than removing the **iatrogenic cause** of the patient's elevated blood pressure.*Continue venlafaxine and commence ramipril 2.5mg daily*- Initiating an ACE inhibitor like **ramipril** is not the first-line action when hypertension is a direct, **reversible side effect** of another medication.- Clinical guidelines prioritize **removing the causative factor** (venlafaxine) over adding another drug to manage a preventable adverse effect.*Reduce venlafaxine dose by half*- While venlafaxine-induced hypertension is dose-related, reducing the dose might **compromise the antidepressant efficacy**, leading to a potential **relapse of depression**.- A more definitive solution that maintains antidepressant effect while resolving hypertension is to switch to a **blood pressure-neutral alternative**.*Continue venlafaxine and monitor blood pressure weekly*- Persistently elevated blood pressure readings (e.g., 155/95 mmHg) require active clinical intervention to prevent **long-term cardiovascular damage**, not just monitoring.- Continuing the **pressor agent** (venlafaxine) without addressing the hypertension directly is not compliant with safe medication management.

Question 163: A 41-year-old man with generalised anxiety disorder has not responded adequately to CBT and is commenced on sertraline 50mg daily. After 6 weeks at 100mg daily, his symptoms have improved but he still has significant residual anxiety (GAD-7 score 12). What is the most appropriate next step in pharmacological management?

A. Increase sertraline to 150mg daily
B. Switch to pregabalin 150mg twice daily
C. Add pregabalin 75mg twice daily to sertraline
D. Switch to duloxetine 60mg daily (Correct Answer)
E. Continue current dose for a further 6 weeks

Explanation: ***Switch to duloxetine 60mg daily*** - According to **NICE guidelines** for Generalised Anxiety Disorder (GAD), if an initial **SSRI** (like sertraline) is only partially effective after an adequate trial, the next step is often to switch to an alternative SSRI or an **SNRI** such as **duloxetine** or venlafaxine. - A **GAD-7 score of 12** after 6 weeks at 100mg indicates significant residual anxiety, justifying a change in medication strategy to achieve better symptom control. *Increase sertraline to 150mg daily* - While sertraline can be increased up to 200mg, evidence suggests that for **GAD**, doses much beyond **100mg** may not consistently provide significant additional benefit and can increase the risk of **side effects**. - Clinical guidelines generally prioritize **switching antidepressant classes** over high-dose escalation when a moderate dose fails to achieve sufficient remission in anxiety disorders. *Switch to pregabalin 150mg twice daily* - **Pregabalin** is typically considered a **third-line option** for patients who have not responded adequately to or cannot tolerate trials of both **SSRIs and SNRIs**. - It is generally not recommended to move directly to pregabalin until a trial of a second-line antidepressant (like an **SNRI**) has been attempted. *Add pregabalin 75mg twice daily to sertraline* - **Augmentation therapy** with pregabalin is not a standard first-line or second-line strategy in the management pathways for GAD. - Managing GAD via **monotherapy** (switching agents) is preferred to minimize **polypharmacy** and potential **drug-drug interactions** when a patient is not yet considered treatment-resistant. *Continue current dose for a further 6 weeks* - A **6-week trial** at a therapeutic dose (100mg sertraline) is typically considered an adequate duration to assess the clinical efficacy of an antidepressant in GAD. - Continuing the same treatment despite **moderate residual symptoms** (**GAD-7 score 12**) delays necessary clinical improvement and increases the risk of chronic GAD.

Question 164: A 47-year-old woman with recurrent depressive disorder has been well-maintained on fluoxetine 20mg daily for 18 months following her most recent depressive episode. She has had three previous moderate-severe episodes over the past 10 years. She feels completely recovered and wishes to discontinue her antidepressant. What is the most appropriate advice regarding continuation of treatment?

A. Discontinue immediately as she has been well for sufficient time
B. Continue for at least another 6 months then gradually discontinue
C. Continue for at least another 4 years before considering discontinuation (Correct Answer)
D. Continue indefinitely given her history of recurrent episodes
E. Switch to a lower dose for 6 months before discontinuing

Explanation: ***Continue for at least another 4 years before considering discontinuation*** - For patients with **recurrent depression** (three or more episodes), clinical guidelines suggest maintaining antidepressant treatment for at least **5 years** to significantly reduce the risk of relapse. - Since the patient has only completed **18 months** of maintenance therapy, stopping now would leave her at high risk, given her history of moderate-to-severe episodes. *Discontinue immediately as she has been well for sufficient time* - **Abrupt discontinuation** of antidepressants can lead to **discontinuation syndrome** and carries the highest risk for immediate relapse of depressive symptoms. - 18 months is not considered "sufficient time" for a patient with multiple **recurrent episodes** to achieve long-term stability without medication. *Continue for at least another 6 months then gradually discontinue* - This would result in a total of 2 years of treatment; while standard for a second episode, it is generally considered inadequate for someone with **four lifetime episodes**. - NICE and other psychiatric guidelines advocate for longer periods of **prophylaxis** when the frequency and severity of past episodes are high. *Continue indefinitely given her history of recurrent episodes* - While **long-term maintenance** might eventually be necessary, it is usually discussed as a shared decision after failing several attempts to taper or if episodes are life-threatening. - Initial medical advice should focus on the evidence-based **5-year milestone** rather than committing a patient to indefinite use immediately upon their first request to stop. *Switch to a lower dose for 6 months before discontinuing* - Antidepressants should be maintained at the **full therapeutic dose** that achieved remission; reducing the dose increases the risk of **sub-therapeutic levels** and relapse. - **Dose reduction** is not a recommended strategy for maintenance therapy in recurrent depression unless prompted by side effects.

Question 165: A 29-year-old man presents with panic attacks occurring 2-3 times per week for the past 2 months. Between attacks, he experiences persistent anticipatory anxiety and has begun avoiding public transport. He is keen to avoid medication if possible. During a panic attack in the consultation, he hyperventilates and reports tingling in his fingers and around his mouth. What is the pathophysiological mechanism underlying his paraesthesia?

A. Hypoxia secondary to inadequate ventilation
B. Respiratory alkalosis causing decreased ionized calcium (Correct Answer)
C. Sympathetic nervous system activation causing peripheral vasoconstriction
D. Hypoglycemia triggered by adrenaline release
E. Lactic acidosis from increased muscle tension

Explanation: ***Respiratory alkalosis causing decreased ionized calcium*** - Hyperventilation causes excessive **carbon dioxide (CO2) washout**, leading to an increase in blood pH (alkalosis). - This alkalotic state promotes the binding of **calcium ions to albumin**, thereby reducing the concentration of **ionized calcium**, which increases nerve excitability and causes **paraesthesia**. *Hypoxia secondary to inadequate ventilation* - During a panic attack, patients are actually over-ventilating, meaning their **arterial oxygen (PaO2)** levels are typically normal or even elevated. - **Hypoxia** involves a lack of oxygen, whereas the symptoms here are driven by the removal of CO2. *Sympathetic nervous system activation causing peripheral vasoconstriction* - While **sympathetic activation** (the "fight or flight" response) causes tachycardia and sweating, it is not the primary mechanism for **perioral tingling**. - Vasoconstriction may cause cold extremities, but the specific **neuromuscular irritability** of paraesthesia is classically biochemical (calcium-related). *Hypoglycemia triggered by adrenaline release* - **Adrenaline** (epinephrine) actually stimulates **glycogenolysis** in the liver, which tends to increase rather than decrease blood glucose levels. - While hypoglycemia can cause shakiness and anxiety, it is not a physiological consequence of the **hyperventilation** seen in panic disorder. *Lactic acidosis from increased muscle tension* - Panic attacks involve **respiratory alkalosis** due to CO2 loss, which is the functional opposite of **acidosis**. - **Lactic acidosis** would lower the blood pH, which would actually increase the fraction of ionized calcium and prevent the symptoms described.

Question 166: A 34-year-old woman presents with low mood, fatigue, and reduced interest in activities for 5 weeks. She reports feeling guilty about being unable to cope with work demands. She has passive suicidal thoughts but no plans or intent. Her past medical history includes bipolar disorder diagnosed 3 years ago, currently stable on lithium. What is the most appropriate immediate management?

A. Add sertraline 50mg daily to current lithium
B. Stop lithium and commence lamotrigine
C. Check lithium level and refer urgently to psychiatry (Correct Answer)
D. Increase lithium dose after checking level
E. Add quetiapine to current lithium

Explanation: ***Check lithium level and refer urgently to psychiatry***- In a patient with **bipolar disorder** presenting with a depressive episode, it is vital to first verify the **therapeutic lithium level** to ensure compliance and rule out sub-therapeutic levels as a cause for relapse.- Managing **bipolar depression** is complex due to the risk of triggering **mania** or **rapid cycling**, requiring **specialist psychiatric input**, particularly when **passive suicidal ideation** is present.*Add sertraline 50mg daily to current lithium*- Using an **SSRI** as monotherapy or even with a mood stabilizer in bipolar disorder carries a high risk of **switching to mania** or hypomania.- Antidepressants should generally only be initiated for bipolar depression under **specialist supervision** and are not first-line choices.*Stop lithium and commence lamotrigine*- Stopping **lithium** abruptly can lead to clinical destabilization and significant risk of **relapse or rebound mania**.- While **lamotrigine** is effective for preventing depressive relapses, it is not the immediate priority over assessing current lithium levels and obtaining a specialist referral.*Increase lithium dose after checking level*- Determining the **lithium level** is the correct first step, but increasing the dose without specialist guidance may lead to **lithium toxicity** if the level is already therapeutic.- Adjusting lithium during an acute depressive episode does not address the complexity of the patient's current **suicidal ideation** and depressive state.*Add quetiapine to current lithium*- **Quetiapine** is an evidence-based treatment for bipolar depression, but it should be initiated in the context of a **specialist management plan** rather than in primary care.- The immediate priority remains safety assessment and ensuring the **lithium level** is within range before adding further pharmacological agents.

Question 167: A 42-year-old woman with generalised anxiety disorder has completed an 8-week course of low-intensity psychological intervention without significant improvement. Her GAD-7 score remains 15. She has no history of depression. According to the stepped care model, what is the most appropriate next step in management?

A. Commence sertraline 50mg daily
B. Refer for high-intensity psychological intervention (CBT or applied relaxation) (Correct Answer)
C. Commence pregabalin 150mg daily
D. Refer to specialist mental health services
E. Commence diazepam 5mg twice daily for 4 weeks

Explanation: ***Refer for high-intensity psychological intervention (CBT or applied relaxation)***- According to the **NICE stepped care model**, after an inadequate response to **Step 2 (low-intensity psychological interventions)**, the next recommended step is **Step 3**.- **Step 3** offers either **high-intensity psychological interventions** (like CBT or applied relaxation) or pharmacological treatment, with patient preference often guiding the choice.*Commence sertraline 50mg daily*- While **SSRIs like sertraline** are a valid pharmacological option in Step 3, the stepped care model generally prioritizes high-intensity psychological interventions if low-intensity ones have failed, especially without a strong patient preference for medication.- Pharmacological treatment is an alternative or can be combined with high-intensity psychological interventions at this stage, but often psychological therapy is tried first if available and accepted.*Commence pregabalin 150mg daily*- **Pregabalin** is typically considered a second-line pharmacological option for GAD, recommended if **SSRIs/SNRIs** are not tolerated or ineffective.- It is not the initial pharmacological choice after failure of low-intensity psychological intervention in the stepped care model.*Refer to specialist mental health services*- Referring to specialist mental health services (often **Step 4**) is usually reserved for more **complex or severe cases**, those with significant risk, or those who have not responded to Step 3 interventions.- This patient's presentation, while persistent, indicates a need for intensified Step 3 treatment within primary care or IAPT services, not immediate specialist referral.*Commence diazepam 5mg twice daily for 4 weeks*- **Benzodiazepines** are not recommended for the long-term management of GAD due to risks of **dependence, tolerance, and withdrawal symptoms**.- Their use should be limited to very **short-term (e.g., 2-4 weeks)** management of acute, severe anxiety, and is not appropriate for ongoing treatment after failure of low-intensity interventions.

Question 168: A 56-year-old man with depression has been taking sertraline 100mg daily for 8 weeks with good response. However, he reports new-onset sexual dysfunction including delayed ejaculation and reduced libido. He wishes to continue antidepressant treatment but is distressed by these side effects. What is the most appropriate management strategy?

A. Add sildenafil as needed
B. Switch to mirtazapine (Correct Answer)
C. Reduce sertraline dose to 50mg daily
D. Add bupropion to current treatment
E. Continue sertraline and provide reassurance that symptoms will resolve

Explanation: ***Switch to mirtazapine*** - **Mirtazapine** is a noradrenergic and specific serotonergic antidepressant (**NaSSA**) known for its very low incidence of **sexual dysfunction** compared to **SSRIs**. - It is an excellent choice for patients experiencing distressing sexual side effects like **delayed ejaculation** or **reduced libido** because it does not have the same direct serotonergic effects on 5-HT2 and 5-HT3 receptors implicated in SSRI-induced sexual side effects. *Add sildenafil as needed* - While **sildenafil** can be effective for **erectile dysfunction**, it typically does not address **reduced libido** or **delayed ejaculation** caused by SSRIs. - This strategy adds an additional medication and does not resolve the underlying antidepressant-induced sexual side effect that is distressing to the patient. *Reduce sertraline dose to 50mg daily* - Reducing the dose of **sertraline** may potentially alleviate some side effects, but it carries a significant risk of **depressive relapse** or loss of the previously achieved therapeutic response. - Furthermore, **sexual dysfunction** can often persist even at lower therapeutic doses of **SSRIs**, meaning this approach might not fully resolve the patient's distress. *Add bupropion to current treatment* - While **bupropion** is known for its favorable sexual side effect profile, adding it to **sertraline** in this context (especially in the UK where it's not a licensed monotherapy for depression) increases the complexity of **polypharmacy** and potential drug interactions. - This strategy might not definitively resolve the SSRI-induced sexual dysfunction and could introduce new side effects or compliance issues. *Continue sertraline and provide reassurance that symptoms will resolve* - **SSRI-induced sexual dysfunction** is often persistent and does not spontaneously resolve over time; it is a leading cause of **medication non-adherence**. - Simply offering reassurance is insufficient given the patient's reported distress, and there are more proactive and effective management strategies available.

Question 169: A 38-year-old woman presents with recurrent panic attacks and has developed significant avoidance of situations where escape might be difficult. She has begun cognitive behavioral therapy (CBT) but requests medication to help manage her symptoms more quickly. According to NICE guidelines, what is the most appropriate initial pharmacological approach for panic disorder?

A. Propranolol 40mg as needed before anxiety-provoking situations
B. Diazepam 5mg three times daily for 2 weeks
C. Sertraline 50mg once daily (Correct Answer)
D. Buspirone 5mg three times daily
E. Pregabalin 75mg twice daily

Explanation: ***Sertraline 50mg once daily*** - **SSRIs** like sertraline are the **first-line pharmacological treatment** for **panic disorder** according to **NICE guidelines** due to their proven efficacy and safety profile. - Patients should be advised that while SSRIs may initially increase anxiety, they should be continued for at least **6 months** after remission to prevent relapse. *Propranolol 40mg as needed before anxiety-provoking situations* - **Beta-blockers** are only effective at managing the **autonomic symptoms** of anxiety, such as palpitations and tremors, but they do not treat the underlying panic disorder or cognitive symptoms. - They are not recommended as a primary treatment for **panic attacks** or the cognitive components of the disorder like **avoidance behavior**. *Diazepam 5mg three times daily for 2 weeks* - **Benzodiazepines** are generally avoided in the long-term management of panic disorder due to the significant risk of **dependence** and **tolerance**. - While they provide rapid relief in acute crises, they are not recommended for routine management and can interfere with the efficacy of **CBT**. *Buspirone 5mg three times daily* - **Buspirone** is primarily used in the management of **Generalized Anxiety Disorder (GAD)** rather than panic disorder. - Evidence for its effectiveness in treating recurrent **panic attacks** or agoraphobia is insufficient, making it an inappropriate choice here. *Pregabalin 75mg twice daily* - **Pregabalin** is licensed and recommended by NICE as a subsequent option for **GAD**, but it is not a first-line agent for panic disorder. - Its use is typically reserved for cases where multiple **SSRIs** or **SNRIs** have failed or are not tolerated well by the patient.

Question 170: A 52-year-old man with a 4-week history of low mood, anhedonia, and early morning wakening is started on citalopram 20mg daily. He returns after 10 days reporting no improvement in symptoms and requests a change of medication. What is the most appropriate management?

A. Switch to venlafaxine immediately
B. Increase citalopram to 40mg daily
C. Add mirtazapine to current treatment
D. Continue current dose and review in 2-3 weeks (Correct Answer)
E. Switch to fluoxetine 20mg daily

Explanation: ***Continue current dose and review in 2-3 weeks*** - Antidepressants like **citalopram** typically require **2 to 4 weeks** of consistent use before a significant therapeutic effect is observed. - Since the patient has only been on the medication for **10 days**, it is premature to assess efficacy, and clinical guidelines recommend waiting **4 weeks** before considering a change. *Switch to venlafaxine immediately* - **Venlafaxine**, an SNRI, is generally reserved as a second-line option for patients who do not respond to an adequate trial of an **SSRI**. - Switching so early (10 days) unnecessarily exposes the patient to **withdrawal symptoms** or new side effects before the first treatment has been tested. *Increase citalopram to 40mg daily* - Increasing the dose is only indicated if there is a **partial response** or no response after a full **4 to 6-week trial** at the therapeutic starting dose. - Raising the dose prematurely increases the risk of **dose-dependent adverse effects**, such as **QT interval prolongation**, without providing therapeutic benefit yet. *Add mirtazapine to current treatment* - **Augmentation therapy** is a specialized strategy used for **treatment-resistant depression**, not for patients just beginning their first course of medication. - Combining antidepressants at this stage significantly increases the risk of **serotonin syndrome** and is not supported by initial treatment protocols. *Switch to fluoxetine 20mg daily* - Switching from one SSRI to another like **fluoxetine** is a valid strategy for non-responders, but only after the initial drug is proven ineffective over a **full course**. - There is no clinical evidence that the patient is failing citalopram; they simply have not reached the **pharmacodynamic window** required for mood improvement.

Question 171: A 28-year-old woman describes experiencing sudden episodes of intense fear accompanied by palpitations, sweating, trembling, shortness of breath, and a sense of impending doom. These episodes peak within 10 minutes and last approximately 20-30 minutes. She has started avoiding crowded places where previous episodes occurred. Between episodes, she constantly worries about having another attack. What is the core diagnostic feature of her condition?

A. Avoidance of crowded places
B. Persistent worry about future attacks
C. Presence of autonomic symptoms during episodes
D. Recurrent unexpected panic attacks (Correct Answer)
E. Duration of individual episodes being less than 30 minutes

Explanation: ***Recurrent unexpected panic attacks*** - The hallmark of **panic disorder** is the presence of **recurrent, unexpected panic attacks** that occur without an obvious external trigger. - Diagnosis requires these attacks to be followed by at least one month of **persistent concern** regarding future episodes or **maladaptive behavioral changes**. *Avoidance of crowded places* - This behavior is consistent with **agoraphobia**, which often co-occurs with panic disorder but is considered a distinct diagnosis or a **secondary manifestation**. - While important for clinical management, it is a consequence of the underlying attacks rather than the **primary diagnostic criterion**. *Persistent worry about future attacks* - Termed **anticipatory anxiety**, this is a crucial component of panic disorder that follows the initial attacks. - It acts as a **complicating feature** or criterion for the disorder, but it must be preceded by the **unexpected panic attacks** themselves. *Presence of autonomic symptoms during episodes* - Autonomic symptoms like **palpitations** and **sweating** are used to define a **panic attack** itself, requiring at least four such symptoms. - Their presence indicates an episode has occurred but does not distinguish **panic disorder** from other anxiety disorders where situational attacks may occur. *Duration of individual episodes being less than 30 minutes* - The **rapid peaking** (usually within 10 minutes) and short duration are descriptive characteristics of a **panic attack profile**. - However, specific **time limits** for the total duration of an attack are not core diagnostic criteria for the disorder itself.

Question 172: A 32-year-old man presents with a 3-month history of persistent worry about multiple aspects of his life including finances, health, and work performance. He reports difficulty controlling these worries, muscle tension, irritability, and poor concentration. He experiences restlessness and fatigue. His symptoms occur on most days and significantly impact his daily functioning. What is the most likely diagnosis?

A. Panic disorder
B. Social anxiety disorder
C. Generalised anxiety disorder (Correct Answer)
D. Obsessive-compulsive disorder
E. Adjustment disorder

Explanation: ***Generalised anxiety disorder***- This patient exhibits **excessive worry** about various life domains (finances, health, work) along with physical symptoms like **muscle tension**, **restlessness**, and **fatigue**.- While the DSM-5 typically requires symptoms for **6 months**, the cluster of persistent, uncontrollable worries and clinical distress strongly points to GAD as the most fitting diagnosis.*Panic disorder*- Characterized by recurrent, **unexpected panic attacks** which are discrete periods of intense fear with physical symptoms like palpitations or shortness of breath.- It involves a persistent concern about having **future attacks** rather than a generalized worry about daily life events.*Social anxiety disorder*- Primarily involves an intense fear of **scrutiny by others** or embarrassment in **social situations**.- The symptoms here are pervasive across multiple non-social areas such as work performance and finances, making social anxiety less likely.*Obsessive-compulsive disorder*- Defined by the presence of **obsessions** (intrusive, repetitive thoughts) and **compulsions** (repetitive behaviors performed to reduce anxiety).- This patient's worries are related to real-life concerns rather than the stereotypical, ego-dystonic themes seen in **OCD**.*Adjustment disorder*- Occurs in response to a **specific, identifiable stressor** within three months of its onset.- This patient's symptoms are generalized and multifaceted, lacking a single triggering event that would define an adjustment reaction.

Question 173: A 45-year-old woman presents to her GP with low mood, poor sleep, and reduced appetite for the past 6 weeks. She describes feeling worthless and has difficulty concentrating at work. She denies suicidal ideation. On examination, she appears tearful and has psychomotor retardation. Her PHQ-9 score is 18. What is the most appropriate first-line pharmacological treatment?

A. Mirtazapine 15mg once daily
B. Venlafaxine 75mg twice daily
C. Amitriptyline 75mg once daily
D. Sertraline 50mg once daily (Correct Answer)
E. Lofepramine 70mg twice daily

Explanation: ***Sertraline 50mg once daily***- In accordance with **NICE guidelines**, selective serotonin reuptake inhibitors (**SSRIs**) like sertraline are the first-line pharmacological treatment for **moderate depression** (PHQ-9 score 15-19).- Sertraline is preferred due to its **favorable side-effect profile**, lower toxicity in overdose, and cost-effectiveness compared to other antidepressant classes.*Amitriptyline 75mg once daily*- This is a **tricyclic antidepressant (TCA)**, which is generally avoided as first-line therapy because it is **highly toxic in overdose**.- It is associated with significant **anticholinergic side effects** such as dry mouth, blurred vision, and urinary retention, which reduce patient compliance.*Mirtazapine 15mg once daily*- While effective, this **NaSSA** (Noradrenergic and specific serotonergic antidepressant) is typically reserved as a **second-line** option or for patients with prominent insomnia/weight loss.- Common side effects include **sedation and weight gain**, making it less appropriate than an SSRI for initial management in most patients.*Venlafaxine 75mg twice daily*- This is a **Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)** usually indicated for **treatment-resistant depression** or after the failure of two SSRIs.- It requires careful monitoring due to the risk of **increased blood pressure** and more severe withdrawal symptoms upon discontinuation.*Lofepramine 70mg twice daily*- Despite being one of the **safer TCAs** regarding cardiovascular toxicity, it remains a secondary option behind SSRIs.- SSRIs are still prioritized as they are **better tolerated** and have fewer interactions with other medications compared to lofepramine.

Practice by Chapter

Depression

Practice Questions

Generalised anxiety disorder

Practice Questions

Panic disorder

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Common Mental Disorders — MCQs

Common Mental Disorders — MCQs

On this page